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Leptin is the prototypical adipokine that circulates in direct proportion to whole body 
adiposity. As such, serum leptin levels decrease when white adipose tissue depletes by 
calorie restriction whereas they increase as white adipose tissue expands by overnutri-
tion. At both sides of the spectrum, i.e. too little and too much leptin, the adipokine con-
tributes to vascular complications such as atherosclerosis and reproductive dysfunction. 
Mice that lack both leptin and the low density lipoprotein receptor (LDLR
−/−
;ob/ob) are 
an ideal model to study atherosclerosis as they present with atherosclerotic plaques in 
the aortic root and brachiocephalic artery. In this thesis, dose-dependent effects of re-
combinant leptin administration from the subphysiological to physiological range on 
atherosclerotic plaque formation and fertility was studied in LDLR
−/−
;ob/ob mice. Lep-
tin dose-dependently reduced plaque lesions and improved Leydig cell function and 
spermatogenesis. The effect of leptin treatment on atherosclerotic plaques was inde-
pendently and significantly associated with improvements in lipid homeostasis and liver 
steatosis, as well as increased adiponectin. The beneficial effects of leptin treatment on 
several measures of fertility such as intratesticular testosterone, circulating follicle stim-
ulating hormone, and seminiferous tubule morphology appeared to be direct and body 
weight-independent. Besides genetic leptin-deficiency, lipodystrophy (LD) patients and 
lipodystrophic mice were studied. LD is a leptin-deficient condition caused by the lack 
of subcutaneous white adipocytes leading to several metabolic complications including 
severe insulin resistance and hypertriglyceridemia. The effects of adipose tissue loss in 
LD on the adipokines chemerin, progranulin, and fibroblast growth factor 21 have not 
been investigated so far. Circulating levels of these three adipokines were all increased 
in LD patients as compared to weight- and age-matched controls. Furthermore, none of 
these adipokines was significantly regulated in 10 LD patients by leptin treatment over 
 II 
 
6 months. In a mouse model of generalized LD, increased expression of these adi-
pokines was found in various adipose tissue depots at the mRNA level providing first 
preliminary evidence as to the source of higher circulating levels in LD patients. Collec-
tively, the findings of this thesis show for the first time dose-dependent beneficial ef-
fects of leptin on atherosclerosis and reproductive function and provide new information 
about the association of LD with changes in various adipokines that have an established 
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Obesity is the major cause behind noncommunicable diseases of civilization such as 
type 2 diabetes mellitus, hypertension, coronary heart disease, reproductive dysfunction, 
nonalcoholic fatty liver disease, respiratory defects, various cancers, arthritis, and nu-
merous psychological disorders. Due to the immense health and economic burden for 
industrialised and non-industrialised nations alike, the World Health Organization has 
made the curtailment in the progression of obesity by 2025 a major goal. 
Adipokines are signalling molecules released by white adipocytes that often circulate 
in proportion to white adipose tissue stores. Some adipokines including leptin provide 
information about energy reserves to the rest of the body and particularly the brain. 
Since the discovery of leptin by the group of Jeffrey Friedman in 1994, quickly fol-
lowed by the cloning of the leptin receptor in 1995, much progress has been made on 
the neuroendocrine control of feeding, energy expenditure, and ultimately whole body 
energy homeostasis. Although controversial at the time it was proposed, Douglas Cole-
man’s early hypothesis some four decades ago that a circulating factor released from 
white adipocytes communicates to the brain to regulate body weight (BW) proved true. 
Leptin signalling is regulated/ dysregulated at various levels: from its release by adi-
pocytes to its transport into the brain where it activates the leptin receptor in key feeding 
circuits. Obesity is characterised by a state of central leptin resistance due to dysfunc-
tion of neuronal leptin receptor signalling. Major efforts are currently underway to ame-
liorate this condition with small molecule compounds that resolve hypothalamic endo-
plasmic reticulum stress showing great promise in mouse studies. 
A major problem of obesity is that it often silently harbours other comorbidities. Var-
ious effects of leptin on hypertension, type 2 diabetes mellitus, reproductive function, 
and nonalcoholic fatty liver disease have been documented in a variety of animal studies 
but could be translated only partly to humans. Nevertheless, the idea that too little or too 
much circulating leptin adversely affects metabolic health is generally accepted. 
In this thesis, dose-dependent effects of leptin treatment on atherosclerotic plaque 
formation and reproductive function in mice were assessed. In addition, regulation of 
the adipokines chemerin, fibroblast growth factor (FGF) 21, and progranulin in a leptin-
deficient human lipodystrophy (LD) cohort and mouse model were described. 
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For the animal studies, a leptin-deficient atherosclerosis-prone mouse model 
(LDLR
−/−
; ob/ob) was first utilised. These mice were treated with saline or different 
doses of recombinant leptin from the subphysiological to the physiological range (0.1, 
0.5, or 3.0 mg/kg BW/d) over the course of 12 weeks.  
In the first publication (Chapter 2), aortic root and brachiocephalic artery atheroscle-
rotic lesions were investigated using histological techniques. Glucose homeostasis, lipid 
metabolism, and liver lipid content, as well as function, were also assessed as independ-
ent factors that could influence lesion size. We demonstrated that leptin treatment in 
leptin-deficient mice dose-dependently decreases BW and atherosclerotic lesions. Mice 
in the 0.1 and 0.5 mg/kg BW/d groups remained heavier (i.e. subphysiological leptin 
dose) and in the 3.0 mg/kg BW/d group had similar weight (i.e. physiological leptin 
dose) as compared to non-leptin-deficient LDLR
−/−
 animals. Recombinant leptin dose-
dependently reduced plaque area in the aortic root and the brachiocephalic artery by 
36% and 58%, respectively, in the 3.0 mg/kg BW/d group as compared to the saline-
treated animals. Leptin-mediated reductions of plasma total and LDL cholesterol re-
mained independent predictors for aortic root plaque area. Cholesterol content in liver, 
as well as hepatic expression of key lipid and proinflammatory genes such as acetyl-
CoA-carboxylase-1, 3-hydroxy-3-methylglutaryl-CoA reductase, Monocyte chemoat-
tractant protein-1, Tumor necrosis factor α, were dose-dependently regulated by leptin. 
Furthermore, leptin treatment increased circulating levels and adipose tissue mRNA 
expression of the adipokine adiponectin. From these findings, leptin appears to mediate 
its antiatherogenic effects indirectly through reduction of hypercholesterolemia and liv-
er steatosis, as well as upregulation of insulin-sensitizing and atheroprotective adiponec-
tin. 
In the second publication (Chapter 3), dose-dependent effects of 12 weeks leptin 
treatment on Leydig cell function and spermatogenesis were investigated. For this work, 
plasma levels of the gonadotropins luteinizing hormone and follicle-stimulating hor-
mone, testis weight, intratesticular testosterone levels, as well as reproductive function 
markers in the testis at the mRNA level were measured by RT-qPCR. In addition, de-
tailed histological analysis in testis was performed to evaluate the effect of leptin treat-
ment on the spermatogenic process by assessing the morphology of seminiferous tu-
bules. Total testis weight increased in the 0.1 mg/kg BW/d and 3.0 mg/kg BW/d groups 
compared with saline controls. Intratesticular testosterone levels relative to testis weight 
increased significantly only in the 0.5 mg/kg BW/d group as compared to saline-treated 
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animals. Follicle-stimulating hormone levels increased in a dose-dependent manner 
with leptin treatment whereas luteinizing hormone levels remained unchanged. Leptin 
treatment significantly increased both mRNA and protein expression of the steroidogen-
ic enzyme cytochrome P450 17A1. Spermatogenesis improved in leptin-treated animals 
as revealed by significantly more seminiferous tubules in stages I to VIII. Additionally, 
there were significantly fewer abnormal seminiferous tubule structures in leptin-treated 
mice. In another set of experiments, acute treatment of ob/ob mice with physiological 
leptin doses over 72 h partially improved male reproductive markers without affecting 
BW. In conclusion, administration of subphysiological to physiological doses of leptin 
improves Leydig cell function and spermatogenesis in mice independently of body 
weight changes. 
For the studies in leptin-deficient LD (Chapters 4 to 6), LD patients were recruited 
who are characterized by loss of adipose tissue, dysregulation of several adipokines, as 
well as severe metabolic complications including insulin resistance and hypertriglycer-
idemia. Regulation of the insulin resistance-inducing and proinflammatory adipokine 
chemerin was assessed in LD for the first time. Serum chemerin, as well as clinical and 
biochemical parameters of glucose metabolism, lipid metabolism, and inflammation, 
were measured in 37 LD patients and 37 age-, gender-, and body mass index-matched 
controls. Chemerin mRNA expression was also determined in various insulin-sensitive 
tissues in a generalized LD mouse model (Tg(aP2-SREBF1c)9884Reh/0) and non-LD 
controls using qRT-PCR. Median serum chemerin levels were significantly higher in 
LD patients (234.3 µg/l) as compared to controls (204.0 µg/l). Multiple linear regression 
analysis showed that circulating chemerin was independently and positively associated 
with glycosylated hemoglobin A1c (HbA1c) and C-reactive protein (CRP). Finally, 
chemerin mRNA expression was significantly increased 2.5-fold in visceral adipose 
tissue (VAT) and 5.3-fold in brown adipose tissue (BAT) of LD mice compared to con-
trols. These data suggest that circulating chemerin is elevated in LD patients, which 
independently and positively associates with HbA1c and CRP. The animal experiments 
are compatible with the hypothesis that increased chemerin in LD originates from VAT 
and BAT. 
Encouraged by the findings summarized above, a more in-depth analysis of how lep-
tin-deficient LD affects adipokines other than chemerin was performed. Regulation of 
adipocyte-expressed fibroblast growth factor (FGF) 21 which acts in an insulin-
mimetic, lipid-lowering, and antiatherogenic manner has not been investigated in non-
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human immunodeficiency virus (HIV) LD. Therefore, circulating FGF21 was quantified 
in the same 37 patients characterized for chemerin who all presented with non-HIV LD 
and 37 matched controls. In addition, FGF21 plasma levels and mRNA expression in 
insulin-sensitive tissues were measured in LD mice and control animals. Median FGF21 
serum concentrations were significantly higher in LD patients (381.2 ng/l) as compared 
to the control group (231.2 ng/l). Multiple linear regression analysis revealed an inde-
pendent and positive association between circulating FGF21 and serum triglycerides 
(TG), as well as fibrate treatment. Similarly, LD mice showed significantly 4.5-fold 
increased FGF21 plasma levels, as well as significant upregulation of FGF21 mRNA 
expression in various adipose tissue depots and liver as compared to controls. The hu-
man data suggest that serum concentrations of FGF21 are elevated in patients with LD 
and that circulating FGF21 independently associates with TG and fibrate treatment. The 
mouse data reveal that adipose tissue and liver are potential sources of increased FGF21 
production in leptin-deficient LD.  
Studies in leptin-deficient LD were completed by focusing on progranulin which has 
proinflammatory and insulin resistance-inducing characteristics and has not been inves-
tigated in LD so far. Circulating progranulin was determined in the same 37 LD patients 
and 37 controls as summarized above. Additionally, progranulin mRNA expression was 
investigated in various insulin-sensitive tissues of LD mice compared to non-LD control 
mice. Median circulating progranulin was significantly increased in patients with LD 
(82.9 µg/l) as compared to controls (73.6 µg/l). Multivariate analysis revealed that CRP 
was an independent and positive predictor of circulating progranulin. In LD mice, 
progranulin mRNA was significantly upregulated in all adipose tissue depots studied 
(visceral, subcutaneous, and BAT), as well as in skeletal muscle (quadriceps) compared 
to wild-type mice. The human data suggest that progranulin serum concentrations are 
increased in LD patients and that circulating FGF21 shows an independent and positive 
correlation with CRP. From the mouse data, it can be hypothesized that adipose tissue 
depots and muscle are potential sources of elevated progranulin in LD. Chemerin, 
FGF21, and progranulin serum levels were not significantly regulated in 10 leptin-
deficient LD patients by leptin treatment over 6 months. 
In summary, leptin is a crucial adipokine that impacts on metabolic and vascular dis-
ease, as well as reproductive function. A fine-tuned level of circulating leptin is required 
for optimal health. LD is a devastating condition in which afflicted individuals are inca-
pable of forming sufficient subcutaneous adipose tissue in different regions and thus 
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lack circulating leptin with metabolic abnormalities including severe insulin resistance 
and hypertriglyceridemia. Other adipokines are also affected in LD but in an upregulat-
ed manner which may contribute to a metabolically compromised state that ironically is 
indistinguishable from obesity. These adipokines include chemerin, FGF21, and 
progranulin and re-establishment of a favourable balance of these and other adipokines 




Adipositas ist die Hauptursache für Zivilisationskrankheiten wie Diabetes mellitus 
Typ 2, Bluthochdruck, koronare Herzerkrankung, reproduktive Dysfunktion, nichtalko-
holische Fettlebererkrankung, Atemwegserkrankungen, verschiedene Krebsarten, Arth-
ritis und zahlreiche psychologische Störungen. Wegen der enormen gesundheitlichen 
und ökonomischen Belastungen, die dies für industrialisierte und nichtindustrialisierte 
Nationen bedeutet, hat sich die Weltgesundheitsorganisation das Beenden des Adiposi-
tasanstiegs bis 2025 zum Ziel gesetzt. 
Adipokine sind Signalmoleküle, die oft im Verhältnis zu Fettgewebsspeichern frei-
gesetzt werden und Informationen über Energiereserven mit dem Körpers – insbesonde-
re dem Gehirn - kommunizieren. Seit der Entdeckung von Leptin durch die Gruppe von 
Jeffrey Friedman im Jahr 1994, gefolgt von der Klonierung des Leptinrezeptors im Jah-
re 1995, wurden große Fortschritte im Bereich der neuroendokrinen Kontrolle der Nah-
rungsaufnahme, des Energieverbrauchs und letztendlich der gesamten Energiehomöo-
stase erzielt. Damit wurde die initial umstrittene Hypothese Douglas Colemans, dass ein 
von weißen Adipozyten produzierter, zirkulierender Faktor mit dem Gehirn kommuni-
ziert, um das Körpergewicht zu regulieren, mehr als vier Jahrzehnte später vollumfäng-
lich bestätigt. 
Die Signalübertragung Leptins wird auf verschiedenen Ebenen reguliert und fehlre-
guliert: von seiner Freisetzung durch Adipozyten bis zu seinem Transport in das Gehirn, 
wo es durch seinen Rezeptor Nahrungsaufnahme-regulierende Kreisläufe beeinflusst. 
Adipositas ist durch eine zentrale Leptinresistenz, d.h. eine Störung der neuronalen Lep-
tinrezeptorsignale, charakterisiert. Langjährige Anstrengungen in Mausstudien, diesen 
unter anderem durch Stress des endoplasmatischen Retikulums im Hypothalamus her-
vorgerufenen Zustand medikamentös zu verbessern, zeigen erste vielversprechende Re-
sultate. 
Ein großes Problem der Adipositas ist, dass sich oft initial unbemerkt andere Komor-
biditäten entwickeln. Vielfältige Effekte von Leptin auf Hypertonie, Diabetes mellitus 
Typ 2, reproduktive Funktion und nichtalkoholische Fettlebererkrankung wurden in 
einer Vielzahl von Tierstudien gefunden, konnten aber nur teilweise auf Menschen 
übertragen werden. Dennoch wird die Hypothese, dass zu wenig oder zu viel zirkulie-
rendes Leptin das metabolische Gleichgewicht negativ beeinflusst, allgemein akzeptiert. 
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In der vorliegenden Arbeit wurden Daten über dosisabhängige Effekte einer Leptin-
behandlung auf die atherosklerotische Plaquebildung und die Reproduktionsfunktion in 
einem leptindefizienten Mausmodell erhoben. Zusätzlich wurden Veränderungen der 
zirkulierenden Adipokine Chemerin, Fibroblastenwachstumsfaktor (FGF) 21 und Pro-
granulin in einer leptindefizienten menschlichen Lipodystrophie (LD)-Kohorte sowie 
LD-Mäusen untersucht. 
Für die Tierstudien wurde zunächst ein leptindefizientes, Atherosklerose-anfälliges 
Mausmodell (LDLR
-/-
;ob/ob) verwendet. Diese Mäuse wurden über 12 Wochen mit 
Kochsalzlösung (Kontrollen) oder unterschiedlichen Dosen rekombinanten Leptins im 
subphysiologischen bis physiologischen Bereich (0,1, 0,5 oder 3,0 mg/kg Körperge-
wicht [KG]/d), behandelt. In der ersten Publikation (Kapitel 2) wurden atheroskleroti-
sche Läsionen der Aortenwurzel und der Arteria brachiocephalica mittels histologi-
scher Verfahren untersucht. Glukosehomöostase, Lipidmetabolismus und Leberlipidge-
halt sowie Leberfunktion wurden ebenfalls als unabhängige Faktoren mit Einfluss auf 
die Läsionsgröße bewertet. Es wurde bestätigt, dass eine Leptinbehandlung in leptinde-
fizienten Mäusen das KG und atherosklerotische Läsionen dosisabhängig verringert. 
Mäuse in den 0,1 und 0,5 mg/kg KG/d-Gruppen behielten ein schwereres KG (entspre-
chen damit subphysiologischen Leptindosen) als Tiere der 3,0 mg/kg KG/d-Gruppe. 
Diese Gruppe entwickelte ein ähnliches Gewicht (entspricht damit einer physiologi-
schen Leptindosis) verglichen mit nicht-leptindefizienten LDLR
-/-
-Tieren. Rekombinan-
tes Leptin verringerte dosisabhängig die Plaquegröße in der Aortenwurzel und der Arte-
ria brachiocephalica um 36% bzw. 58% in der 3,0 mg/kg KG/d-Gruppe verglichen mit 
Kochsalz-behandelten Kontrollen. Leptin-vermittelte Reduktionen von Gesamtcholeste-
rin und low density lipoprotein (LDL) Cholesterin blieben unabhängige Prädiktoren für 
Aortenwurzelläsionen. Der Cholesteringehalt in der Leber sowie die hepatische Expres-
sion von Lipidstoffwechsel- und proinflammatorischen Genen, wie acetyl-CoA-
carboxylase-1, 3-hydroxy-3-methylglutaryl-CoA reductase, Monocyte chemoattractant 
protein-1, Tumor necrosis factor α, wurden dosisabhängig durch Leptin reguliert. Wei-
terhin erhöhte die Leptinbehandlung die zirkulierenden Spiegel des Adipokins Adi-
ponektin sowie dessen mRNA-Expression im Fettgewebe. Aus diesen Befunden kann 
die Hypothese abgeleitet werden, dass Leptin seine antiatherogenen Effekte indirekt 
durch die Reduktion von Hypercholesterinämie und Lebersteatose sowie die Hochregu-
lation von insulinsensibilisierendem und atheroprotektivem Adiponectin vermittelt. 
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In der zweiten Publikation (Kapitel 3) wurden die dosisabhängigen Effekte von Lep-
tin auf die Leydig Zell-Funktion und die Spermatogenese untersucht. Für diese Arbeit 
wurden die Plasmaspiegel der Genotropine Luteinisierendes Hormon und Follikel-
stimulierendes Hormon, Testisgewicht, intratestikuläre Testosteronspiegel sowie Re-
produktionsfunktionsmarker im Hoden auf mRNA-Ebene gemessen. Zusätzlich erfolg-
ten detaillierte histologische Analysen des Hodens, um die Wirkung der Leptinbehand-
lung auf die Spermatogenese zu untersuchen. Dazu wurde die Morphologie der Samen-
kanälchen analysiert. Das Hodengewicht erhöhte sich in den 0,1 und 3,0 mg/kg KG/d-
Gruppen im Vergleich zur kochsalzbehandelten Kontrollgruppe. Intratestikuläre Testos-
teronspiegel bezogen auf das Hodengewicht verzeichnete in der 0,5 mg/kg KG/d-
Gruppe einen signifikanten Anstieg verglichen zur Kontrollgruppe. Follikel-
stimulierendes Hormon-Spiegel erhöhten sich unter Leptinbehandlung dosisabhängig, 
während Luteinisierendes Hormon-Spiegel sich nicht änderten. Die Leptinbehandlung 
erhöhte sowohl die mRNA als auch die Proteinexpression des steroidogenen Enzyms 
Cytochrom P450 17A1 signifikant. Unter Leptinbehandlung verbesserte sich zudem die 
Spermatogenese, gemessen als signifikant mehr Samenkanälchen in den Stufen I bis 
VIII. Zusätzlich gab es signifikant weniger anomale Strukturen in den Samenkanälchen. 
Eine akute Behandlung von ob/ob-Mäusen über 72 h mit einer physiologischen Leptin-
dosis verbesserte männliche Reproduktionsmarker partiell ohne Beeinflussung des KG. 
Zusammenfassend lässt sich sagen, dass die Verabreichung von subphysiologischen und 
physiologischen Dosen von Leptin die Leydig Zell-Funktion und die Spermatogenese 
bei Mäusen verbessert und dies bei physiologischen Leptindosen unabhängig von den 
Veränderungen des Körpergewichts geschieht. 
Für die Studien bei leptindefizienter LD (Kapitel 4 bis 6) wurden LD-Patienten re-
krutiert und ein LD-Mausmodell (Tg(aP2-SREBF1c)9884Reh/0) weiterführend charak-
terisiert. LD ist gekennzeichnet durch den Verlust von subkutanem Fettgewebe in ver-
schiedenen Körperarealen, Dysregulation mehrerer Adipokine und damit einhergehend 
schweren metabolischen Komplikationen wie schwerer Insulinresistenz und Hypertrig-
lyzeridämie. Erstmals wurden Serumspiegel des insulinresistenzinduzierenden und pro-
inflammatorischen Adipokins Chemerin im Krankheitsbild der LD untersucht. Hierfür 
wurden Serumchemerin sowie klinische und biochemische Parameter des Glukose-
stoffwechsels, des Lipidstoffwechsels und der Inflammation bestimmt bei 37 LD-
Patienten sowie 37 Alters-, Geschlechts- und Körpergewichts-gematchten Kontrollen. 
Die Chemerin-mRNA-Expression wurde zudem in verschiedenen insulinsensitiven Ge-
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weben in LD-Mäusen und Kontrollen unter Verwendung von qRT-PCR bestimmt. Der 
mediane Chemerinspiegel bei den 37 LD-Probanden war signifikant höher (234,3 μg/l) 
verglichen zu den Kontrollprobanden (204,0 μg/l). In einer multiplen linearen Regressi-
onsanalyse war zirkulierendes Chemerin unabhängig und positiv mit dem glykosylierten 
Hämoglobin A1c (HbA1c) und dem C-reaktiven Protein (CRP) assoziiert. Abschließend 
wurde im Mausmodell gezeigt, dass die Chemerin-mRNA-Expression signifikant um 
das 2,5-fache in viszeralem Fettgewebe (VAT) und 5,3-fach in braunem Fettgewebe 
(BAT) in LD-Mäusen verglichen mit Kontrolltieren erhöht war. Aus diesen Daten kann 
geschlussfolgert werden, dass zirkulierende Chemerinspiegel in LD erhöht sind und 
dass diese unabhängig und positiv mit HbA1c und CRP assoziiert sind. Die Daten aus 
Mausexperimenten sind vereinbar mit der Hypothese, dass erhöhtes Chemerin bei LD 
aus den Fettgeweben VAT und BAT stammen könnte. 
Ermutigt durch diese Ergebnisse führten wir weiterführende Analysen zu anderen 
Adipokinen bei leptindefizienter LD neben Chemerin durch. In einer weiteren Arbeit 
wurde die Regulation des insulinmimetischen, lipidsenkenden und antiatherogenen 
Adipokins FGF21 in der gleichen LD- und Kontroll-Kohorte untersucht. Die medianen 
FGF21-Serumkonzentrationen waren in den LD-Patienten (381,2 ng/l) signifikant höher 
im Vergleich zur Kontrollgruppe (231,2 ng/l). In der multiplen linearen Regressionsana-
lyse ergab sich eine unabhängige und positive Assoziation zwischen zirkulierendem 
FGF21 und den Serumtriglyceriden sowie Fibratgabe. Die LD-Mäuse zeigten ähnlich zu 
den humanen Ergebnissen signifikant erhöhte FGF21-Plasmaspiegel (4,5-fach) sowie 
zusätzlich erhöhte mRNA-Expression in verschiedenen Fettgewebedepots und der Le-
ber verglichen zu den Kontrolltieren. Diese Daten weisen nach, dass die Serumkonzent-
ration von FGF21 bei Patienten mit LD erhöht ist verglichen zu nicht-LD-Kontrollen. 
Die Daten der Tierexperimente sind vereinbar mit der Hypothese, dass Fettgewebe und 
Leber potentielle Quellen erhöhter FGF21-Produktion bei LD sind. 
Die oben zusammengefassten LD-Studien wurden in einer letzten Arbeit in derselben 
LD- und Kontroll-Kohorte um die Untersuchung von Progranulin ergänzt. Proganulin 
besitzt proentzündliche und insulinresistenzinduzierende Eigenschaften und wurde bis-
her noch nicht bei LD untersucht. Zirkulierendes Progranulin war bei LD-Patienten 
(82,9 µg/l) im Vergleich zu Kontrollen (73,6 µg/l) signifikant erhöht. In einer multivari-
aten Analyse waren die Progranulin-Serumspiegel unabhängig mit CRP assoziiert. Bei 
LD-Mäusen war die Progranulin-mRNA in allen untersuchten adipösen Geweben (vis-
zerales, subkutanes und braunes Fettgewebe) sowie im Skelettmuskel (Quadrizeps) im 
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Vergleich zu Wildtyp-Mäusen signifikant hochreguliert. Daraus kann geschlussfolgert 
werden, dass die Progranulinkonzentration im Serum von LD-Patienten erhöht ist sowie 
unabhängig und positiv mit CRP korreliert. Die Mausdaten sind vereinbar mit der Hy-
pothese, dass verschiedene Fettgewebedepots und Muskel potenzielle Quellen der er-
höhten Progranulinspiegel bei LD-Patienten sind. Zirkulierendes Chemerin, FGF21 und 
Progranulin wurden nicht signifikant beeinflusst bei 10 leptindefizienten LD-Patienten 
durch eine Leptinbehandlung über 6 Monate. 
Zusammenfassend ist Leptin ein essentielles Adipokin, welches die vaskuläre und 
metabolische Gesundheit sowie die Reproduktionsfähigkeit signifikant beeinflusst. Fein 
regulierte Leptinspiegel sind dabei für eine optimale Gesundheit erforderlich. LD ist 
eine schwere Erkrankung, bei der Betroffene subkutanes Fettgewebe in verschiedenen 
Arealen nicht ausreichend bilden können. Der damit verbundene Leptin-Mangel führt 
zu metabolischen Abweichungen insbesondere zu schwerer Insulinresistenz und Hyper-
triglyzeridämie. Die Spiegel anderer Adipokine sind bei LD ebenfalls verändert, aller-
dings in entgegengesetzter Weise zu Leptin. Dies kann ebenfalls zu den metabolischen 
Beeinträchtigungen bei LD beitragen, welche sich ironischerweise häufig nicht von 
Adipositas, einem Überschuss an Fettgewebe, unterscheiden lassen. Diese Adipokine 
umfassen Chemerin, FGF21 und Progranulin und die Wiederherstellung einer optimalen 
Balance zwischen diesen und anderen Adipokinen könnte zur Verbesserung der metabo-
lischen Gesundheit bei LD beitragen. 
 
 





1.1.1 Definition of Obesity 
Obesity, defined as an accumulation of fat mass with the potential to cause chronic 
disease [1], is one of the major health problems of the 21st century. A commonly used 
metric to assess obesity severity is the body mass index (BMI) which relates the body 
weight of an individual (in kg) to their height (in m²). The World Health Organization 
(WHO) has classified that a BMI range of 25-30 kg/m² is overweight, 30-35 kg/m² is 
class I obesity, 35-40 kg/m² is class II obesity, and above 40 kg/m² is class III obesi-
ty [2]. 
1.1.2 Prevalence 
According to recent global estimates between the years of 1975 to 2014, the average 
BMI has increased from 21.7 kg/m² to 24.2 kg/m² for men, and 22.2 kg/m² to 
24.4 kg/m² for women [3]. In 2014, as many as 266 million men and 375 million wom-
en worldwide were classified as obese [3]. Alarming numbers such as these led the 
WHO to add curtailing the rise in obesity by 2025 to their ‘Global Action Plan’ [4]. 
Despite these efforts, forecasts made by a reanalysis of 1,698 population-based studies 
predict that if the current trend remains, obesity prevalence will continue to grow [3]. 
1.2 Adipose tissue 
1.2.1 Types of adipocytes 
Excess energy is mainly stored in the form of triacylglycerides in white adipose tis-
sue (WAT). Mice are the most frequently used model to study adipose tissue but im-
portant differences exist compared to humans. For example, epididymal fat is a visceral 
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white adipose tissue (VAT) depot routinely investigated in mice which humans lack [5]. 
On the other hand, omental fat is a prominent VAT depot in humans but is barely pre-
sent in mice. The significant presence of mammary glands in mouse inguinal subcuta-
neous white adipose tissue (SAT) renders it appreciably different from the equivalent 
depot in humans [6]. Brown adipose tissue (BAT) is located in the interscapular region 
in mice and was initially thought to be present in the supraclavicular region in adult 
humans [7]. Recent gene expression studies, however, suggest that supraclavicular fat 
more resembles mouse beige adipocytes which arise in WAT (SAT and VAT) upon 
numerous stimuli including chronic cold exposure, exercise, and various endocrine fac-
tors, e.g. fibroblast growth factor (FGF) 21 [7].  
Lineage tracing studies in mice have shown that brown and white adipocytes have a 
different origin. Brown adipocytes derive from myogenic factor (Myf) 5-positive stem 
cells which are also able to differentiate into skeletal muscle or dermis cells [5,7]. In 
contrast, white and beige adipocytes are both derived from Myf5-negative stem cells 
although it is still under discussion whether they are from different precursor cells [5,7]. 
For example, a prominent theory holds that beige adipocytes are transdifferentiated 
from white adipocytes [5] while a separate lineage tracing study suggested that they 
derive from myosin heavy chain 11-positive smooth muscle precursor cells [8]. 
1.2.2 Structure and function of the different adipocytes 
Form follows function also applies for adipocytes. Brown adipocytes have an abun-
dance of mitochondria and numerous small lipid droplets. Considering the main func-
tion of brown adipocytes, i.e. thermogenesis, this cell anatomy is optimal since the large 
surface area of the small lipid droplets combined with the high number of mitochondria 
permit efficient heat production [6,9]. Beige adipocytes have a similar anatomy to 
brown adipocytes and also a similar function [9,10]. They are enriched with mitochon-
dria and have more than one lipid droplet but they are located within WAT [9,10]. 
White adipocytes are characterized by a single large lipid droplet ideal for storing a high 
amount of triglycerides (TG) allowing them to fulfil their main function, i.e. energy 
storage. Another important role of white adipocytes is hormone production. As a result, 
WAT regulates various diverse processes ranging from whole-body energy homeostasis 
to immune and reproductive function [6,9]. 
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1.3 Leptin 
1.3.1 The archetypal adipokine 
Adipokines are defined as bioactive peptides released or secreted by adipocytes [11]. 
In human adipocytes, there are more than 600 potentially secretory proteins that have 
been identified [12]. Adiponectin [13–15], vaspin [16,17], and FGF21 [18–20] are some 
of the best characterised adipokines. The first discovered adipokine, and the most im-
portant for this thesis, is leptin [21]. 
1.3.2 History of leptin 
In 1949, a spontaneous mutation appeared in a C57BL/6 mouse strain in the Jackson 
Laboratory in Main, USA [22]. These mice were called ob – short for obese – because 
they gained weight rapidly: approximately 2- to 3 times as much as normal wild-type 
mice [22]. In 1965 another spontaneous mutation appeared in the Jackson Laboratory 
but this time in the C57BL/Ks mouse strain. These mice developed a diabetic phenotype 
in addition to their obesity and were called db – short for diabetic [23]. Coleman and co-
workers performed extensive parabiosis experiments on both of these mutated mouse 
strains as well as on wild-type mice. They connected the circulation of any two mice in 
different combinations and discovered that ob/ob and wild-type mice starved to death 
when connected to a db/db mouse. Through these findings along with hypothalamic 
lesion experiments in rats, the idea came up of a circulating satiety factor produced by 
adipose tissue that interacts with the brain [24,25]. Decades later in 1994, the group of 
Jeffrey Friedman discovered the obese gene in mice [21] as well as its human homo-
logue [26] and called it leptin. Evidence soon followed that leptin is a circulating satiety 
factor that also suppresses feeding when infused directly into the brain [27–29] finally 
substantiating Coleman’s early hypothesis. 
1.3.3 Structure of leptin 
Leptin is a 167 amino acid long-chain helical protein translated from a 4.5 kb mRNA 
with a molecular weight of 16 kDa [21,30]. The leptin coding obese gene is located on 
chromosome 6 in mice and chromosome 7 in humans [21,26]. The main source of leptin 
is WAT [21] but it is also produced by BAT [31], bone marrow [32], skeletal muscle 
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[31], stomach [33], ovaries and placenta [34–36]. As circulating leptin positively corre-
lates with fat mass [37,38], it is often used as an indirect marker of adiposity. 
1.3.4 Leptin production and release from adipocytes 
Adipocytes continuously produce and secrete leptin through an endoplasmic reticu-
lum (ER)-Golgi pathway [39]. Leptin release can further be stimulated by insulin 
[40,41], amino acids [40], and short-chain fatty acids produced from bacteria in the gut 
through the action of G protein-coupled receptor 41 and 43 [42,43]. In contrast, extra-
cellular free fatty acids (FFA) have no influence [44] and intracellular FFA derived by 
lipolysis potently inhibit [45–47] leptin secretion. Together these findings suggest that 
anabolic conditions stimulate whereas catabolic conditions inhibit leptin release. In line 
with this, early studies revealed that exposure to cold and exercise both reduce leptin 
synthesis [48,49]. Conflicting data exist on the role of inflammation on leptin synthesis 
and release. The cytokine tumor necrosis factor (TNF) α stimulates leptin release in vivo 
and in vitro in an acute setting but inhibits it in a chronic one [50–52]. Recently, Gao 
and co-workers discovered an unexpected effect of iron supplementation on circulating 
leptin levels in mice and humans [53]. They found that serum leptin inversely correlates 
with serum iron in individuals with metabolic syndrome and that serum leptin in mice 
decreases substantially when adding iron to their diet. A mechanistic explanation for 
these findings was provided by experiments on cultured adipocytes which revealed that 
iron downregulates leptin expression via activation of cAMP- responsive element bind-
ing protein [53].  
1.3.5 Leptin receptor signaling 
Leptin binds to the leptin receptor (LepR) which is encoded by the db gene [54]. 
There are six known isoforms of the LepR produced through alternative mRNA splic-
ing. These isoforms are classified into short, soluble, and long forms [55–59]. The short 
forms comprise LepRa, c, d, and f which might have the function of transporting leptin 
across the blood-brain barrier [60,61]. LepRe is the soluble form whose function is not 
yet clear but it might stabilize or sequestrate circulating leptin [62–64]. The most im-
portant LepR isoform is LepRb, i.e. the long form. It is highly expressed in the hypo-
thalamus and also in numerous other tissues such as testis, kidney, liver, lung, adrenal 
gland, heart, and lymph node [65,66]. LepRb is unique compared to other LepR 
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isoforms as it possesses signaling capacity [54,67]. It belongs to the interleukin (IL)-6 
receptor family and is composed of an extracellular leptin-binding domain, a mem-
brane-spanning domain, and an intracellular domain with binding sites for several dif-
ferent signaling proteins [54,67]. In contrast, the other LepRs miss an intracellular do-
main and LepRe additionally lacks a membrane-spanning domain [55–59]. LepRb ap-
pears on the cell surface as a mixture of monomers and dimers [68]. Leptin-binding to 
the extracellular domain of LepRb leads to a conformational change of the intracellular 
domain. Janus kinase (JAK) 2 then binds to the Box 1 motif of the receptor and auto-
phosphorylates, thereby, activating itself [69]. Only then is JAK2 able to phosphorylate 
tyrosine (Tyr) residues Tyr985, Tyr1077, and Tyr1138 of LepRb. These key Tyr residues 
have Src homology 2-binding motifs that enable Src homology 2-containing proteins to 
phosphorylate and mediate signaling [70–72]. Tyr985 mediates signaling to src-
homology-2 domain protein /extracellular signal–regulated kinases (ERKs), Tyr1077 me-
diates signaling to signal-transducer-and-activator-of-transcription (STAT) 5, and 
Tyr1138 mediates signaling to STAT3 [70–75]. Tyr residue-independent signaling occurs 
via insulin receptor substrate (IRS)/phosphatidylinositol-3-kinase that mediates mam-
malian-target-of-rapamycin and 5’-adenosine monophosphate-activated protein kinase 
signaling [76–82]. All these signaling pathways combined mediate the effect of leptin 
on energy homeostasis [70–72,75,79–83]. STAT3 is a transcription factor that increases 
the expression of suppressor-of-cytokine-signaling-3 (Socs3) which binds to phosphory-
lated Tyr985, thereby, blocking JAK2 activation [84–87]. In this fashion, Socs3 fulfils its 
role as a negative signal as part of a leptin feedback loop. 
1.3.6 Central leptin sensing 
For circulating leptin to exert its effects on feeding, it must gain access to the brain. 
The relatively large size of leptin prevents it from crossing the blood-brain barrier by 
simple diffusion so other more complex transport mechanisms are in place. One pro-
posed route of entry is through hypothalamic tanycytes, a specialized type of glial cell 
uniquely located in the hypothalamic median eminence. The median eminence contains 
fenestrated capillaries which give blood-borne substances access to hypothalamic neu-
rons. Balland and co-workers provided evidence that tanycytes transport circulating 
leptin from the median eminence into the cerebrospinal fluid where it reaches hypotha-
lamic neurons [88]. The mechanism first involves the endocytosis of extracellular leptin 
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at the pial surface by tanycytic end-feet through an unknown LepR signaling pathway. 
Leptin is then shuttled to the tanycytic cell body and subsequently released into the cer-
ebrospinal fluid of the adjacent third ventricle under the influence of ERK signaling 
[88]. From the third ventricle, leptin then accesses the adjacent arcuate nucleus followed 
by deeper hypothalamic nuclei. Balland and co-workers suggested that these tanycytes 
have a checkpoint function that controls the amount of leptin that enters the brain [88]. 
An additional and more direct way of brain leptin-sensing is mediated by another 
specialized glial cell referred to as NG2-glia. These mitotically active oligodendrocyte 
precursor cells surround and maintain the dendrites of LepR expressing neurons of the 
arcuate nucleus which extend all the way into the median eminence [89]. When NG2-
glial cells are selectively ablated, arcuate nucleus LepR-expressing neurons no longer 
respond to leptin and severe obesity, equivalent to full-blown leptin-deficiency, soon 
develops [89].  
1.3.7 Leptin regulation of feeding 
In the hypothalamus where LepRs are highly expressed compared to other brain re-
gions [90,91], leptin has numerous effects. So called first-order neurons reside in the 
arcuate nucleus and are classified according to their production of proopiomelanocortin 
(POMC) which is cleaved into α-melanocyte-stimulating hormone (α-MSH), or neuro-
peptide Y (NPY)/agouti-related peptide (AgRP). Leptin has the dual effect of depolariz-
ing POMC neurons and stimulating POMC synthesis [92,93] resulting in overall in-
creases in α-MSH secretion. α-MSH binds to the melanocortin receptor 3 and melano-
cortin receptor 4 (MC4R) expressed on second-order neurons in the paraventricular hy-
pothalamus or ventromedial hypothalamus leading to suppression of food intake [94–
97]. NPY/AgRP expressing neurons block the α-MSH effect through AgRP, an inverse 
agonist of the MC4R, which results in increased food intake [98]. Leptin hyperpolarizes 
NPY/AgRP neurons thereby relieving α-MSH signaling blockade [99,100]. Leptin also 
decreases AgRP expression by STAT3-mediated nuclear exclusion of the transcription 
factor forkhead box-containing protein of the O subfamily-1 otherwise associated with a 
transcriptional co-activator [101]. Leptin also regulates the rewarding aspects of feeding 
by binding to LepRs expressed in dopaminergic neurons of the ventral tegmental area 
[102]. 
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1.3.8 Leptin regulation of body temperature 
Soon after its discovery, leptin was found to increase expression of thermogenic un-
coupling protein 1 in BAT via the sympathetic nervous system [103,104]. This led to 
the belief that leptin increases energy expenditure by stimulating BAT thermogenesis. 
Recently, this hypothesis has been challenged as leptin-deficient mice do not have com-
promised BAT function [105]. Systemic leptin treatment in these leptin-deficient ani-
mals increased body temperature solely through heat conservation in the tail [105]. Lep-
tin does, however, increase energy expenditure when co-infused into the brain with in-
sulin by stimulating WAT browning [106]. This effect seems to be mediated by hypo-
thalamic POMC neurons as simultaneously enhancing both leptin and insulin signaling 
specifically within these cells similarly leads to WAT browning, increased energy ex-
penditure, and protection from diet-induced obesity (DIO) [106].  
1.3.9 Additional functions of leptin 
As well as its critical role in regulating energy homeostasis, leptin influences many 
other processes most notably reproductive and immune function. The reproductive sys-
tem is tightly controlled by the hypothalamus-pituitary-gonadal-axis. Kisspeptin in the 
hypothalamus stimulates gonadotropin releasing hormone (GnRH) secretion, leading to 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) release from the ante-
rior pituitary gland. LH and FSH mainly target the ovaries in women and testis in men 
causing the production and release of the sex hormones estradiol/progesterone and tes-
tosterone, respectively. Leptin has an influence on two sides of this system, i.e. the hy-
pothalamus and the gonads. In the hypothalamus, leptin functions as a start signal to 
initiate puberty via stimulation of GnRH release [107]. In the gonads of both genders, 
leptin influences the maturation of germ cells which highly express the LepR [108–
111]. 
The immune system comprises an innate branch and an adaptive one with leptin in-
fluencing both. The innate immune response engenders the recruitment of various im-
mune cell types including macrophages, dendritic cells, neutrophils, eosinophils, baso-
phils, natural killer cells, and mast cells. Leptin is as a chemoattractant for all of these 
cells and consequently influences migratory capacity [112–116]. In neutrophils, eosino-
phils, and basophils, leptin delays apoptosis and extends their survival rate [116–118]. 
Leptin-deficiency decreases the ability of dendritic cells to recognize and present anti-
CHAPTER 1 26 
 
gens to T cells [119]. Leptin also influences the activity and development of natural 
killer cells [120,121] and the development of macrophages from monocytes [122]. Add-
tionally, leptin affects macrophage phagocytotic ability and expression of various pro-
inflammatory cytokines including TNFα, IL-6, and IL-18 [122–124]. Leptin stimulates 
mast cells to polarize macrophages from the pro-inflammatory M1 type to the anti-
inflammatory M2 type [125]. 
The adaptive immune system comprises T cells and B cells. T cells can be differenti-
ated into CD4+ T cells (T helper cells), CD8+ T cells (cytotoxic T cells), and regulatory 
T cells. Leptin affects proliferation, cytokine secretion, migration, and survival of T 
helper cells [126–129]. Additionally, the adipokine influences the polarization of naïve 
T cells to type 1 and type 2 T helper cells [130]. In cytotoxic T cells, leptin upregulates 
the secretion of IL-2 and interferon γ, as well as blocking the production of IL-4 and IL-
10 [131]. Leptin suppressess the proliferation of regulatory T cells [132–134] and pro-
motes the survival of B cells and, therefore, the production of antibodies [127,135]. 
1.3.10 Leptin resistance 
Leptin resistance is defined as a state of inadequate responses by neuronal circuits to 
endogenous or exogenous leptin [136]. Various causes of leptin resistance have been 
proposed such as disturbed leptin transport to the brain [137,138] and downregulation of 
hypothalamic LepRs [139]. Hypothalamic ER stress [140] has been suggested as a ma-
jor cause of leptin resistance from a high fat diet which recently has been attributed to 
activation of the small GTPase Ras-related protein 1 [141]. Contrary to these findings, 
Ottaway and co-workers describe persistent endogenous leptin action in DIO when us-
ing a LepR antagonist [142]. Remarkably, this compound was equally effective in caus-
ing weight gain in both lean and DIO mice [142] strongly suggesting that LepRs func-
tion normally in DIO. 
1.3.11 Diseases of leptin-deficiency 
Montague and co-workers described for the first time a mutation in the leptin gene in 
humans [143]. This rare genetic defect is associated with severe hyperphagia and adi-
posity [144]. Further irregularities include a higher risk of infection, hypothalamic hy-
pothyroidism, and hypogonadotropic hypogonadism [144–146]. Later complications 
include hepatic steatosis and hyperinsulinemia with the possible progression to type 2 
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diabetes mellitus [145,147]. Leptin treatment in this condition is suitable to reduce the 
symptoms of leptin-deficiency [144,146–148]. 
Lipodystrophy (LD) is another leptin-deficient state in which a lack of SAT in sever-
al depots develops. Partial and generalized LD is diagnosed depending on the severity 
of missing fat [149]. Patients generally suffer from metabolic disease including severe 
insulin resistance, diabetes mellitus, hypertriglyceridemia, hepatic steatosis, and acan-
thosis nigricans [149]. Lipodystrophic patients present with similar symptoms as obese 
patients which can partially be normalized by leptin treatment [149]. 
1.4 Comorbidities of obesity and the influence of leptin 
A major problem of obesity is that it often silently harbors other comorbidities. It is 
well established that obesity is associated with numerous chronic disease states includ-
ing hypertension, coronary heart disease, diabetes mellitus, reproductive dysfunction, 
non alcoholic fatty liver disease, pulmonary disease, various cancers, arthritis, and psy-
chological disorders [150,151]. It is perhaps less well recognized that high levels of 
leptin, such as occurs in obesity, directly contributes to some of these conditions.  
1.4.1 Hypertension 
Obesity is strongly associated with hypertension. Blood pressure increases with 
weight gain and vice-versa [152,153]. Leptin might be a mediator of this effect through 
the sympathetic nervous system [154,155]. Thus, Simonds and co-workers found that 
despite their severe obesity, ob/ob mice have normal blood pressure and that administra-
tion of leptin to normal weight mice raises blood pressure [154]. By blocking LepRs in 
the dorsomedial hypothalamus of DIO mice, hypertension was ameliorated without 
body weight changes [154]. However, these findings have not been translated into the 
human condition, i.e. human LD patients treated with leptin do not show a change in 
blood pressure [155]. 
1.4.2 Coronary heart disease 
Coronary heart disease is an atherosclerotic disease state which shows an independ-
ent association with obesity [156–159]. Findings on the association of leptin with coro-
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nary heart disease are conflicting with current meta-analyses indicating no direct rela-
tion in humans [160,161]. 
1.4.3 Type 2 diabetes mellitus 
The development of type 2 diabetes mellitus is a complex process involving different 
mechanisms. The influence of FFA on insulin resistance was suggested for the first time 
by Randle and co-workers in 1963 [162]. In obesity, there is an increase in circulating 
FFA which accumulate in the liver causing hepatic insulin resistance [163,164]. This 
leads to uncontrolled hepatic glucose production raising blood glucose levels [163,164]. 
The effect of insulin on adipose tissue is blunted by inflammatory mechanisms making 
appropriate blood glucose clearance impossible [163,164]. Another suggested cause of 
obesity-associated insulin resistance is increased resistin [165]. Resistin is an adipokine 
produced exclusively by white adipocytes which blocks insulin signaling in adipose 
tissue, thereby, reducing glucose uptake [165]. However, it remains controversial if re-
sistin functions in the same way in humans [166–169]. Ye and co-workers found that 
small molecule inhibitors of the transient receptor potential vanilloid 4 channel improve 
insulin sensitivity [170]. This ion channel is highly expressed in WAT and is activated 
by mechanical stimuli such as stretch [170]. TRPV4 knockout mice have higher insulin 
sensitivity than wild type mice on a high fat diet [170]. While not formally tested, it is 
possible that swelling adipocytes cause the opening of TRPV4 leading to defective insu-
lin receptor signaling. Leptin appears to ameliorate insulin resistance. Thus, leptin 
treatment in ob/ob mice improves glucose homeostasis without affecting body weight or 
food intake [28,171]. A similar outcome was observed in human LD patients under lep-
tin therapy [172]. 
1.4.4 Reproductive dysfunction 
Obesity has a considerable influence on reproductive function. Obese women have 
more menstrual cycle irregularities than normal weight women [173–176] and fertility 
decreases with increasing BMI [177–179]. Obese men suffer more often from erectile 
dysfunction than normal weight men [180–182] and sperm concentration and total 
sperm count decrease with increasing BMI [183–185]. At the hormonal level, some 
studies suggest that FSH and LH are downregulated in obesity [173,186–188] whereas 
others do not [189–192]. 
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1.4.5 Nonalcoholic fatty liver disease (NAFLD) 
Pathological accumulation of TG in hepatocytes is the hallmark of NAFLD ranging 
from simple steatosis to nonalcoholic steatohepatitis. Triglyceride accumulation as the 
starting point of the disease leads to inflammation and later fibrosis followed by insulin 
resistance [193]. As leptin levels rise with increasing fat mass [37,38], effects of leptin 
change from protective to deleterious during the progression of NAFLD. Overlapping 
signaling of leptin and insulin via IRS might explain the protective effect during the 
early stage [77]. At this time point the leptin effect of inhibiting hepatic glucose produc-
tion and lipogenesis prevails [194–196]. With the progress of the disease, leptin drives 
hepatic inflammation, as well as fibrosis [197,198]. 
1.5 Aims 
The work presented in this thesis aims to delineate mechanisms for the development 
of atherosclerosis and reproductive dysfunction in mice as a function of circulating lep-
tin from the subphysiological to the physiological range. In addition, insights into 
changes in the adipokines chemerin, FGF21, and progranulin are given in leptin-
deficient LD.  
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2.1 Abstract 
Objectives: Conflicting evidence concerning leptin in atherosclerosis has been pub-
lished. Furthermore, dosedependent effects of leptin on atherogenesis have not been 
studied. 
Methods: Leptin-deficient low-density lipoprotein receptor (LDLR) knockout 
(LDLR
−/−
;ob/ob) mice were treated with saline, 0.1, 0.5, or 3.0 mg/kg body weight 
(BW)/d recombinant leptin over 12 weeks starting at 8 weeks of age. Aortic root and 
brachiocephalic artery (BCA) atherosclerotic lesions were analyzed by oil red O stain-
ing. Furthermore, glucose homeostasis, lipid metabolism, and liver function including 
tissue studies were assessed in all animals. 
Results: Leptin treatment dose-dependently decreased BW in LDLR
−/−
;ob/ob mice as 
compared to saline. Mice in the 0.1 and 0.5 mg/kg BW/d groups remained heavier 
(i.e. subphysiological leptin dose) and in the 3.0 mg/kg BW/d group had similar weight 
(i.e. physiological leptin dose) as compared to non-leptin-deficient LDLR
−/−
 animals. 
Recombinant leptin dose-dependently reduced plaque area in the aortic root and the 
BCA by 36% and 58%, respectively. Leptin-mediated reductions of plasma total and 
LDL-cholesterol (Chol) remained independent predictors for aortic root plaque area. 
Chol content in liver, as well as hepatic expression of key lipid and proinflammatory 
genes, were dose-dependently regulated by leptin. Furthermore, leptin treatment in-
creased circulating levels and adipose tissue mRNA expression of the adipokine adi-
ponectin. 
Conclusions: Leptin administration within the subphysiological to physiological 
range diminishes atherosclerotic lesions. Leptin appears to mediate its antiatherogenic 
effects indirectly through reduction of hypercholesterolemia and liver steatosis, as well 
as upregulation of insulin-sensitizing and atheroprotective adiponectin. 
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2.2 Introduction 
Atherosclerosis is a lipid-driven chronic inflammatory disease and the main cause of 
cardiovascular morbidity and mortality. It has been recognized that obesity which is 
associated with an expansion of adipose tissue is a predisposing risk factor for athero-
sclerosis [1]. Adipose tissue has pleiotropic effects beyond energy storage and functions 
as an endocrine organ that secretes various bioactive molecules [2]. Proteins that are 
secreted by adipose tissue and that provide an extensive network of para- and endocrine 
communication are collectively called adipokines [3]. 
Among those, leptin is a 16 kDa adipokine which is dysregulated in obesity and in-
fluences appetite and body weight (BW) [4,5]. The adipokine is transported across the 
blood–brain barrier where it binds to specific receptors of appetite-modulating neurons 
most notably in the hypothalamus [6]. In accordance with an appetite-suppressive ef-
fect, leptin-deficient ob/ob mice, as well as human subjects, develop severe hyperphagia 
and excessive morbid obesity associated with dyslipidemia, fatty liver disease, insulin 
resistance (IR), hyperinsulinemia, and diabetes mellitus type 2 [7,8]. Administration of 
recombinant leptin in leptin-deficient mice and humans reduces food intake, BW, and 
fat mass [9,10]. 
Whereas leptin has been well-established as an appetitesuppressive adipokine, its 
role in vascular disease is far from clear since conflicting data have been published. 
Thus, various independent studies suggest that the adipokine has antiatherogenic prop-
erties. Among those, Lloyd and co-workers have shown convincingly that leptin treat-
ment ameliorates atherosclerotic disease in atherosclerosis-prone apolipoprotein 




;ob/ob) and low-density lipoprotein recep-




;ob/ob) mice [11]. Furthermore, leptin 




 mice by 
attenuating hypercholesterolemia [12]. In addition leptin-deficiency in LDLR knockout 
(LDLR
−/−
;ob/ob) mice resulted in accelerated IR-associated atherosclerosis and 
dyslipidemia as compared to LDLR
−/−
 controls [13,14]. In contrast to these findings, 
leptin treatment increased atherosclerosis and shortened the time to occlusive throm-
bosis after vascular injury [15]. Similarly, Zeadin and co-workers convincingly demon-
strated that leptin-treated animals were characterized by an increase in lesion calcifica-
tion, as well as valvular calcification, as compared to vehicle-treated controls [16]. Fur-
thermore, daily administration of recombinant leptin to ob/ob mice over 3 weeks after 
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carotid artery injury with ferric chloride dramatically increased neointimal thickness and 
the severity of luminal stenosis [17]. 
Taking these studies into consideration, leptin appears to have both pro- and anti-
atherogenic effects which might depend on the dose of the adipokine used. However, to 
the best of our knowledge dose-dependent effects of leptin on atherogenesis have not 
been assessed so far. Furthermore, it remains unclear which metabolic parameters pre-
dict the impact of the adipokine on vascular disease. To address these open points, ath-
erosclerosis-prone and leptin-deficient LDLR
−/−
;ob/ob mice were treated in the current 
study with three increasing fixed doses of recombinant mouse leptin. Leptin doses 
ranged from subphysiological levels, i.e. doses not sufficient to normalize BW, to phys-
iological levels, i.e. doses sufficient to normalize BW to LDLR
−/−
 control levels. We 
hypothesized that within this subphysiological to physiological range, leptin has potent 
antiatherogenic effects in LDLR
−/−
;ob/ob mice which are mediated through improved 
metabolic function. 
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2.3 Materials and methods 
Animal care 
The local ethics committee (Landesdirektion Sachsen, Leipzig) of the state of Saxo-
ny approved the protocol of all animal experiments (approval no. TVV37/12). Breeding 
and husbandry of homozygous male LDLR knockout and leptin-deficient 
(LDLR
−/−
;ob/ob) mice was done in our local animal facility, the Medical Experimental 
Center of the University of Leipzig. All mice were maintained in a room under patho-
gen-free conditions with controlled 21 ± 1 °C on a 12:12 h light/dark cycle 
(6 AM/6 PM). Water and chow pellet diet (V1534 from Sniff, Soest, Germany) was 




;ob/ob mice were fed ad libitum with a modified, cholesterol (Chol)-
enriched semisynthetic Clinton/Cybulsky diet (Sniff, Soest, Germany) starting at the 
age of 4 weeks. At 8 weeks of age, body weight (BW)-matched mice were separated 
into four groups and treated daily over a period of 12 weeks i.p. with saline or increas-
ing concentrations of recombinant mouse leptin (0.1 mg/kg BW, 0.5 mg/kg BW, and 
3.0 mg/kg BW) (R&D Systems, Wiesbaden—Nordenstadt, Germany). At 20 weeks of 
age, mice were sacrificed by exsanguination under deep anesthesia. 
Metabolic characterization 
BW was recorded daily and whole body composition (fat mass and lean mass) was 
determined in awake mice by using EchoMRI700 (Echo Medical Systems, Houston, 
TX) at 8, 14, and 20 weeks of age. 
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and glucose 
were analyzed by standard laboratory methods in a certified laboratory. Plasma concen-
trations of insulin (Mercodia, Uppsala, Sweden) and adiponectin (Mediagnost, Reut-
lingen, Germany) were measured by commercial ELISA systems according to the man-
ufacturers' instructions. Homeostasis model assessment of IR (HOMA-IR) was calculat-
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ed as previously described [18]. Lipoproteins were isolated by sequential ultracentrifu-
gation from 60 μl plasma at densities (d) < 1.006 g/ml (very low-density lipoprotein 
[VLDL]), 1.006 ≤ d ≤ 1.063 g/ml (low-density including intermediate-density lipopro-
tein [LDL]), and d > 1.063 g/ml (high-density lipoprotein [HDL]) as described [19]. 
Chol and triglycerides (TG) were determined in these lipid fractions enzymatically by 
using a colorimetric method (Roche, Mannheim, Germany). 
Lipids were extracted from mouse liver tissue according to ref. 20 [20]. Liver Chol 
and TG content were assessed by a colorimetric assay kit (Wako, Neuss, Germany). 
Quantification and characterization of atherosclerotic lesions 
The extent of atherosclerosis in the aortic root and brachiocephalic artery (BCA) was 
determined in a blinded fashion as recently described [21,22]. In brief, aortic lesions 
were quantified in five equidistant (200 μm) oil red O-stained sections in the region 
beginning at the end of the aortic sinus and extending into the ascending aorta [21]. Fur-
thermore, atherosclerotic lesions lumenal to the internal elastic lamina were quantified 
in three equidistant (200 μm) oil red O-stained sections per BCA. For both aortic root 
and BCA, mean lesion sizes in equidistant oil red O-stained sections were calculated for 
each animal and included in further analyses. Macrophage content of BCA lesions was 
determined by immunohistochemistry using specific CD68-antibodies (Bio-Rad AbD 
Serotec GmbH, Puchheim, Germany). All lesions were photographed and analyzed us-
ing AxioVision Rel 4.8, KS400 image analysis, and ZEN 2012 blue edition 1.1.1.0 (all 
Carl Zeiss Microscopy GmbH, Jena, Germany). 
Quantitative real-time RT-PCR analysis 
Acetyl-CoA-carboxylase-1 (ACC-1), adiponectin (Adipo), 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR), monocyte chemoattractant protein-1 
(MCP-1), and tumor necrosis factor (TNF) α mRNA expression was determined relative 
to 36B4 by quantitative real-time RT-PCR in a fluorescent temperature cycler (Roche, 
Heidelberg, Germany) as described previously [23]. Primers sequences used are sum-
marized in Supplemental Table 1. 
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Data analysis and statistics 
Data sets were analyzed using Statistical Package for Social Science, version 20 
(SPSS 20; IBM, Armonk, NY) and GraphPad Prism 6 (GraphPad Software, San Diego, 
CA). Statistical significance was assessed as indicated in the table and figure legends. A 
p-value < 0.05 was considered as statistically significant in all analyses. 
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2.4 Results 
Leptin dose-dependently reduces atherosclerotic disease 
Recombinant leptin treatment starting at 8 weeks of age dosedependently decreased BW 
in LDLR
−/−
;ob/ob mice as compared to saline over the course of 12 weeks (Figure 1A). 
At 20 weeks of age, LDLR
−/−
;ob/ob mice treated with 3.0 mg/kg BW/d had similar 
weight (physiological leptin dose) whereas the groups treated with 0.1 and 0.5 mg/kg 
BW/d remained heavier (subphysiological leptin dose) as compared to non-leptin-
deficient LDLR
−/−
 animals (Figure 1A). Leptin-mediated decreased BW was due to 
changes in fat mass (Figure 1B) but not lean mass (Figure 1C). 
Recombinant leptin reduced plaque area in the aortic root with a most pronounced and 
significant 36% reduction observed at 3.0 mg/kg BW/d as compared to control mice 
(p < 0.001) (Figure 2A). Similarly, leptin treatment significantly reduced lesion size in 
the BCA with a significant 58% decrease seen in the 3.0 mg/kg BW/d group as com-
pared to saline-treated controls (p < 0.001) (Figure 2B, D). Lesion size was significantly 
and negatively correlated to leptin dose for both aortic root and BCA (p < 0.05, data not 
shown). Furthermore, lesional macrophages as determined by CD68-positive plaque 
area was significantly lower in mice treated with 3.0 mg/kg BW/d leptin 









(p < 0.05) (Figure 2C, D). However, there was no significant difference in CD68-
positive plaque area relative to whole plaque area between the different treatment 
groups (data not shown). 
Leptin improves glucose homeostasis, lipid metabolism, and liver function 
After 12 weeks of treatment, glucose homeostasis parameters including fasting glucose, 
insulin, and HOMA-IR significantly improved with recombinant leptin as compared to 
saline (Table 1). Similarly, lipid metabolism, i.e. plasma TG and Chol, as well as TG 
and Chol content in VLDL, LDL, and HDL dose-dependently and significantly de-
creased in leptin-treated animals as compared to controls (Table 1). Concomitant with 
the decrease in circulating TG and Chol, leptin treatment significantly improved hepatic 
TG (Figure 3A) and Chol (Figure 3B) content (p < 0.05). Furthermore, leptin treatment 
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significantly improved liver function with lower AST and ALT seen in mice treated 
with the adipokine (Table 1). 
To identify potential mechanisms underlying the effect of leptin treatment, hepatic ex-
pression of key genes involved in lipid metabolism was analyzed. Hepatic mRNA ex-
pression of ACC-1 which is a key regulator of fatty acid synthesis was significantly 
down-regulated by more than 40% in leptin-treated animals (0.1 and 3.0 mg leptin/kg 
BW/d) as compared to saline-treated mice (p < 0.05) (Figure 3C). Similarly, the rate-
limiting enzyme for Chol biosynthesis HMGCR was significantly decreased in leptin-
treated animals as compared to controls (p < 0.05) (Figure 3D). Hepatic mRNA expres-
sion of the proinflammatory cytokines MCP-1 (Figure 3E) and TNFα (Figure 3F) was 
significantly down-regulated by more than 70% in animals treated with 3.0 mg leptin/kg 
BW/d as compared to saline controls (p < 0.001). In addition, further key genes in-
volved in fatty acid synthesis and transport (fatty acid synthase, CD36), in lipoprotein 
metabolisms (hepatic triglyceride lipase, lipoprotein lipase, ApoA-IV), in lipoprotein 
clearance (VLDL receptor), in fibrosis (transforming growth factor [TGF] β), and in 
inflammation (chemokine [C–X–C motif] ligand 1[Cxcl1]) were significantly regulated 
by leptin treatment as compared to controls (Supplemental Figure 1). 
Changes in total Chol predict effects of leptin on atherosclerotic disease 
Atherosclerotic lesion size at the aortic root was positively and significantly correlated 
with BW, fat mass, total TG, total Chol, VLDL-TG, VLDL-Chol, LDL-TG, LDL-Chol, 
HDL-TG, and ALT in all animals in univariate analysis (p < 0.05) (Table 2). Multivari-
ate regression analysis revealed that total Chol remained independently and positively 
associated with aortic root plaque area after adjustment for fat mass, LDL-TG, and ALT 
(p = 0.035) (Table 2). In addition, LDL-Chol (β = 0.319; p = 0.026) remained signifi-
cantly and independently associated with aortic root plaque area when included in the 
multivariate model instead of total Chol. 
Adiponectin is dose-dependently increased by leptin treatment 
Plasma adiponectin levels were significantly increased by leptin treatment in a dose-
dependent fashion from 6.7 mg/l (saline control) to 8.5 mg/l (0.1 mg/kg BW/d; 
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p < 0.05), 9.1 mg/l (0.5 mg/kg BW/d; p < 0.01), and 10.7 mg/l (3.0 mg/kg BW/d; 
p < 0.001), respectively (Figure 4A). Leptin-mediated increased circulating adiponectin 
was accompanied by upregulated mRNA expression of the adipokine in epididymal 
(Figure 4B), subcutaneous (Figure 4C), epirenal (Figure 4D), and epicardial (Figure 4E) 
but not brown (Figure 4F) adipose tissue.  
















Figure 1 (A) BW (N ≥ 19 per group LDLR
−/−
;ob/ob; N = 8 LDLR
−/−
), (B) fat mass (N ≥ 9 per group), and 
(C) lean mass (N ≥ 9 per group) over the course of treatment in leptin- and saline-treated LDLR
−/−
;ob/ob 
mice. Statistical analysis was performed by one-way ANOVA of (A) area under the curve or (B, C) raw 
data corrected for multiple testing by Bonferroni–Holm. Data are presented as means ± standard error. 
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Figure 2 Dose-dependent effects of recombinant leptin (0.1, 0.5, and 3.0 mg/kgBW/d) as compared to 
saline on (A) aortic root plaque area (N ≥ 19 per group), (B) BCA plaque area (N ≥ 10 per group), and (C) 
BCA macrophage infiltration (N ≥ 8 per group). Lesion size analyses and immunostaining for CD68 were 
performed as further described in Materials and Methods. Data are presented as means ± standard error. 
Differences were assessed by one-way ANOVA corrected by Bonferroni–Holm. * indicates p < 0.05, 
** p < 0.01, *** p < 0.001. (D) Representative oil red O (ORO)- and CD68-stained BCA sections in 
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Figure 3 Effect of leptin treatment on hepatic function in vivo. Hepatic (A) TG and (B) Chol content, as 
well as (C–F) mRNA expression of (C) ACC-1, (D) HMGCR, (E) MCP-1, and (F) TNFα in mice treated 
with saline or 0.1, 0.5, and 3.0 mg/kgBW/d recombinant leptin relative to 36B4 (N ≥ 7). Data are present-
ed as means ± standard error. Differences were assessed by one-way ANOVA corrected by Bonferroni–
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Figure 4 Effect of leptin treatment (0.1, 0.5, and 3.0 mg/kg BW/d) on (A) circulating adiponectin (N ≥ 19 
per group) and (B–F) adiponectin mRNA expression relative to 36B4 (N ≥ 6 per group) in (B) epididymal 
(Epidy AT), (C) subcutaneous (SAT), (D) epirenal (Epir AT), (E) epicardial (Epic AT), and (F) brown 
(BAT) adipose tissue. Data are presented as means ± standard error. Differences were assessed by one-
way ANOVA corrected by Bonferroni–Holm. * indicates p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001. 
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Leptin (mg/kg BW/d) 
0.1 0.5 3.0 
Glucose homeostasis 
Glucose (mmol/l) 23.2 ± 1.2 18.4 ± 0.7
1
 20.4 ± 1.3 16.7 ± 1.2
1
 
Insulin (µg/l) 3.3 ± 0.5 1.0 ± 0.1
1
 0.5 ± 0.1
1,2
 1.0 ± 0.3
1
 
HOMA-IR 77.6 ± 11.0 19.5 ± 2.3
1
 12.7 ± 2.6
1
 14.0 ± 3.8 
1
 
     
Lipid metabolism 
Total TG (mg/dl) 784.7 ± 19.8 690.7 ± 48.1 487.0 ± 55.4
1
 338.8 ± 54.1
1,2
 
Total Chol (mg/dl) 1693.7 ± 24.3 1547.8 ± 65.4 1401.6 ± 79.2 1049.5 ± 83.2
1,2,3 
VLDL-TG (mg/dl) 605.8 ± 16.2 527.9 ± 39.9 363.8 ± 48.5
1
 249.1 ± 47.8
1,2
 
VLDL-Chol (mg/dl) 537.7 ± 8.5 479.2 ± 31.3 394.4 ± 37.7 292.8 ± 41.8
1,2
 
LDL-TG (mg/dl) 154.1 ± 6.9 143.3 ± 10.2 106.2 ± 7.5
1,2
 77.8 ± 7.3
1,2
 
LDL-Chol (mg/dl) 1050.6 ± 19.1 983.5 ± 36.1 911.5 ± 47.9 663.3 ± 47.6
1,2,3
 
HDL-TG (mg/dl) 24.9 ± 2.8 19.5 ± 2.2 17.0 ± 1.9 11.8 ± 1.5
1,2 
HDL-Chol (mg/dl) 105.5 ± 7.3 85.1 ± 4.3 95.7 ± 3.6 93.5 ± 5.1
1,2
 
     
Liver function 
AST (µkat/l) 7.3 ± 0.9 3.9 ± 0.9 2.8 ± 0.4
1
 2.4 ± 0.5
1
 
ALT (µkat/l) 5.6 ± 0.4 3.5 ± 0.4 1.8 ± 0.2
1,2
 1.0 ± 0.3
1,2,3
 
Table 1 Glucose homeostasis, lipid metabolism, and liver function in LDLR−/−;ob/ob mice treated over 
12 weeks i.p. with saline or recombinant leptin (0.1, 0.5, and 3.0 mg leptin/kg BW/d). ALT, alanine ami-
notransferase; AST, aspartate aminotransferase; BW, bodyweight; Chol, cholesterol; HDL, high-density 
lipoprotein; HOMA-IR, homeostasismodel assessment of insulin resistance; LDL, low-density lipopro-
tein; TG, triglycerides; VLDL, very low-density lipoprotein; means ± standard errors are shown. p < 0.05 




0.1 mg leptin/kg BW/d; 
3
0.5 mg leptin/kg BW/d using one-way ANOVA cor-
rected by Bonferroni–Holm. 
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 Univariate correlations Multivariate regression analysis 
 r/p β p 
BW (g, lg) 0.492/<0.001* - - 
Fat mass (%, lg) 0.565/<0.001* 0.219 0.267 
Lean mass (%, lg) 0.132/0.267 - - 
Glucose (mmol/l) 0.130/0.274 - - 
Insulin (µg/l, lg) 0.162/0.163 - - 
HOMA-IR (lg) 0.184/0.118 - - 
Total TG (mg/dl, lg) 0.486/<0.001* - - 
Total Chol (mg/dl, lg) 0.587/<0.001* 0.309 0.035† 
VLDL-TG (mg/dl, lg) 0.460/<0.001* - - 
VLDL-Chol (mg/dl, lg) 0.517/<0.001* - - 
LDL-TG (mg/dl) 0.565/<0.001* 0.233 0.136 
LDL-Chol (mg/dl, lg) 0.582/<0.001* - - 
HDL-TG (mg/dl, lg) 0.266/0.022* - - 
HDL-Chol (mg/dl, lg) -0.076/0.522 - - 
AST (µkat/l, lg) 0.060/0.704 - - 
ALT (µkat/l, lg) 0.454/<0.001* -0.011 0.952 
Table 2 Univariate correlationswith aortic root plaque area in all animals and multivariate regression 
analysis between plaque area (dependent variable) and fat mass (lg), total Chol (lg), LDL-TG, and ALT 
(lg). For covariates (e.g. total Chol and LDL-Chol), only the parameter with the strongest association in 
univariate analysis was included in the multivariate model. Non-normally distributed variables were loga-
rithmically transformed (lg) prior to uni- and multivariate testing. r- and p-values, as well as standardized 
β-coefficients and p-values are given, respectively. Abbreviations are indicated in Table 1. * indicates 
significant correlation as assessed by Pearson's correlation method. † indicates significant correlation in 
multivariate analysis. 
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2.5 Discussion 
In the current study, we show for the first time that leptin administration within the 
subphysiological to physiological range reduces atherosclerotic lesions in mice. All lep-
tin concentrations used significantly decrease BW of LDLR
−/−
;ob/ob mice. The 
3.0 mg/kg BW/d dosage group normalizes BW to LDLR
−/−
 control levels (physiological 





 animals (subphysiological dose) at 20 weeks of age. It is interesting to 
note in this context that most studies demonstrating beneficial effects of leptin on ather-
ogenesis have also administered leptin in the subphysiological to physiological range. 
Thus, Lloyd and co-workers adjust all leptin doses within the subphysiological range to 









;ob/ob mice [11]. In their hands, recombinant leptin doses with 
beneficial effects on atherogenesis range from 0.02 to 0.12 mg/kg BW/d [11]. Similarly, 





 mice [12]. In contrast, most reports demonstrating proather-
ogenic effects of recombinant leptin use higher doses of the adipokine as compared to 
these reports and our current study. Thus, the two studies demonstrating increased le-
sion size [15], as well as lesion calcification [16], in ApoE
−/−
 mice use recombinant lep-
tin at 125 μg/d. These published findings and our current results are in agreement with 
the hypothesis that the effect of leptin on atherogenesis is dose-dependent. 
Mechanisms by which subphysiological to physiological leptin doses improve ather-
ogenesis have been further assessed in the current study and in published reports. Our 
data and published evidence suggest that leptin mediates its antiatherogenic effects indi-
rectly through induction of better metabolic control in leptin-deficient states. Thus, lep-
tin dose-dependently improves parameters of glucose homeostasis, lipid metabolism, 
and liver function in our current study. Furthermore, total Chol and LDL-Chol remain 
independent and positive predictors of aortic root lesion size. These findings are in 













[12], mice where 
reduction in atherosclerotic lesion size is closely linked to improved plasma Chol con-
centrations. Leptin-mediated improvements in Chol metabolism are accompanied by 
decreased hepatic Chol content, as well as mRNA expression of the rate-limiting en-
zyme in Chol synthesis HMGCR, in the current study similar to published re-
ports [24-26]. Furthermore, leptin reduces local hepatic inflammation by downregula-
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tion of proinflammatory cytokines including Monocyte chemoattractant protein-1, 
TNFα, and Clxc1, as well as the fibrosis marker TGFβ. Steatosis and associated in-
flammation, as well as fibrosis, are independent predictors of occurrence and progres-
sion of atherosclerosis [27,28]. Taking these findings into consideration, improved he-
patic cholesterol metabolism appears as a key factor contributing to the antiatherogenic 
effects of subphysiological to physiological doses of leptin. Furthermore, nitric oxide 
release triggered by leptin that counteracts in part the sympathetic activation might be 
an additional mechanism for the antiatherogenic effects of the adipokine at subphysio-
logical to physiological concentrations [29]. Moreover, the lipolytic effect of leptin 
which is located at the adenylate cyclase/Gi proteins level and opposes the tonic inhibi-
tion of endogenous adenosine in white fat cells might also contribute to decreased ath-
erogenesis in leptin-treated animals [30]. Clearly, more work is needed to better eluci-
date mechanisms for the antiatherogenic effects of subphysiological to physiological 
concentrations of the adipokine leptin. 
In the current study, leptin increases circulating levels of the adipokine adiponectin 
besides its beneficial effects on lipid metabolism. Elevated plasma adiponectin levels 
are probably caused by induced mRNA expression of the adipokine in epididymal, sub-
cutaneous, epirenal, and epicardial adipose tissue. Adiponectin possesses potent anti-
atherogenic activities which are mediated through its vasodilator, antiapoptotic, anti-
inflammatory, and antioxidative activities in cardiac and vascular cells [31]. Further-
more, adiponectin decreases IR in insulin-sensitive tissues including muscle, adipose 
tissue, and liver [3]. Elevation of circulating adiponectin by either adenoviral-mediated 
or transgenic overexpression decreases atherogenesis in ApoE
−/−
 mice [32,33]. Taking 
these results into consideration, the atheroprotective effects of subphysiological to phys-
iological leptin doses might be mediated in part by induction of adiponectin. 
It needs to be pointed out that our study does not rule out direct proatherogenic ef-
fects of leptin especially at supraphysiological doses. It is interesting to note in this con-
text that two studies demonstrating proatherogenic effects of leptin use the adipokine at 
higher doses as compared to our study, i.e. 125 μg/d [15,16]. Mechanisms by which 
leptin might induce atherogenesis include activation of the sympathetic nervous system, 
stimulation of cholesterol esters accumulation in foam cells, upregulation of proinflam-
matory cytokines, chemokines, and reactive oxygen species, as well as induction of en-
dothelin-1, platelet hyperaggregability, and vascular smooth muscle cell hypertro-
phy [34,35]. Furthermore, leptin and its receptor are expressed within mice and human 
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atherosclerotic plaques [36,37]. Moreover, convincing evidence has been presented that 
at high concentrations leptin increases the levels of other cardiovascular risk factors 
such as circulating fibrinogen [38]. Based on these studies and our current findings, it 
can be hypothesized that subphysiological to physiological concentrations of leptin are 
atheroprotective by indirect mechanisms whereas leptin at higher doses might have di-
rect proatherogenic effects. However, two well-controlled studies also demonstrate 
proatherogenic effects of leptin at lower doses [17,39]. Clearly, more work is needed to 
better elucidate mechanisms for pro- and antiatherogenic effects of the adipokine leptin. 
Taken together, leptin administration within the subphysiological to physiological 
range diminishes atherosclerotic disease. Leptin appears to mediate its antiatherogenic 
effects indirectly through reduction of hypercholesterolemia and liver steatosis, as well 
as upregulation of insulin-sensitizing and atheroprotective adiponectin. 
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Supplemental Figure 1 Effect of leptin treatment on mRNA expression of (A) fatty acid synthase (FAS), 
(B) CD36, (C) hepatic triglyceride lipase (LIPC), (D) lipoprotein lipase (LPL), (E) ApoA IV, (F) VLDL 
receptor (VLDLR), (G) TGFβ, and (H) chemokine [C-X-C motif] ligand 1 (Cxcl1) in mice treated with 
saline or 0.1, 0.5, and 3.0 mg/kg BW/d recombinant leptin relative to 36B4 (N ≥ 7). Data are presented as 
means ± standard error. Differences were assessed by one-way ANOVA corrected by Bonferroni–Holm. 
*indicates p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001  
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Gene Forward sequence Reverse sequence 
ACC-1 AGCATGTCTGGCTTGCACCTAGTA CTGCTGCAATACCATTGTTGGCGA 
Adipo AAGGACAAGGCCGTTCTCT TATGGGTAGTTGCAGTCAGTTGG 
HMGCR GTCCAATTTGGCAGCTCAGCCATT TCCAGCGACTATGAGCGTGAACAA 
MCP-1 GCCCCACTCACCTGCTGCTACT CCTGCTGCTGGTGATCCTCTTGT 
TNFα GTCCCCAAAGGGATGAGAAGT GCTCCTCCACTTGGTGGTTT 
36B4 AAGCGCGTCCTGGCATTGTCT CCGCAGGGGCAGCAGTGGT 
Supplemental Table 1 Primer sequences 5’-3’ used for quantitative real-time RT-PCR analysis. 
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3.1 Abstract 
Obesity has recently been linked with reduced fertility, and the mechanisms under-
pinning this effect are currently unknown. The adipokine leptin is dysregulated in obesi-
ty and affects reproductive tracts; therefore, we investigated the dose-dependent effects 
of leptin on Leydig cell function and spermatogenesis. Eight-week-old leptin-deficient 
obese (ob/ob) male mice were treated with subphysiological (0.1 or 0.5 mg/kg body 
weight [BW]/d) or physiological (3.0 mg/kg BW/d) doses of leptin or saline for 
12 weeks (chronic treatment) or 72 hours (acute treatment). We then evaluated male 
reproductive function markers. Mean testis weight increased significantly in the 
0.1 mg/kg BW/d and 3.0 mg/kg BW/d groups compared with saline controls (both 
p < 0.05). Intratesticular testosterone levels relative to testis weight significantly in-
creased in the 0.5 mg/kg BW/d group compared with saline controls (p < 0.05). Follicle-
stimulating hormone levels increased in a dose-dependent manner with leptin treatment, 
whereas luteinizing hormone levels did not change. Leptin treatment significantly up-
regulated both mRNA and protein expression of the steroidogenic enzyme cytochrome 
P450 17A1. Spermatogenesis improved in leptin-treated animals. Significantly more 
seminiferous tubules were observed in stages I-VIII (p < 0.01), and there were fewer 
abnormal seminiferous tubule structures (p < 0.01). Acute treatment with physiological 
leptin doses partially improved male reproductive markers without changing BW. Ad-
ministration of subphysiological to physiological doses of leptin improves Leydig cell 
function and spermatogenesis. 
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3.2 Introduction 
Obesity plays a major role in the development of metabolic syndrome-related 
comorbidities such as hypertension, dyslipidemia, and insulin resistance, which reduce 
quality of life and life span [1]. There is mounting evidence supporting the hypothesis 
that obesity adversely affects male reproductive function [2,3]. It has been shown that 
male obesity negatively impacts sperm motility [4], alters acetylation status in late 
round spermatids, and is correlated with increased DNA damage in germ cells [5]. Sev-
eral epidemiological studies have demonstrated a negative correlation between obesity 
measures and testosterone levels [6–8]. However, the factors linking obesity and fertili-
ty have yet to be elucidated. 
Adipokines, proteins secreted from adipocytes, become dysregulated when weight 
increases, and have been implicated as key factors in various obesity-related complica-
tions [9]. Dysregulation of adipokines could also contribute to the molecular mecha-
nisms behind obesity-related male infertility [10]. The most prominent adipokines, in-
cluding adiponectin, leptin, and their associated receptors, have been isolated in male 
reproductive tracts [10–13]. Adiponectin has general insulin-sensitizing and atheropro-
tective roles, but at the testicular level, it supports male reproductive function by pro-
moting steroidogenesis [13]. Leptin, when administered to leptin-deficient mice and 
humans, generally reduces food intake, body weight (BW), and fat mass [14,15], and 
improves fertility in rodents [16,17]. 
Treatment with leptin produces different effects on metabolic syndromes depending 
on the concentration used. At subphysiological levels (i.e., doses not sufficient to nor-
malize BW) to physiological levels (i.e., doses sufficient to normalize BW), leptin ad-
ministration improves atherosclerotic disease in leptin-deficient mice compared with 
littermate controls [18]. Other studies have confirmed the atheroprotective effects of 
low-dose leptin treatment [19,20]. In contrast, high doses of leptin consistently aggra-
vate atherosclerotic disease [21,22]. Subphysiological doses of leptin also stimulate oth-
er biological processes, such as lipolysis [23]. Notably, leptin demonstrates dose-
dependent effects on hypothalamic-pituitary fertility regulation. Subnanomolar concen-
trations induce gonadotropin-releasing hormone (GnRH) secretion from rat median em-
inence-arcuate nuclear explants ex vivo; however, at micromolar concentrations, the 
stimulatory effect is lost [24]. Both low leptin levels, such as those seen in congenital 
leptin-deficiency and lipodystrophy, and high leptin levels, observed in obesity, are as-
sociated with impaired fertility [3,25–28]. 
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To date, the dose-dependent effects of adipokines on in vivo testicular functions, 
such as steroidogenesis and spermatogenesis, have not been elucidated. To address this 
knowledge gap, we treated leptin-deficient mice with mouse recombinant leptin using 
fixed doses ranging from subphysiological to physiological levels. We hypothesized 
that subphysiological to physiological levels of leptin would improve male reproductive 
function in a dose-dependent manner by affecting both steroidogenesis through Leydig 
cell function and spermatogenesis through germ cell and Sertoli cell function. 
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3.3 Materials and methods 
Animal care 
The local ethics committee of the state of Saxony (Regierungspräsidium Leipzig) ap-
proved all animal-experiment protocols (approval no. TVV37/12). All animal experi-
ments were performed in the Medical Experimental Center at the University of Leipzig. 
All mice were maintained under pathogen-free conditions at 21 ± 1°C on a 12 hour 
light/dark cycle (6 AM–6 PM). The study presented here was part of a larger study elu-
cidating dose-dependent effects of leptin on atherogenesis [18] using ob/ob mice on a 
low-density lipoprotein (LDL) receptor knockout background. 
Animal treatment 
Treatments in ob/ob mice started at 8 weeks of age because male reproductive matu-
ration is complete and gonadotropin levels are stable at this time point [29]. We per-
formed two sets of treatment experiments. To model chronic leptin administration, BW-
matched male mice were separated into four groups and treated daily over a period of 
12 weeks. We administered saline or one of three recombinant mouse leptin concentra-
tions (0.1 mg/kg BW, 0.5 mg/kg BW, or 3.0 mg/kg BW; R&D Systems, Wiesbaden-
Nordenstadt, Germany) intraperitoneally (i.p.). To model leptin administration over an 
acute time frame, BW-matched male mice were separated into two groups, and i.p. sa-
line or 3.0 mg/kg BW recombinant mouse leptin was administered daily over a period 
of 72 hours. At the end of their respective treatment periods, mice were sacrificed by 
exsanguination under deep anesthesia with ketamine (WDT, Garbsen, Germany) und 
xylazine (Bayer Health Care, Wuppertal, Germany). 
Measurement of Follicle-stimulating hormone (FSH), luteinizing hormone 
(LH), and intratesticular testosterone 
FSH and LH were quantified in plasma samples using a commercial multiplex en-
zyme-linked immunosorbent assay (ELISA) (Merck Millipore, Darmstadt, Germany). 
Steroids were extracted from mouse testis using the protocol described by Robertson et 
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al. [30]. Briefly, the tissue was weighed and sonicated. Testosterone was extracted with 
ethyl acetate (Sigma Aldrich, Taufkirchen, Germany) and evaporated overnight. The 
pellet was resuspended in phosphate buffered saline, and intratesticular testosterone was 
assessed using ELISA (DRG Instruments GmbH, Marburg, Germany) according to the 
manufacturer´s instructions. 
Histological analysis 
Testes were fixed in 4% paraformaldehyde and processed for paraffin-embedding 
and sectioning. We evaluated the effect of leptin treatment on the spermatogenic pro-
cess by assessing the morphology of seminiferous tubules. Different spermatogenic 
stages were identified based on cell types defined by size, shape, and location in the 
seminiferous tubules as described by Russel and colleagues [31]. Ten randomly selected 
fields of hematoxylin/eosin-stained testis slices were evaluated per animal. Fifty tubules 
were analyzed per slide at 20× magnification using a Nikon microscope (Nikon Instru-
ments Inc., Melville, NY). 
We quantified the Leydig cell marker cytochrome P450 (CYP) 17A1 by performing 
immunohistochemistry on paraffin-embedded testis sections using a CYP17A1-specific 
primary antibody (Santa Cruz Biotechnology, Heidelberg, Germany: catalog number: 
sc66850; dilution: 1:100) and the Dako Real EnVision detection system (Dako, Ham-
burg, Germany) according to the manufacturer’s instructions. No fewer than five ran-
domly selected fields were evaluated per animal. All slides were photographed and ana-
lyzed manually by two independent evaluators using a Zeiss Axioskop microscope (Carl 
Zeiss Microscopy GmbH, Jena, Germany) along with Cell F image analysis (Olympus, 
Hamburg, Germany) and NIH Image/ImageJ (http://imagej.nih.gov/ij/). 
Quantitative real-time RT-PCR analysis 
Cyp17a1, Cyp11a1, 17β-hydroxysteroid dehydrogenase B3 (Hsd17b3), insulin-like 
peptide 3 (Insl3), luteinizing hormone receptor (Lhr), and steroidogenic acute regulatory 
protein (Star) mRNA levels were determined relative to acidic ribosomal phosphopro-
tein P0 (36B4) using quantitative real-time RT-PCR and a fluorescent temperature cy-
cler (Roche, Heidelberg, Germany) as described previously [32]. Primer sequences used 
are summarized in Supplemental Table 1.  
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Data analysis and statistics  
Data sets were analyzed using GraphPad Prism 6 (GraphPad Software, San Diego, 
CA). The statistical significance of the leptin treatment groups compared with saline 
controls was assessed using the Mann-Whitney U test and p < 0.05 was considered sta-
tistically significant in all analyses. 
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3.4 Results 
Leptin increases testis weight, intratesticular testosterone, and FSH 
Chronic leptin treatment significantly decreased mean BW in a dose-dependent man-
ner from 50.4 g in saline-treated controls to 36.5 g in the 0.1 mg leptin/kg BW/d group, 
30.9 g in the 0.5 mg leptin/kg BW/d group, and 25.9 g in the 3.0 mg leptin/kg BW/d 
group at 12 weeks (p < 0.0001) (Figure 1A and Supplemental Figure 1A). The leptin-
mediated decrease in BW was due to a significant decline in total fat mass rather than 
total lean mass (Supplemental Figure 1, B and C). Mean testis weight increased signifi-
cantly in the 0.1 mg/kg BW/d and 3.0 mg/kg BW/d groups (95.1 mg and 92.4 mg, re-
spectively) compared with 86.5 mg in the saline controls (both p < 0.05) (Figure 1B).  
Testis weight relative to BW significantly increased in a dose-dependent manner in 
all leptin treatment groups compared with saline controls (p < 0.0001) (Figure 1C). In-
tratesticular testosterone relative to testis weight significantly increased to 491.5 ng/g in 
the 0.5 mg/kg BW/d group compared with 279.5 ng/g in saline controls (p < 0.05) (Fig-
ure 1D). There was also a trend (p = 0.057) towards higher intratesticular testosterone in 
the 3.0 mg/kg BW/d group (573.2 ng/g) (Figure 1D).  
Plasma FSH levels significantly increased in a dose-dependent manner following 
leptin treatment from 1273 pg/ml in the saline controls to 1790 pg/ml in the 0.5 mg/kg 
BW/d group (p < 0.01) and 1954 pg/ml in the 3.0 mg/kg BW/d group (p < 0.05) (Fig-
ure 1E). In contrast, plasma LH levels were not significantly different between leptin-
treated and control animals (Figure 1F). 
Leptin increases markers of Leydig cell function 
We performed a comprehensive analysis of steroidogenic gene expression to identify 
the molecular basis for increased testosterone production by Leydig cells following lep-
tin treatment. Lhr expression is necessary for stimulating testosterone production in 
Leydig cells. Lhr was upregulated approximately 2-fold in the 3.0 mg/kg BW/d group 
compared with the saline group (p < 0.001) (Figure 2A). Star plays a central role in ini-
tiating and supporting steroidogenesis in Leydig cells. Star was upregulated by 1.9-fold 
in the 0.5 mg/kg BW/d group (p < 0.01) and 1.8-fold in the 3.0 mg/kg BW/d group 
(p < 0.05) (Figure 2B). Both testicular Cyp17a1 (Figure 2C) and Cyp11a1 (Figure 2D) 
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mRNA expression showed dose-dependent upregulation as high as 2.9-fold in the 
3.0 mg/kg BW/d group compared with saline controls (p < 0.01). Expression of 
Hsd17b3, a key steroidogenic enzyme, increased 1.5-fold in the 0.5 mg/kg BW/d group 
(p < 0.05) and 1.9-fold in the 3.0 mg/kg BW/d group (p < 0.001) compared with saline 
controls (Figure 2E). Insl3, a marker of Leydig cell function, was upregulated 1.7-fold 
in the 0.5 mg/kg BW/d group compared with saline controls (p < 0.05) (Figure 2F). 
Consistent with the transcriptional data, immunohistochemical data showed the mean 
percent CYP17A1-positive area was 1.4-fold higher in the 3.0 mg/kg BW/d group than 
in saline controls (p < 0.05), indicating increased testicular CYP17A1 protein synthesis 
(Figure 3A). 
Leptin improves markers of spermatogenesis 
To assess whether improved Leydig cell function following leptin treatment is asso-
ciated with improved spermatogenesis markers, we evaluated testes morphology. The 
lumen of seminiferous tubules appeared hollow in saline controls compared with the 
3.0 mg/kg BW/d group (Figure. 3B). Leptin significantly increased the percentage of 
seminiferous tubules in stages I through VIII, (i.e., tubules containing spermatogonia, 
spermatocytes, round spermatids, and elongated spermatids) from 41.6% in controls to 
87.2% in the 3.0 mg/kg BW/d group (p < 0.01) (Figure. 3C). There was no significant 
difference between control and leptin-treated animals in the percentage of seminiferous 
tubules in stages IX through XII (i.e., only excluding round spermatids present) (data 
not shown). Abnormal tubules were classified as having one of three different patholo-
gies: a) premeiotic arrest (only spermatogonia), b) meiotic arrest (no round or elongated 
spermatids), and c) postmeiotic arrest (no elongated spermatids). The fraction of ab-
normally structured seminiferous tubules significantly decreased in a dose-dependent 
manner following leptin treatment from 37.6% in control animals to 7.6% in the 
0.5 mg/kg BW/d group (p < 0.05) and 2.0% in the 3.0 mg/kg BW/d group (p < 0.01) 
(Figure 3D). 
We also investigated mRNA levels of Sertoli cell markers, including inhibin B (In-
hbb), sex determining region Y-box (Sox) 9, and vimentin (Vim), as well as germ cell 
markers, including DEAD box protein (Ddx) 4, kit oncogene (Kit), and cAMP respon-
sive element modulator (Crem). None of these markers were significantly affected by 
leptin treatment (Supplemental Figure 2). 
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Acute leptin treatment improves markers of male gonadal function 
independent of body weight changes and metabolic improvements 
Leptin-deficient ob/ob mice were treated daily with physiological leptin doses 
(3.0 mg/kg BW) over 72 hours to assess if leptin influences male gonadal function in-
dependent of body weight changes and metabolic improvements. Acute leptin admin-
istration had no significant effect on body weight, testis weight, HbA1c, fasting glucose, 
or cholesterol and triglycerides, including the LDL, high-density lipoprotein (HDL), and 
very-low-density lipoprotein (VLDL) fractions (Supplemental Figure 3). However, 
treatment with leptin for 72 hours induced a 2-fold increase in Lhr mRNA levels com-
pared with controls (p < 0.01) (Figure 4A). Testicular mRNA expression of Cyp17a1 
(Figure 4C), Cyp11a1 (Figure 4D), and Hsd17b3 (Figure 4E), all of which are down-
stream targets of LHR, was significantly upregulated following leptin administration 
compared with saline controls (all p < 0.05). There was a trend towards increased Star 
mRNA levels (p = 0.10) (Figure 4B). No change was observed in Insl3 mRNA levels 
(Figure 4F) or plasma FSH and LH levels (Figure 4, G and H) under these conditions. 
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Figure 1 (A) Body weight (BW), (B) absolute testis weight, (C) testis weight relative to BW, (D) in-
tratesticular (lT) testosterone relative to testis weight, and plasma (E) FSH and (F) LH in chronic 
(12 week) leptin administration groups. Data are presented as mean ± standard error and represent N ≥ 6 
per group. * indicates p < 0.05, ** p < 0.01, **** p < 0.0001 compared with saline controls. 
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Figure 2 (A) Lhr, (B) Star, (C) Cyp17a1, (D) Cyp11a1, (E) Hsd17b3, and (F) lnsl3 mRNA expression in 
testis in chronic (12 week) leptin administration groups. Quantification of mRNA was performed as de-
scribed in Materials and methods section. Data are presented as mean ± standard error and represent N ≥ 7 
per group. * indicates p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with saline con-
trols. 
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Figure 3 (A) Testicular CYP17A1 protein synthesis, (B) hematoxylin and eosin-stained testis sections, 
(C) percent tubules in stages I-VIII (containing all spermatogenic stages including spermatogonia, sper-
matocytes, round spermatids, and elongated spermatids), and (D) percent abnormal tubules, defined as 
tubules undergoing spermatogenic arrests: (a) premeiotic arrest (only spermatogonia), (b) meiotic arrest 
(no round or elongated spermatids), or (c) postmeiotic arrest (no elongated spermatids present) in ob/ob 
mice treated with saline or leptin over 12 weeks. Data are presented as mean ± standard error and repre-
sent N ≥ 4 per group. Representative images are shown in (A) and (B). * indicates p < 0.05, ** p < 0.01 
compared with saline.  
CHAPTER 3 69 
 
 
Figure 4 Influence of acute leptin administration (3.0 mg/kg BWd for 72 hours) on (A) Lhr, (B) Star, (C) 
Cyp17a1, (D) Cyp11a1, (E) Hsd17b3, and (F) Insl3 mRNA expression in testis and plasma (G) FSH and 
(H) LH levels. Quantification of mRNA expression and plasma FSH and LH concentrations was per-
formed as described in the Materials and Methods section. Data are presented as mean ± standard error 
and represent N ≥ 6 per group. * indicates p < 0.05, ** p < 0.01 compared with saline controls.  
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3.5 Discussion 
Here we show for the first time that administration of subphysiological to physiolog-
ical levels of leptin improves male gonadal function markers in leptin-deficient mice in 
a dose-dependent manner. Our findings suggest that leptin exposure increases in-
tratesticular testosterone levels and testis weight. These data also show that testis weight 
increased despite the animals’ weight loss following leptin treatment. These findings are 
consistent with previous work by Mounzih and colleagues who demonstrated that testis 
weight is significantly increased in leptin-deficient rodents following 60 days of leptin 
treatment [17]. In this study, we aimed to elucidate the mechanisms by which leptin 
improves Leydig cell function. We show that leptin treatment induces Lhr gene expres-
sion in the testis. Because LH stimulates testosterone production and supports steroido-
genic genes expression in Lhr-expressing Leydig cells [33], we hypothesize that leptin 
improves steroidogenesis through LH response in Leydig cells. We demonstrate that 
leptin induces mRNA expression of Star, which regulates the first steps of steroidogen-
esis [34], as well as genes associated with the sequential conversion of steroid precur-
sors to testosterone, including Cyp17a1, Cyp11a1, and Hsd17b3 [35], in a dose-
dependent manner. Leptin treatment induces Insl3, also known as Leydig insulin-like 
hormone, which is an indicator of differentiation status and functional Leydig cells [36]. 
Given our results and those of previous studies, it seems likely that leptin improves 
Leydig cell function by inducing key steroidogenic enzymes. Additionally, these im-
provements are probably not dependent on metabolic and body weight changes because 
Lhr, Cyp17a1, Cyp11a1, and Hsd17b3 were upregulated in ob/ob mice treated with lep-
tin for 72 hours. These in vivo results are consistent with those seen in an in vitro mouse 
Leydig cell model (MA-10 cells, data not shown). In that system, leptin significantly 
upregulated Lhr mRNA by 1.4-fold, providing further evidence that leptin directly in-
duces Lhr expression in Leydig cells. 
In the chronic leptin administration experiments, ob/ob mice treated with leptin at 
subphysiological (0.5 mg/kg BW/d) to physiological (3.0 mg/kg BW/d) levels for 
12 weeks showed a significant increase in plasma FSH levels, whereas plasma LH lev-
els remained relatively unchanged. These results are consistent with those of Barash and 
colleagues in which ob/ob animals treated with leptin over 2 weeks had significantly 
increased FSH, but not LH, levels [16]. Unlike the chronic experiments, acute leptin 
administration did not affect plasma FSH and LH concentrations in ob/ob mice despite 
the significant change in Lhr, Cyp17a1, Cyp11a1, and Hsd17b3 mRNA expression. 
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These findings support the hypothesis that some of the recovery observed in the chronic 
leptin administration group could be due to recovery of gonadotropic function rather 
than the direct effects of leptin on Leydig cells alone. Furthermore, chronic leptin-
mediated decreases in body fat, seen with both subphysiological and physiological lep-
tin levels, could also play a role in reproductive outcomes. 
The signaling mechanisms by which subphysiological to physiological levels of lep-
tin mediate their effects on male gonadal function need to be investigated in future stud-
ies. Leptin is known to act through well-established pathways and expression of targets, 
including signal transducer and activator of transcription 3 and p44/42 mitogen-
activated protein kinase phosphorylation, and suppressor of cytokine signaling-3 [37]; 
however, in our study, these targets were not upregulated in the testis following either 
chronic or acute leptin treatment (data not shown). These data indicate that leptin might 
mediate its effects on testicular function using alternative pathways.  
While leptin has beneficial effects on male reproductive function at subphysiological 
to physiological levels, supraphysiological leptin levels, such as those seen with com-
mon obesity, might directly impair Leydig cell function. This hypothesis would explain 
why hyperleptinemic mice have decreased reproductive parameters, including testos-
terone, testis weight, Leydig cell number, and offspring number [38]. Tena-Sempere 
and colleagues convincingly demonstrated that recombinant leptin significantly inhibits 
chorionic gonadotropin (CG)-stimulated testosterone secretion, which is accompanied 
by impaired gene expression of Star and Cyp11, but not Hsd17b3, in rat testis tissue ex 
vivo [39]. Acute incubation of rat Leydig cells with recombinant leptin also significantly 
inhibits human CG-stimulated testosterone production ex vivo [40]. Thus, leptin could 
have differential effects on Leydig cell function depending on leptin concentration, 
treatment duration, and experimental design; i.e., in in vivo vs ex vivo settings. 
Here we show that subphysiological to physiological leptin doses improve spermato-
genesis markers. Leptin significantly increased the number of tubules in the first half of 
the spermatogenic cycle (stages I-VIII) compared with saline-treated mice and acted in 
a dose-dependent manner. Leptin-treated animals had significantly decreased abnormal 
tubules compared with controls. However, germ cell markers, such as Ddx4, Kit, and 
cAMP-responsive element modulator [41], and Sertoli cell markers, including Inhbb, 
Sox9, and Vim [41], were not significantly modulated by leptin treatment in our study. 
This result is consistent with a previous report by Mounzih et al. in which they show 
that seminiferous tubules become more abundant and contain mature germ cells follow-
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ing leptin treatment of ob/ob mice [17]. Leptin levels in seminal plasma positively cor-
relate with sperm concentration and motility in humans [10], and leptin significantly 
increases progressive and total sperm motility, acrosome reaction, and nitric oxide pro-
duction in sperm [42,43]. Based on our results and those of previous studies, subphysio-
logical to physiological leptin levels appear to improve both spermatogenesis and 
Leydig cell function. Whether these observed leptin-mediated changes in male gonadal 
function translate into an effect on actual offspring is currently unknown and should be 
addressed in the future.  
In summary, leptin administered at subphysiological to physiological levels improves 
reproductive function via improved Leydig cell function, increased intratesticular testos-
terone, and improved spermatogenesis parameters. Further studies are needed to eluci-
date the effects of supraphysiological leptin concentrations, such as those seen in com-
mon obesity, on reproductive function markers. 
Conflict of interest 
The authors declare that there is no conflict of interest. 
Acknowledgements 
We would like to thank Eva Jung, Eva Böge, Claudia Gebhardt, and Jessica-Michelle 
Jannicke of the University of Leipzig for their excellent technical assistance. 
This study was supported by grants from the Deutsche Forschungsgemeinschaft 
(DFG, SFB 1052/1, C06 to M.F., B01 to M.B., and B04 to N.K.), the Federal Ministry 
of Education and Research (BMBF), Germany, FKZ: 01EO1001 (IFB Adiposity Dis-
eases, projects K6a-87 to M.F. and FKZ: 01EO1501 to N.K.), the Deutsche Gesellschaft 
für Andrologie to S.K., and the Deutsche Hochdruckliga e.V. to M.F.. I.V.W. is sup-
ported by the IFB Adiposity Diseases, ESPE Research Fellowship, Samariten Stiftelsen 
and Skällskapet Bårnavard. 
  
CHAPTER 3 73 
 
3.6 References 
[1] S.J. Olshansky, D.J. Passaro, R.C. Hershow, J. Layden, B.A. Carnes, J. Brody, 
L. Hayflick, R.N. Butler, D.B. Allison, D.S. Ludwig, A potential decline in life 
expectancy in the United States in the 21st century, N. Engl. J. Med. 352 (2005) 
1138–1145. 
[2] A.M. Isidori, M. Caprio, F. Strollo, C. Moretti, G. Frajese, A. Isidori, A. Fabbri, 
Leptin and androgens in male obesity: evidence for leptin contribution to re-
duced androgen levels, J. Clin. Endocrinol. Metab. 84 (1999) 3673–3680.  
[3] K. Michalakis, G. Mintziori, A. Kaprara, B.C. Tarlatzis, D.G. Goulis, The com-
plex interaction between obesity, metabolic syndrome and reproductive axis: a 
narrative review, Metabolism. 62 (2013) 457–478.  
[4] C.D.B. Fernandez, F.F. Bellentani, G.S.A. Fernandes, J.E. Perobelli, A.P.A. 
Favareto, A.F. Nascimento, A.C. Cicogna, W.D.G. Kempinas, Diet-induced 
obesity in rats leads to a decrease in sperm motility, Reprod. Biol. Endocrinol. 
RBE. 9 (2011) 32. 
[5] N.O. Palmer, T. Fullston, M. Mitchell, B.P. Setchell, M. Lane, SIRT6 in mouse 
spermatogenesis is modulated by diet-induced obesity, Reprod. Fertil. Dev. 23 
(2011) 929–939. 
[6] A.R. Glass, R.S. Swerdloff, G.A. Bray, W.T. Dahms, R.L. Atkinson, Low serum 
testosterone and sex-hormone-binding-globulin in massively obese men, J. Clin. 
Endocrinol. Metab. 45 (1977) 1211–1219. 
[7] B. Zumoff, G.W. Strain, L.K. Miller, W. Rosner, R. Senie, D.S. Seres, R.S. 
Rosenfeld, Plasma free and non-sex-hormone-binding-globulin-bound testos-
terone are decreased in obese men in proportion to their degree of obesity, J. 
Clin. Endocrinol. Metab. 71 (1990) 929–931. 
[8] J. Svartberg, D. von Mühlen, J. Sundsfjord, R. Jorde, Waist circumference and 
testosterone levels in community dwelling men. The Tromsø study, Eur. J. Epi-
demiol. 19 (2004) 657–663. 
[9] M. Fasshauer, M. Blüher, Adipokines in health and disease, Trends Pharmacol. 
Sci. 36 (2015) 461–470. 
CHAPTER 3 74 
 
[10] S. Thomas, D. Kratzsch, M. Schaab, M. Scholz, S. Grunewald, J. Thiery, U. 
Paasch, J. Kratzsch, Seminal plasma adipokine levels are correlated with func-
tional characteristics of spermatozoa, Fertil. Steril. 99 (2013) 1256–1263.e3. 
[11] N. Hoggard, J.G. Mercer, D.V. Rayner, K. Moar, P. Trayhurn, L.M. Williams, 
Localization of leptin receptor mRNA splice variants in murine peripheral tis-
sues by RT-PCR and in situ hybridization, Biochem. Biophys. Res. Commun. 
232 (1997) 383–387. 
[12] T. Jope, A. Lammert, J. Kratzsch, U. Paasch, H.-J. Glander, Leptin and leptin 
receptor in human seminal plasma and in human spermatozoa, Int. J. Androl. 26 
(2003) 335–341. 
[13] J.E. Caminos, R. Nogueiras, F. Gaytán, R. Pineda, C.R. González, M.L. Bar-
reiro, J.P. Castaño, M.M. Malagón, L. Pinilla, J. Toppari, C. Diéguez, M. Tena-
Sempere, Novel expression and direct effects of adiponectin in the rat testis, En-
docrinology. 149 (2008) 3390–3402. 
[14] J.L. Halaas, K.S. Gajiwala, M. Maffei, S.L. Cohen, B.T. Chait, D. Rabinowitz, 
R.L. Lallone, S.K. Burley, J.M. Friedman, Weight-reducing effects of the plasma 
protein encoded by the obese gene, Science. 269 (1995) 543–546. 
[15] I.S. Farooqi, E. Bullmore, J. Keogh, J. Gillard, S. O’Rahilly, P.C. Fletcher, Lep-
tin regulates striatal regions and human eating behavior, Science. 317 (2007) 
1355. 
[16] I.A. Barash, C.C. Cheung, D.S. Weigle, H. Ren, E.B. Kabigting, J.L. Kuijper, 
D.K. Clifton, R.A. Steiner, Leptin is a metabolic signal to the reproductive sys-
tem, Endocrinology. 137 (1996) 3144–3147. 
[17] K. Mounzih, R. Lu, F.F. Chehab, Leptin treatment rescues the sterility of genet-
ically obese ob/ob males, Endocrinology. 138 (1997) 1190–1193. 
[18] A. Hoffmann, T. Ebert, N. Klöting, J. Dokas, F. Jeromin, B. Jessnitzer, R. , M. 
Fasshauer, S. Kralisch, Leptin dose-dependently decreases atherosclerosis by at-
tenuation of hypercholesterolemia and induction of adiponectin, Biochim. Bio-
phys. Acta. 1862 (2016) 113–120. 
CHAPTER 3 75 
 
[19] D.J. Lloyd, J. McCormick, J. Helmering, K.W. Kim, M. Wang, P. Fordstrom, 
S.A. Kaufman, R.A. Lindberg, M.M. Véniant, Generation and characterization 
of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: 
Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr, Am. J. Physiol. Endocrinol. 
Metab. 294 (2008) E496-505. 
[20] J.Y. Jun, Z. Ma, R. Pyla, L. Segar, Leptin treatment inhibits the progression of 
atherosclerosis by attenuating hypercholesterolemia in type 1 diabetic 
Ins2(+/Akita):apoE(-/-) mice, Atherosclerosis. 225 (2012) 341–347. 
[21] P.F. Bodary, S. Gu, Y. Shen, A.H. Hasty, J.M. Buckler, D.T. Eitzman, Recombi-
nant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-
deficient mice, Arterioscler. Thromb. Vasc. Biol. 25 (2005) e119-122. 
[22] M. Zeadin, M. Butcher, G. Werstuck, M. Khan, C.K. Yee, S.G. Shaughnessy, 
Effect of leptin on vascular calcification in apolipoprotein E-deficient mice, Ar-
terioscler. Thromb. Vasc. Biol. 29 (2009) 2069–2075. 
[23] G. Frühbeck, J. Gómez-Ambrosi, J. Salvador, Leptin-induced lipolysis opposes 
the tonic inhibition of endogenous adenosine in white adipocytes, FASEB J. 15 
(2001) 333–340. 
[24] W.H. Yu, M. Kimura, A. Walczewska, S. Karanth, S.M. McCann, Role of leptin 
in hypothalamic-pituitary function, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 
1023–1028. 
[25] M.C. Vantyghem, D. Vincent-Desplanques, F. Defrance-Faivre, J. Capeau, C. 
Fermon, A.S. Valat, O. Lascols, A.C. Hecart, P. Pigny, B. Delemer, C. 
Vigouroux, J.L. Wemeau, Fertility and obstetrical complications in women with 
LMNA-related familial partial lipodystrophy, J. Clin. Endocrinol. Metab. 93 
(2008) 2223–2229. 
[26] K.J. Teerds, D.G. de Rooij, J. Keijer, Functional relationship between obesity 
and male reproduction: from humans to animal models, Hum. Reprod. Update. 
17 (2011) 667–683. 
[27] N. Sermondade, Obesity and increased risk for oligozoospermia and azoo-
spermia, Arch. Intern. Med. 172 (2012) 440. 
CHAPTER 3 76 
 
[28] B. Donadille, P. D’Anella, M. Auclair, N. Uhrhammer, M. Sorel, R. Grigorescu, 
S. Ouzounian, G. Cambonie, P. Boulot, P. Laforêt, B. Carbonne, S. Christin-
Maitre, Y.-J. Bignon, C. Vigouroux, Partial lipodystrophy with severe insulin 
resistance and adult progeria Werner syndrome, Orphanet J. Rare Dis. 8 (2013) 
106. 
[29] A.S. Berkowitz, J.A. Lloyd, M. Chowdhury, Effects of the method of exsanguin-
ation on measurements of developmental changes in serum concentrations of fol-
licle-stimulating hormone and luteinizing hormone in prepubertal and adult 
male house mice, J. Endocrinol. 83 (1979) 61–66. 
[30] K.M. Robertson, G.U. Schuster, K.R. Steffensen, O. Hovatta, S. Meaney, K. 
Hultenby, L.C. Johansson, K. Svechnikov, O. Söder, J.-A. Gustafsson, The liver 
X receptor-{beta} is essential for maintaining cholesterol homeostasis in the tes-
tis, Endocrinology. 146 (2005) 2519–2530. 
[31] L.D. Russell, R.A. Ettlin, A.P.S. Hikim, E.D. Clegg, Histological and Histo-
pathological Evaluation of the Testis, Int. J. Androl. 16 (1993) 83–83. 
[32] S. Kralisch, N. Klöting, T. Ebert, M. Kern, A. Hoffmann, K. Krause, B. Jess-
nitzer, U. Lossner, I. Sommerer, M. Stumvoll, M. Fasshauer, Circulating adipo-
cyte fatty acid-binding protein induces insulin resistance in mice in vivo, Obes. 
Silver Spring Md. 23 (2015) 1007–1013. 
[33] L. Luo, H. Chen, D.M. Stocco, B.R. Zirkin, Leydig cell protein synthesis and 
steroidogenesis in response to acute stimulation by luteinizing hormone in rats, 
Biol. Reprod. 59 (1998) 263–270. 
[34] B.J. Clark, J. Wells, S.R. King, D.M. Stocco, The purification, cloning, and ex-
pression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 
mouse Leydig tumor cells. Characterization of the steroidogenic acute regulato-
ry protein (StAR), J. Biol. Chem. 269 (1994) 28314–28322. 
[35] A.H. Payne, D.B. Hales, Overview of steroidogenic enzymes in the pathway from 
cholesterol to active steroid hormones, Endocr. Rev. 25 (2004) 947–970. 
[36] R. Ivell, J.D. Wade, R. Anand-Ivell, INSL3 as a biomarker of Leydig cell func-
tionality, Biol. Reprod. 88 (2013) 147. 
CHAPTER 3 77 
 
[37] G. Frühbeck, Intracellular signalling pathways activated by leptin, Biochem. J. 
393 (2006) 7–20. 
[38] M. Yuan, G. Huang, J. Li, J. Zhang, F. Li, K. Li, B. Gao, L. Zeng, W. Shan, P. 
Lin, L. Huang, Hyperleptinemia directly affects testicular maturation at different 
sexual stages in mice, and suppressor of cytokine signaling 3 is involved in this 
process, Reprod. Biol. Endocrinol. RBE. 12 (2014) 1-13. 
[39] M. Tena-Sempere, P.R. Manna, F.P. Zhang, L. Pinilla, L.C. González, C. Dié-
guez, I. Huhtaniemi, E. Aguilar, Molecular mechanisms of leptin action in adult 
rat testis: potential targets for leptin-induced inhibition of steroidogenesis and 
pattern of leptin receptor messenger ribonucleic acid expression, J. Endocrinol. 
170 (2001) 413–423. 
[40] M. Caprio, A.M. Isidori, A.R. Carta, C. Moretti, M.L. Dufau, A. Fabbri, Expres-
sion of functional leptin receptors in rodent Leydig cells, Endocrinology. 140 
(1999) 4939–4947. 
[41] J.B. Stukenborg, E. Colón, O. Söder, Ontogenesis of testis development and 
function in humans, Sex. Dev. 4 (2010) 199–212. 
[42] F. Lampiao, S.S. du Plessis, Insulin and leptin enhance human sperm motility, 
acrosome reaction and nitric oxide production, Asian J. Androl. 10 (2008) 799–
807. 
[43] H.W.R. Li, P.C.N. Chiu, M.P.L. Cheung, W.S.B. Yeung, W.S. O, Effect of leptin 
on motility, capacitation and acrosome reaction of human spermatozoa, Int. J. 
Androl. 32 (2009) 687–694. 
 
  
CHAPTER 3 78 
 
3.7 Supplementary Figures 
 
Supplemental Figure 1 Dose-dependent effects of chronic (12 week) leptin administration on (A) BW, 
(B) total fat mass, and (C) total lean mass assessed in awake mice using EchoMRI700 (Echo Medical 
Systems, Houston, TX) before administration (N ≥ 2) and at 6 weeks (N ≥ 6) and 12 weeks (N ≥ 7) after 
leptin administration initiation. Data are presented as mean ± standard error. ** indicates p < 0.01, 
*** p < 0.001, **** p < 0.0001 compared with saline controls.  
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Supplemental Figure 2 (A) Inhbb, (B) Sox9 (C) Vim, (D) Ddx4, (E) Kit, and (F) Crem mRNA expres-
sion in chronic (12 week) leptin administration groups. Quantification of mRNA was performed as de-
scribed in the Materials and methods section. Data are presented as mean ± standard error and represent 
N ≥ 7 per group. 
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Supplemental Figure 3 Influence of acute leptin administration (3.0 mg/kg BW/d for 72 h) on (A, B) 
body weight, (C) testis weight, (D) HbA1c, (E) fasting glucose, as well as cholesterol (Chol) and triglyc-
erides (TG) in the (F) LDL, (G) HDL, and (H) VLDL fractions. Data are presented as mean ± standard 
error and represent N ≥ 6 per group. 
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Gene Forward sequence Reverse sequence 
36B4 AAGCGCGTCCTGGCATTGTCT CCGCAGGGGCAGCAGTGGT 
Crem ATCTGTCTCTGCAATTGTTGCT AGGCAAATGACCATGGAAAC 
Cyp11a1 GGTTCCACTCCTCAAAGCCA AGCCAACGAGTTGGGTCAAA 
Cyp17a1 TTCGCCTGGGTACCACAACTGC TAGAGTCACCATCTGGGGCCGA 
Ddx4 GAGGGGGAAGAGGCAGTTTC TGGTAAGTGTCACCATTGCCT 
Hsd17b3 AGACCGCCGATGAGTTTGTT TCAGGAGGAATCGTTGAGCG 
Inhbb TACGTGTGTCCAGAAGTGGC TTCGCCTAGTGTGGGTCAAC 
Insl3 GCCCACGCTGGTCGC TGGGGAGCAATTAAGGACGC 
Kit AGGTAACAACAAAGAGCAAATCCA GCTGCAACCACAAAGCCAAT 
Lhr TGCCTTTGACAACCTCCTCA AAGCGTTCCCTGGTATGGTG 
Sox9 CAGTACCCGCATCTGCACAA TCCGCTTGTCCGTTCTTCAC 
Star TGGATGGGTCAAGTTCGACG CTTAGCACTTCGTCCCCGTT 
Vim TGCTTCAAGACTCGGTGGAC AAGCGCACCTTGTCGATGTA 
Supplemental Table 1 Primer sequences 5’-3’ used for quantitative real-time RT-PCR analysis. 
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4.1 Summary 
Objective: Lipodystrophy (LD) is characterized by loss of adipose tissue, dysregula-
tion of adipokines and severe metabolic complications. Regulation of the insulin re-
sistance-inducing and proinflammatory adipokine chemerin has not been assessed in 
LD. Therefore, we determined chemerin serum levels in LD, chemerin mRNA expres-
sion in insulin-sensitive tissues of LD mice, as well as the impact of metreleptin treat-
ment on circulating chemerin in LD patients.  
Research Design and Methods: Serum chemerin, as well as clinical and biochemical 
parameters of glucose metabolism, lipid metabolism, and inflammation, was measured 
in 37 LD patients and 37 age-, gender- and body mass index-matched controls. Fur-
thermore, chemerin mRNA expression was determined in LD mice and controls. More-
over, circulating chemerin was assessed at five different time points in 10 LD patients 
treated with metreleptin over 1 year. 
Results: Median serum chemerin levels were significantly higher in 37 subjects with 
LD (234.3 µg/l) as compared to controls (204.0 µg/l) (p = 0.002). Multiple linear re-
gression analysis showed that circulating chemerin was independently and positively 
associated with glycosylated haemoglobin A1c (HbA1c) and C-reactive protein (CRP). 
Chemerin mRNA expression was significantly increased 2.5-fold in visceral adipose 
tissue (VAT) and 5.3-fold in brown adipose tissue (BAT) of LD mice as compared to 
controls (p < 0.01). Circulating chemerin was not significantly altered by metreleptin 
treatment. 
Conclusions: Circulating levels of the adipokine chemerin are elevated in LD, as 
well as independently and positively associated with HbA1c and CRP. Increased 
chemerin might originate from VAT and BAT. 
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4.2 Introduction 
Lipodystrophies (LD) are rare acquired or genetic disorders characterized by the se-
lective loss of adipose tissue [1]. LD is associated with severe metabolic dysfunctions 
such as insulin resistance, diabetes mellitus, dyslipidemia, non-alcoholic fatty liver dis-
ease, cardiomyopathy and hypogonadotropic hypogonadism which can cause severe 
complications including pancreatitis, liver cirrhosis and congestive heart failure [1]. 
Within the last two decades, considerable progress has been made elucidating the path-
ogenesis of LD. Thus, adipocyte-secreted factors including adiponectin and leptin were 
significantly decreased in LD [2,3]. Furthermore, leptin and adiponectin substitution 
alone or in combination led to significant and sustained improvements in glycemic con-
trol and dyslipidemia in humans and rodents [4–8]. 
Recently, chemerin (also known as RARRES2 or TIG2) has been identified as a 
novel adipokine by four independent groups [9–12]. Chemerin is secreted as an 18-kDa 
pro-protein that undergoes C-terminal processing through a serine protease which forms 
the 16-kDa active chemerin [10]. Chemerin is expressed at high levels in white adipose 
tissue (WAT) and hepatocytes, as well as to a lesser extent in lung, brown adipose tissue 
(BAT) and kidney [9,10]. It mediates its effects through the chemokine-like receptor 
(CMKLR)-1, chemokine receptor-like 2 (CCRL2) and the orphan receptor GPR1 
[13,14]. Chemerin is dramatically upregulated during adipogenesis in vitro [10,11]. Fur-
thermore, insulin resistance-inducing [15–17] and pro-inflammatory [18–20] effects 
have been described for the adipokine. Weight loss due to bariatric surgery, exercise or 
reduction of caloric intake reduced serum chemerin concentrations [21,22]. Further-
more, circulating chemerin is positively associated with facets of the metabolic syn-
drome in several populations [9,23]. In addition, chemerin levels correlate with tumor 
necrosis factor (TNF) α, interleukin-6 and C-reactive protein (CRP) [24,25]. Taking 
these studies into consideration, chemerin is a novel adipokine with insulin resistance-
inducing and proinflammatory properties which is positively linked to facets of the met-
abolic syndrome and inflammation. 
In contrast to the adipokines leptin and adiponectin [2,3]. regulation of chemerin has 
not been investigated in LD until now. Therefore, we evaluated serum chemerin concen-
trations in 37 well-phenotyped LD patients as compared to 37 age-, gender- and body 
mass index (BMI)-matched controls. Furthermore, we correlated circulating chemerin to 
clinical and biochemical parameters of glucose and lipid metabolism, as well as to 
markers of inflammation. Moreover, chemerin mRNA expression in insulin-sensitive 
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tissues was studied in a mouse model of generalized LD as compared to controls. In 
addition, circulating chemerin before and 6 months after initiation of metreleptin treat-
ment was quantified in a pilot study consisting of 10 patients with LD who met clinical 
criteria for metreleptin treatment. We hypothesized that chemerin would be elevated in 
LD patients due to insulin resistance and chronic inflammation and leptin treatment 
would reverse this effect. 
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4.3 Research design and methods 
LD subjects – cross-sectional cohort  
Thirty-seven LD patients (5 male, 32 female) were recruited from the Lipodystrophy 
Centre of the Department of Endocrinology and Nephrology, University of Leipzig. LD 
was defined according to the American Association of Clinical Endocrinologists 
(AACE) consensus statement criteria 2013 [26]. Four (one male, three female) patients 
had generalized LD, and 33 (4 male, 29 female) patients had partial LD. Twenty-four 
LD patients had an established genetic diagnosis, 7 additional LD patients were sus-
pected to have a genetic origin because of a positive family history, two patients were 
affected by autoimmune LD, and four patients had idiopathic LD. Thirty-two of the 
33 partial LD cases had femorogluteal LD, whereas one patient had a localized form 
and none had craniocaudal LD. All patients underwent a thorough clinical examination 
and a number of questionnaires about the history of their LD. Thirty-seven age-, gen-
der-, and BMI-matched subjects without LD were recruited from the outpatient care unit 
of the Department of Endocrinology and Nephrology, University of Leipzig as controls. 
Pilot study on metreleptin treatment in LD patients 
Ten LD patients (2 male/8 female; 2 generalized LD/8 partial LD) met clinical crite-
ria for metreleptin treatment. Inclusion criteria were confirmed lipodystrophy, age ≥ 5 
years at baseline, insufficiently controlled diabetes mellitus and/or hypertriglyceridemia 
despite adequate antihyperglycemic and/or lipid-lowering medication, and estimated 
glomerular filtration rate (eGFR) > 40 ml/min. Exclusion criteria included pregnancy or 
lactation, HIV infection, infectious liver disease, active malignant tumour, primary 
haematologic abnormalities and hypersensitivity to E. coli-derived proteins. Metreleptin 
was provided by Amylin (San Diego, CA, USA)/Bristol–Myers–Squibb (Munich, Ger-
many)/Astra Zeneca (London, UK)/Aegerion (Cambridge, MA, USA), respectively. 
Patients 1-3 (all female) administered metreleptin subcutaneously at 0.04 mg/kg for the 
first week and thereafter at 0.08 mg/kg body weight. For patients 4–10, dosing instruc-
tions changed to 2.5 mg metreleptin per day for men and 5 mg metreleptin per day for 
women. Metreleptin doses after the first week of treatment ranged from 2.5 to 7.8 mg 
per day. Antihyperglycemic and lipid-lowering medication was modified if clinically 
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indicated. Clinical and laboratory assessment was performed prior as well as at five dif-
ferent time points over 1 year after initiation of metreleptin treatment. The assessment 
after 6 months was chosen for this analysis because metabolic response to metreleptin 
was most pronounced at this time point. 
Patient characterization and assays 
BMI was determined as weight divided by squared height. Waist-to-hip ratio (WHR) 
was calculated after waist and hip circumferences were assessed. The whole study 
population was between 16 and 75 years old and BMI ranged from 17.4 to 46.1 kg/m
2
. 
Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as pre-
viously described [27]. eGFR was calculated by CKD-EPI equation [28] after assess-
ment of serum creatinine. The study was approved by the local Ethics Committee, and 
all subjects gave written informed consent before taking part in the study. 
Blood samples were taken after an overnight fast. Chemerin (Biovendor, Modrice, 
Czech Republic), adiponectin (Mediagnost, Reutlingen, Germany) and leptin (Mediag-
nost, Reutlingen, Germany) serum concentrations were determined with commercially 
available enzyme-linked immunosorbent assays according to manufacturers’ instruc-
tions. In our hands, the degree of precision of the chemerin ELISA system in terms of 
intra-assay coefficient of variance (CV) was between 2.6% and 4.0%, interassay CV 
was between 1.5% and 6.2%, and linearity was in a range of 86.4% and 111.1% (data 
not shown). These assay characteristics were comparable to the data given by the manu-
facturer, that is intra-assay CV 5.1% to 7.0%, interassay CV 6.9 to 8.3%, and linearity 
100.3% to 106.7%. Furthermore, the manufacturer indicated that the sensitivity of the 
chemerin ELISA was 0.1 µg/l, as well as that the assay was specific for human chemer-
in and did not cross-react with bovine, dog, goat, hamster, horse, monkey, mouse, pig, 
rabbit, rat and sheep sera. Fasting insulin (FI), fasting glucose (FG), glycosylated hae-
moglobin A1c (HbA1c), creatinine, triglycerides (TG), cholesterol, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, free fatty acids 
(FFA) and CRP were measured by standard laboratory methods in a certified laboratory. 
CHAPTER 4 88 
 
Animal care 
Breeding and husbandry of all C57BL/6NTac mice (F15) (N = 3) and Tg(aP2-
SREBF1c)9884Reh/0 (Jackson Laboratory, Bar Harbor, ME, USA) (N = 3) was carried 
out in the Medical Experimental Center of the University of Leipzig. All mice were 
maintained in a room under pathogen-free conditions with controlled 21 ± 1 °C on a 
12/12 h light/dark cycle (6 AM/6 PM). Water and a normal pellet diet (V1534 from 
Sniff, Soest, Germany) were provided ad libitum. The local ethics committee (Regier-
ungspräsidium Leipzig) of the state of Saxony approved the protocol of all animal ex-
periments (approval no. TVV37/12). 
At 9–10 weeks of age, mice were weighted and sacrificed by an overdose of Sevoflu-
rane (Abbott, Wiesbaden, Germany). Liver was immediately removed and weighed, and 
frozen in liquid nitrogen. Muscle, subcutaneous (SAT), visceral (VAT) and brown 
(BAT) adipose tissue were frozen in liquid nitrogen. 
Quantitative real-time RT-PCR analysis 
Chemerin (Chem) mRNA synthesis was determined relative to 36B4 by quantitative 
real-time RT-PCR in a fluorescent temperature cycler (Roche, Heidelberg, Germany) as 
described previously [29] using the following mouse primers: Chem: 5’-
TACAGGTGGCTCTGGAGGAGTTC-3’ (forward), 5’-CTTCTCCCGTTTGGTTT 
GATTG-3’ (reverse); 36B4: 5’-AAGCGCGTCCTGGCATTGTCT-3’ (forward), 5’-
CCGCAGGGGCAGCAGTGGT-3’ (reverse). 
Statistical analysis 
SPSS Statistics version 20.0 (IBM, Armonk, NY, USA) was used in all statistical 
analyses. Differences between controls and LD patients were assessed by 
Mann-Whitney U test. Correlations were performed using Spearman’s rank correlation 
method. To adjust the effects of covariates and identify independent relationships, mul-
tivariate linear regression analyses were performed. Before performing multivariate 
analyses, distribution was tested for normality using Shapiro-Wilk W-test and non-
normally distributed parameters were logarithmically transformed. Differences in pa-
tients before and 6 months after initiation of metreleptin treatment were assessed by 
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Wilcoxon signed rank test. A p-value of < 0.05 was considered as statistically signifi-
cant in all analyses. 
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4.4 Results 
Chemerin serum levels are significantly higher in LD patients as compared 
to controls 
Median (interquartile range) serum chemerin was 219.0 µg/l (63.2 µg/l) in the total 
sample. Clinical characteristics of the subgroups studied (controls, LD) are shown in 
Table 1. Median serum chemerin levels were significantly higher in subjects with LD 
(234.3 µg/l) as compared to controls (204.0 µg/l) (p = 0.002) (Table 1). Glucose control, 
that is HbA1c, FI and HOMA-IR, as well as lipid homeostasis, that is HDL cholesterol 
and TG, was significantly impaired in LD patients as compared to controls (p ≤ 0.001) 
(Table 1). Furthermore, the adipokines adiponectin and leptin were significantly re-
duced in LD patients (p < 0.001) (Table 1). In the LD cohort, chemerin serum levels 
were not significantly affected by gender, LD type (i.e. partial vs generalized), LD aeti-
ology (i.e. genetic vs autoimmune vs idiopathic), fat loss distribution in partial LD 
(i.e. femorogluteal vs localized) and menopausal status (data not shown). 
Univariate and multivariate analyses 
When analysing all subjects, serum chemerin concentrations positively correlated 
with age, BMI, WHR, systolic blood pressure (SBP), HbA1c, FG, FI, HOMA-IR, TG 
and CRP (p < 0.05) (Table 2). Furthermore, the adipokine was negatively correlated 
with HDL cholesterol and LDL cholesterol (p < 0.05) (Table 2). In contrast, serum lev-
els of chemerin were not significantly associated with diastolic blood pressure (DBP), 
cholesterol, FFA, creatinine, eGFR, adiponectin and leptin in univariate analysis (Ta-
ble 2). Multiple linear regression analysis showed that circulating chemerin remained 
independently and positively associated with HbA1c and CRP (Table 2). 
Chemerin expression in insulin-sensitive tissues in a rodent model of 
generalized LD 
Mean ± SEM liver weight/body weight ratio was significantly higher in 
Tg(aP2-SREBF1c)9884Reh/0 LD mice (6.56 ± 0.58%; N = 3) as compared to wild-type 
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controls (4.82 ± 0.03%) (p = 0.04) (Figure 1A). Chemerin mRNA was significantly up-
regulated 2.5-fold in VAT (Figure 1B) and 5.3-fold in BAT (Figure 1D) of Tg LD mice 
as compared to wild-type animals (p < 0.01). In contrast, chemerin mRNA production 
in SAT (Figure 1C), liver (Figure 1E) and skeletal muscle (Figure 1F) was not signifi-
cantly different between Tg and wild-type mice. 
Influence of metreleptin treatment on circulating chemerin in LD patients – 
pilot study 
Characteristics of the 10 patients before and 6 months after initiation of metreleptin 
treatment are summarized in Table 3. At 6 months, TG were significantly lower 
(5.27 mmol/l vs 12.39 mmol/l) (p = 0.014) and CRP was significantly higher (6.3 mg/l 
vs 2.8 mg/l) (p = 0.049) as compared to baseline (Table 3). In contrast, chemerin serum 
levels were not significantly different between baseline and 6 months (Table 3). 
  
CHAPTER 4 92 
 
 Controls LD p 
N 37 37  
Chemerin (µg/l) 204.0 (69.0) 234.3 (61.0) 0.002
*
 
Age (years) 48 (22) 43 (23)  0.382 
Gender (male/female) 5/32 5/32 - 
BMI (kg/m
2
) 26.2 (3.3) 26.3 (4.8) 0.440 
WHR 0.86 (0.14) 0.98 (0.08) <0.001
*
 
SBP (mmHg) 124 (24) 131 (17) 0.093 
DBP (mmHg) 78 (13) 80 (16) 0.659 
HbA1c (%) 5.2 (0.5) 6.4 (2.4) <0.001
*
 
HbA1c (mmol/mol) 33.3 (4.9) 46.4 (26.2) <0.001
*
 
FG (mmol/l) 5.4 (1.5) 5.8 (5.0) 0.130 
FI (pmol/l) 61.2 (45.6) 131.7 (250.8) <0.001
*
 
HOMA-IR 2.2 (1.9) 5.2 (13.9) 0.001* 
Cholesterol (mmol/l) 5.46 (1.35) 5.88 (1.92) 0.220 
HDL cholesterol (mmol/l) 1.48 (0.44) 0.95 (0.68) <0.001
*
 
LDL cholesterol (mmol/l) 3.43 (0.95) 2.92 (2.02) 0.497 
TG (mmol/l) 1.15 (0.59) 2.95 (6.97) <0.001
*
 
FFA (mmol/l) 0.47 (0.30) 0.59 (0.26) 0.065 
Creatinine (µmol/l) 63 (25) 65 (18) 0.981 
eGFR (ml/min/1.73m²) 94.9 (13.9) 100.6 (27.5) 0.131 
CRP (mg/l) 1.1 (4.1) 2.7 (3.7) 0.308 
Adiponectin (mg/l) 7.7 (10.0) 2.3 (2.7) <0.001
*
 
Leptin (µg/l) 13.8 (11.7) 5.3 (3.9) <0.001
*
 
Table 1 Baseline characteristics of the entire study population (N = 74). BMI, Body mass-index; 
CRP, C reactive protein; DBP, Diastolic blood pressure; eGFR, Estimated glomerular filtration rate; FFA, 
Free fatty acids; FG, Fasting glucose; FI, Fasting insulin; HbA1c, Glycosylated hemoglobin A1c; HDL, 
High-density lipoprotein; HOMA-IR, Homeostasis model assessment of insulin resistance; LD, Lipo-
dystrophy; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; TG, Triglycerides; WHR, 
Waist-hip-ratio. Values for median (interquartile range) are shown. * indicates p < 0.05 as assessed by 
Mann-Whitney U test. 
  













Age (years) 0.330/0.004* - - 
Group (LD vs Non-LD) - -0.278 0.069 
BMI (kg/m
2
) 0.370/0.001* - - 
WHR 0.435/<0.001* - - 
SBP (mmHg; lg) 0.230/0.050* -0.033 0.767 
DBP (mmHg) 0.069/0.0563 - - 
HbA1c (%;lg) 0.534/<0.001* 0.302 0.028† 
HbA1c (mmol/mol; lg) 0.534/<0.001* - - 
FG (mmol/l) 0.333/0.004* - - 
FI (pmol/l) 0.383/0.001* - - 
HOMA-IR 0.416/<0.001* - - 
Cholesterol (mmol/l) -0.003/0.983 - - 
HDL cholesterol (mmol/l; lg) -0.381/0.001* 0.075 0.667 
LDL cholesterol (mmol/l; lg) -0.305/0.008* 0.220 0.216 
TG (mmol/l; lg) 0.469/<0.001* 0.074 0.760 
FFA (mmol/l) 0.123/0.368 - - 
Creatinine (µmol/l) -0.192/0.101 - - 
eGFR (ml/min/1.73 m
2
) 0.014/0.908 - - 
CRP (mg/l; lg) 0.437/<0.001* 0.380 0.004† 
Adiponectin (mg/l) -0.220/0.060 - - 
Leptin (µg/l) 0.198/0.091 - - 
Table 2 Univariate and multivariate analyses. Univariate correlations with chemerin in the entire study 
population and multivariate regression analysis between chemerin (dependent variable) and group, SBP 
(lg), HbA1c (lg), HDL cholesterol (lg), LDL cholesterol (lg), TG (lg) and CRP (lg). Non-normally dis-
tributed variables were logarithmically transformed (lg) prior to multivariate testing. r- and p-values, as 
well as standardized β-coefficients and p-values, are given, respectively. Abbreviations are indicated in 
Table 1. 
* Indicates significant correlation as assessed by Spearman’s correlation method. 
† Indicates significant correlation in multivariate analysis. 
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Chemerin (µg/l) 243.5 (87.2) 224.1 (107.6) 0.322 
BMI (kg/m
2
) 27.4 (4.6) 27.2 (5.1) 0.066 
WHR 0.95 (0.14) 0.96 (0.09) 0.820 
SBP (mmHg) 129 (22) 130 (10) 0.844 
DBP (mmHg) 85 (16) 81 (11) 1.000 
HbA1c (%) 7.8 (2.0) 7.1 (1.4) 0.123 
HbA1c (mmol/mol) 61.8 (21.6) 54.1 (15.0) 0.123 
FG (mmol/l) 8.5 (4.5) 7.7 (6.1) 0.898 
FI (pmol/l) 325.6 (413.3) 302.0 (384.3) 0.492 
HOMA-IR 16.0 (17.9) 12.6 (20.0) 0.770 
Cholesterol (mmol/l) 7.49 (5.74) 4.85 (7.53) 0.492 
HDL cholesterol (mmol/l) 0.57 (0.26) 0.61 (0.31) 0.865 
LDL cholesterol (mmol/l) 1.23 (1.80) 1.43 (1.62) 0.557 
TG (mmol/l) 12.39 (15.24) 5.27 (5.95) 0.014
*
 
FFA (mmol/l) 0.72 (0.27) 0.68 (0.39) 0.945 
Creatinine (µmol/l) 62.5 (33) 49 (27) 0.633 
eGFR (ml/min/1.73m²) 102.3 (35.1) 123.8 (31.9) 0.652 
CRP (mg/l) 2.8 (7.3) 6.3 (6.1) 0.049
*
 
Adiponectin (mg/l) 1.9 (2.0) 1.4 (1.9) 0.910 
Leptin (µg/l) 5.5 (7.4) 11.8 (20.9) 0.109 
Table 3. Influence of metreleptin treatment on circulating chemerin in LD patients – pilot study. 
Baseline characteristics, as well as parameters before and 6 months after initiation of metreleptin treat-
ment in LD patients (N = 10). Abbreviations are indicated in Table 1. Values for median (interquartile 
range) or absolute numbers (N) are shown. * indicates p < 0.05 as assessed by Wilcoxon signed rank test. 
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Figure 1 Increased chemerin mRNA expression in an animal model of generalized LD. (A) liver 
weight/body weight [%] and (B-F) mRNA expression of chemerin relative to 36B4 in (B) visceral adi-
pose tissue (VAT), (C) subcutaneous adipose tissue (SAT), (D) brown adipose tissue (BAT), (E) liver 
and (F) muscle of 9- to 10-week-old wild-type female mice (Con; N = 3) and transgenic 
Tg(aP2-SREBF1c)9884Reh/0 littermate (LD; N = 3). Statistical analysis was performed by unpaired 
Student’s t-test. Data are presented as means ± standard error. 
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4.5 Conclusions 
In the current study, we show for the first time that serum levels of the adipokine 
chemerin are significantly higher in LD patients as compared to age-, gender- and BMI-
matched controls. In contrast to chemerin, the adipokine adiponectin and leptin are sig-
nificantly decreased in our LD cohort as compared to control subjects. The latter find-
ings are in accordance with published evidence and overall loss of adipose tissue in pa-
tients with LD is the most probable reason for these results [2,3]. To better define the 
source of elevated chemerin in LD, chemerin mRNA expression has been assessed in 
insulin-sensitive tissues of a mouse model of congenital generalized LD. We demon-
strate that chemerin mRNA synthesis is significantly increased in VAT and BAT of LD 
mice as compared to control rodents. These results are in accordance with the hypothe-
sis that increased circulating chemerin in LD might be derived from mRNA induction in 
VAT and BAT. It is interesting to note in this context that one characteristic symptom 
in LD besides loss of SAT is increased amount of VAT [26]. 
The pathophysiological significance of elevated chemerin in LD remains to be estab-
lished. Chemerin has recently been introduced as an insulin resistance-inducing and 
proinflammatory adipokine. Thus, Ernst and co-workers demonstrate convincingly that 
administration of exogenous chemerin exacerbates glucose intolerance in obese and 
diabetic mice [16]. Furthermore, chemerin induces insulin resistance in human skeletal 
muscle cells by impairing activation of insulin receptor substrate 1, Akt and glycogen 
synthase kinase 3 phosphorylation [15]. In agreement with these findings, our group has 
shown that chemerin impairs insulin-induced glucose uptake in 3T3-L1 adipocytes [17]. 
Concerning proinflammatory effects, increased chemerin and CMKLR-1 concentrations 
are detected in plasma, body fluids and tissue lesions of patients with several inflamma-
tory diseases including pancreatitis, ulcerative colitis, Crohn’s disease, arthritis and lu-
pus erythematosus [19,30–32]. Moreover, neutrophil granulocytes secrete serine prote-
ases that mediate activation of human pro-chemerin into bioactive chemerin [18]. 
CMKLR-1 is expressed on macrophages, immature myeloid and plasmacytoid dendritic 
cells, as well as natural killer cells [20,30]. In vitro studies demonstrate convincingly 
that recombinant chemerin promotes chemotaxis of all leucocyte populations that ex-
press CMKLR-1 [19,30]. Taking these results into consideration, it is tempting to 
speculate that increased circulating chemerin in LD might aggravate impaired glucose 
metabolism in patients affected by the disease. Clearly, more work is needed to better 
elucidate the role of chemerin in LD pathophysiology and complications. 
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We demonstrate that chemerin serum levels are positively and independently associ-
ated with markers of glucose intolerance, that is HbA1c, and inflammation, that is CRP. 
These findings are in accordance with results from non-LD populations. Thus, Yang 
and co-workers [33] demonstrate that plasma chemerin levels are independently related 
to HbA1c in patients with type 2 diabetes mellitus and hypertension. Our group has re-
cently shown that chemerin significantly and positively correlates with HOMA-IR in 
women with gestational diabetes mellitus [23]. Moreover, in obese and type 2 diabetic 
Psammomys obesus, chemerin gene expression in mesenteric adipose tissue is positively 
correlates with FG and FI [9]. Regarding CRP, Weigert and co-workers describe a posi-
tive correlation of chemerin levels with CRP in a cohort of normal weight, overweight, 
and type 2 diabetes patients [25]. A strong correlation of chemerin levels with CRP is 
also convincingly demonstrated in patients with stable chest pain [24]. 
Chemerin serum concentrations are not significantly altered by metreleptin treatment 
over 6 months in a pilot study comprising of 10 LD patients. Similarly, concentrations 
of the adipokine are not significantly changed at the other time points of this prospec-
tive study (data not shown). In agreement with our findings, metreleptin does not influ-
ence circulating chemerin when given in increasing doses to healthy female volunteers 
under well-controlled conditions [34]. However, several limitations of our study need to 
be emphasized: the number of treated patients is small and individual patients show a 
high variability of metreleptin treatment effects (data not shown). Furthermore, patients 
with partial LD are overrepresented in our study group compared to other metreleptin 
treatment studies [5–7]. It is interesting to note in this context that patients with general-
ized LD often show more severe metabolic abnormalities and a better response to 
metreleptin as compared to patients with partial LD [6,35]. Clearly, studies with larger 
patient cohorts are necessary to address whether metreleptin treatment has small but 
clinically significant effects on circulating chemerin. 
In summary, we show for the first time that circulating levels of the adipokine 
chemerin are elevated in LD, as well as independently and positively associated with 
HbA1c and CRP. Increased chemerin might originate from VAT and BAT. The patho-
physiological significance of chemerin in LD remains to be determined in future stud-
ies. 
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5.1 Abstract 
Objective: Patients with lipodystrophy (LD) suffer from loss of subcutaneous adi-
pose tissue accompanied by dysregulation of several adipocyte-secreted factors. How-
ever, regulation of adipocyte-expressed fibroblast growth factor (FGF) 21 which acts in 
an insulin-mimetic, lipid-lowering, and antiatherogenic manner has not been investigat-
ed in non-human immunodeficiency virus (HIV) LD.  
Material and methods: Circulating serum FGF21 levels were quantified in 
37 patients with non-HIV LD and 37 controls matched for age, gender, and body mass 
index. Moreover, FGF21 plasma levels and mRNA expression were measured in LD 
mice and control animals. Additionally, serum FGF21 levels were assessed in 10 LD 
patients before and during metreleptin therapy. 
Results: Median FGF21 serum concentrations were significantly higher in LD pa-
tients (381.2 ng/l) as compared to the control group (231.2 ng/l; p = 0.023). There was 
an independent and positive association between circulating FGF21 and serum triglyc-
erides (TG), as well as fibrate treatment, in multiple linear regression analysis. LD mice 
showed significantly upregulated FGF21 plasma levels (4.5-fold), as well as mRNA 
expression in various adipose tissue depots and liver as compared to controls (p < 0.05). 
Metreleptin treatment did not significantly alter circulating FGF21 levels in human sub-
jects. 
Conclusions: Serum concentrations of FGF21 are elevated in patients with non-HIV 
LD with adipose tissue and liver being potential sources of increased production. TG 
and fibrate treatment are independent positive predictors of circulating FGF21. 
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5.2 Introduction 
Adipose tissue plays a crucial role in regulating overall energy homeostasis besides 
energy storage in the form of lipids [1]. Both too much and too little adipose tissue con-
tributes to severe metabolic abnormalities. Thus, obesity, which is characterized by hy-
perplasia and hypertrophy of adipocytes, is linked to insulin resistance, diabetes melli-
tus, hyperlipidemia, hepatic steatosis, and premature coronary heart disease [2]. Interest-
ingly, the same complications can be found in lipodystrophy (LD) which is a heteroge-
neous disease group of congenital or acquired origin and characterized by the selective 
reduction of subcutaneous adipose tissue (SAT) [3]. Similar to obesity, LD patients suf-
fer from consecutive risks of metabolic derangement which include pancreatitis, liver 
cirrhosis, and myocardial infarction [3]. 
Dysregulation of several adipocyte-derived proteins - so called adipokines - has been 
described as a pathogenetic factor of both obesity and LD. Thus, both disease states are 
characterized by downregulation of the insulin-sensitizing adipokine adiponectin [4,5]. 
Furthermore, resistance to leptin, an appetite-suppressive adipokine, develops in obesity 
whereas leptin is decreased due to adipose tissue loss in LD patients [4,5]. Both mecha-
nisms contribute to hyperphagia which is present in both obesity and LD [2,6]. Interest-
ingly, leptin administration in LD resulted in significant improvements in glucose ho-
meostasis and lipid metabolism in affected humans [7] whereas adiponectin supplemen-
tation has only been tested in rodents so far [8]. 
Fibroblast growth factor (FGF) 21 is another adipokine besides leptin and adiponec-
tin that has recently been implied in the pathogenesis of obesity complications. FGF21 
was cloned in 2000 and belongs to the FGF family which currently consists of 
22 members [9]. Besides adipose tissue, FGF21 is produced by skeletal muscle, pancre-
atic β cells, and liver [9]. It acts through cell-surface receptors, i.e. FGF receptor iso-
types 1–4, and activation of FGF receptors depends on the co-receptor β-Klotho [10]. 
FGF21 has potent insulin-mimetic and lipid-lowering effects in both rodents and mon-
keys [11,12]. Furthermore, anti-atherogenic properties of the adipokine have been de-
scribed recently [13]. Despite these beneficial metabolic and vascular effects, our group 
and others have consistently shown upregulation of circulating FGF21 in various vascu-
lar and metabolic disease states including obesity, nonalcoholic fatty liver disease, insu-
lin resistance, type 2 diabetes, dyslipidemia, hypertension, polycystic ovarian syndrome, 
renal impairment, and human immunodeficiency virus (HIV)-associated LD [14–22]. 
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In contrast to obesity-associated disease states and HIVassociated LD, the adipokine 
FGF21 has not been investigated in congenital or acquired non-HIV LD until now. 
Therefore, we measured FGF21 serum concentrations in 37 patients with congenital or 
acquired non-HIV LD as compared to 37 controls matched for age, gender, and body 
mass index (BMI). Moreover, FGF21 serum concentrations were correlated to parame-
ters of inflammation, as well as glucose homeostasis and lipid metabolism. To define 
the sources of FGF21, we analyzed FGF21 mRNA expression in liver, muscle and adi-
pose tissue of LD mice as compared to control animals. Furthermore, we measured 
FGF21 serum concentration in 10 LD patients before and after 6 months of metreleptin 
therapy. We hypothesized that FGF21 is elevated in patients with non-HIV LD and that 
treatment with metreleptin reverses this upregulation. 
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5.3 Material and methods 
Patients and control group 
We included 37 patients with non-HIV LD in our study as recently described [23]. In 
brief, medical history of LD was obtained by using a standardized questionnaire. More-
over, LD patients underwent comprehensive physical examination. The control group 
consisted of 37 subjects without LD and was matched for age, gender, and BMI. Pa-
tients and controls were recruited from the outpatient clinic of the Endocrine Depart-
ment, University of Leipzig. 
Metreleptin treatment study 
Ten of the 37 patients with LD met inclusion criteria for metreleptin therapy. Inclu-
sion and exclusion criteria, as well as metreleptin dosing, has been described in detail 
recently [23]. Patients underwent clinical examination and laboratory investigation be-
fore and at 1 week, 1 month, 3 months, 6 months, and 1 year of metreleptin treatment. 
Since metreleptin’s effect on glucose homeostasis and lipid metabolism was most pro-
nounced after 6 months treatment, we chose this time point for investigating the influ-
ence of metreleptin treatment on FGF21 serum concentration in LD. 
Patient characterization and laboratory assessment 
BMI was calculated as weight in kilogram divided by squared height in meters. After 
assessment of waist and hip circumferences, waist-to-hip ratio (WHR) was evaluated. 
Age of the whole study population ranged from 16 to 75 years. BMI was between 
17.4 and 46.1 kg/m
2
. Calculation of homeostasis model assessment of insulin resistance 
(HOMA-IR) was performed as previously described [24]. The CKD-EPI equation [25] 
was used for calculation of the renal function marker estimated glomerular filtration rate 
(eGFR) after assessment of serum creatinine. Approval by the local Ethics Committee 
and written informed consent of all subjects before taking part in the study was ob-
tained. 
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Blood was taken in the fasted state after at least 8 h fasting. Commercially available 
enzyme-linked immunosorbent assays were used for determining serum concentrations 
of adiponectin (Mediagnost, Reutlingen, Germany), FGF21 (Biovendor, Modrice, 
Czech Republic), and leptin (Mediagnost, Reutlingen, Germany) according to the manu-
facturers´ instructions. Parameters of glucose homeostasis, i.e. fasting insulin (FI), fast-
ing glucose (FG), as well as glycosylated hemoglobin A1c (HbA1c), of renal function, 
i.e. creatinine, of lipid metabolism, i.e. free fatty acids (FFA), triglycerides (TG), total, 
high density lipoprotein (HDL), as well as low density lipoprotein (LDL) cholesterol, 
and C reactive protein (CRP) were determined in a certified laboratory by standard la-
boratory methods. 
Animal experiments and characterization 
All animal experiments were conducted in the Medical Experimental Center, Univer-
sity of Leipzig. Tg(aP2-SREBF1c)9884Reh/0 mice (Jackson Laboratory, Bar Harbor, 
ME) were used as an animal model of lipodystrophy and C57BL/6NTac mice (F15; 
Jackson Laboratory, Bar Harbor, ME) served as controls. Both mouse models were on a 
low-density lipoprotein receptor knockout background, housed on a 12:12 h 
(6 AM/6 PM) light/dark cycle with 21 ± 1 °C room temperature, and they were main-
tained on a cholesterolenriched semisynthetic Clinton/Cybulsky diet (V1534, Sniff, 
Soest, Germany). After euthanasia at 20 weeks of age, insulin-sensitive tissues includ-
ing liver, muscle, as well as brown (BAT), visceral (VAT), and subcutaneous (SAT) 
adipose tissue samples, were removed and immediately frozen in liquid nitrogen. The 
local ethics committee approved all animal experiments (approval no. TVV37/12). 
Commercially available enzyme-linked immunosorbent assays were used for quanti-
fication of insulin (Mercodia, Uppsala, Sweden), adiponectin (Mediagnost, Reutlingen, 
Germany), leptin (Crystalchem, Zaandam, Netherlands), and FGF21 (Biovendor, Brno, 
Czech Republic) according to the instructions of the manufacturer. Lipids were extract-
ed from mouse hepatic tissue according to Ref. [26]. Liver cholesterol and TG content 
were assessed by a colorimetric assay kit (Wako, Neuss, Germany). 
Quantitative real-time RT-PCR for determination of FGF21 mRNA synthesis relative 
to 36B4 was performed with a protocol described in [27]. Mouse primer sets were as 
follows: FGF21: 5’-AGATCAGGGAGGATGGAACA-3’, and 5’-TCAAAGTGAGGC 
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GATCCATA-3’; 36B4: 5’-AAGCGCGTCCTGGCATTGTCT-3’, and 5’-CCGCAG 
GGGCAGCAGTGGT-3’ (forward and reverse, respectively). 
Statistical analysis 
All statistical analyses were performed with SPSS Statistics Version 20.0 (IBM, Ar-
monk, NY). Differences between LD patients and controls were determined by 
Mann-Whitney U test and differences between LD mice and controls were determined 
by unpaired Student’s t-test. For correlations, the Spearman´ s rank correlation method 
was used. Shapiro-Wilk W-test was performed to test for normal Gaussian distribution 
of parameters. Multivariate linear regression analysis was performed for identification 
of independent relationships after logarithmic transformation of nonnormally distributed 
parameters. Wilcoxon signed rank test was used to assess differences in the course of 
metreleptin therapy. p < 0.05 was considered as statistically significant. 
  
CHAPTER 5 111 
 
5.4 Results 
Characteristics of LD patients at baseline 
Table 1 summarizes clinical characteristics of LD patients and the control group. LD 
patients showed significantly higher median FGF21 levels (381.2 ng/l) than controls 
(231.2 ng/l; p = 0.023; Table 1). Patients with LD showed signs for impaired glucose 
homeostasis (increased HbA1c, FI, HOMA-IR) and lipid metabolism (decreased HDL 
cholesterol, increased TG) as compared to controls (p ≤ 0.001; Table 1). Adiponectin 
and leptin serum concentrations of the LD group were significantly lower as compared 
to controls (p < 0.001; Table 1). LD patients with fibrate treatment had higher median 
FGF21 levels (1010.8 ng/l; N = 11) as compared to LD patients not on fibrates 
(289.3 ng/l; N = 26; p = 0.002). 
Univariate and multivariate analyses 
Circulating FGF21 was positively associated with BMI, WHR, HbA1c, FG, FI, 
HOMA-IR, TG, and CRP in the entire study cohort whereas a negative correlation with 
HDL cholesterol, LDL cholesterol, as well as adiponectin was found (p < 0.05; Ta-
ble 2). No significant association between FGF21 serum concentration and age, blood 
pressure, cholesterol, FFA, renal function parameters, and leptin could be detected (Ta-
ble 2). 
Serum FGF21 remained positively and independently associated with serum TG in 
multiple linear regression analysis (Table 2). When fibrate treatment was included in the 
multivariate model, TG remained a significant predictor for FGF21 (β = 0.411, 
p = 0.041). Moreover, FGF21 was still significantly and positively associated with TG 
even when all LD patients with fibrate treatment were excluded from the analysis 
(β = 0.398, p = 0.042). When fibrates were included instead of TG in the multivariate 
model, fibrate treatment correlated positively and significantly with FGF21 (β = 0.325, 
p = 0.008). 
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FGF21 plasma levels and expression in an LD animal model 
LD mice had a significantly higher mean liver weight/body weight ratio (14.75%) as 
compared to wild-type animals (6.88%; p < 0.0001; Figure 1A). Cholesterol (Figure 1B) 
and TG (Figure 1C) content in liver tissue was significantly increased in LD mice 
(p < 0.0001). In agreement with the findings in humans, FGF21 plasma levels were in-
creased 4.5-fold in LD animals (Figure 1D) whereas circulating adiponectin (Supple-
mental Figure 1G) and leptin (Supplemental Figure 1H) were significantly decreased 
(p < 0.0001). LD mice showed significant FGF21 mRNA upregulation in SAT (37-fold; 
p < 0.0001; Figure 1E), VAT (102-fold; p < 0.01; Figure 1F), BAT (253-fold; 
p < 0.0001; Figure 1G), and liver (4-fold; p < 0.05; Figure 1H) but not in muscle (data 
not shown). Further metabolic characteristics of LD and control mice are summarized in 
Supplemental Figure 1. 
FGF21 serum concentration during metreleptin treatment 
Table 3 summarizes characteristics of 10 LD patients undergoing metreleptin therapy 
before and after 6 months of treatment, respectively. As compared to baseline, there was 
a significant decrease of TG (5.27 mmol/l vs 12.39 mmol/l; p = 0.014) and a significant 
increase of CRP (6.3 mg/l vs 2.8 mg/l; p = 0.049) at 6 months of treatment (Table 3). 
However, FGF21 serum concentrations did not significantly differ between baseline and 
6 months of metreleptin treatment (Table 3). 
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 Controls LD p 
N 37 37  
FGF21 (ng/l) 231.2 (251.3) 381.2 (606.7) 0.023
*
 
Age (years) 48 (22) 43 (23)  0.382 
Gender (male/female) 5/32 5/32 - 
BMI (kg/m
2
) 26.2 (3.3) 26.3 (4.8) 0.440 
WHR 0.86 (0.14) 0.98 (0.08) <0.001
*
 
SBP (mmHg) 124 (24) 131 (17) 0.093 
DBP (mmHg) 78 (13) 80 (16) 0.659 
HbA1c (%) 5.2 (0.5) 6.4 (2.4) <0.001
*
 
HbA1c (mmol/mol) 33.3 (4.9) 46.4 (26.2) <0.001
*
 
FG (mmol/l) 5.4 (1.5) 5.8 (5.0) 0.130 
FI (pmol/l) 61.2 (45.6) 131.7 (250.8) <0.001
*
 
HOMA-IR 2.2 (1.9) 5.2 (13.9) 0.001* 
Cholesterol (mmol/l) 5.46 (1.35) 5.88 (1.92) 0.220 
HDL cholesterol (mmol/l) 1.48 (0.44) 0.95 (0.68) <0.001
*
 
LDL cholesterol (mmol/l) 3.43 (0.95) 2.92 (2.02) 0.497 
TG (mmol/l) 1.15 (0.59) 2.95 (6.97) <0.001
*
 
FFA (mmol/l) 0.47 (0.30) 0.59 (0.26) 0.065 
Creatinine (µmol/l) 63 (25) 65 (18) 0.981 
eGFR (ml/min/1.73m²) 94.9 (13.9) 100.6 (27.5) 0.131 
CRP (mg/l) 1.1 (4.1) 2.7 (3.7) 0.308 
Adiponectin (mg/l) 7.7 (10.0) 2.3 (2.7) <0.001
*
 
Leptin (µg/l) 13.8 (11.7) 5.3 (3.9) <0.001
*
 
Table 1 Baseline characteristics of the entire study population (N = 74). BMI, Body mass-index; CRP, 
C reactive protein; DBP, Diastolic blood pressure; eGFR, Estimated glomerular filtration rate; FFA, Free 
fatty acids; FG, Fasting glucose; FGF21, Fibroblast growth factor 21; FI, Fasting insulin; HbA1c, Glyco-
sylated hemoglobin A1c; HDL, High-density lipoprotein; HOMA-IR, Homeostasis model assessment of 
insulin resistance; LD, Lipodystrophy; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; TG, 
Triglycerides; WHR, Waist-hip-ratio. Values for median (interquartile range) are shown. *indicates 
p < 0.05 as assessed by Mann-Whitney U test. 
  













Age (years) 0.146/0.214* 0.129 0.272 
Group (LD vs Non-LD) - 0.151 0.393 
Gender - -0.035 0.761 
BMI (kg/m
2
) 0.243/0.037* - - 
WHR 0.276/0.019* -0.112 0.508 
SBP (mmHg; lg) 0.100/0.398 - - 
DBP (mmHg) 0.154/0.1953 - - 
HbA1c (%;lg) 0.446/<0.001* - - 
HbA1c (mmol/mol; lg) 0.446/<0.001* - - 
FG (mmol/l) 0.480/<0.001* - - 
FI (pmol/l) 0.438/<0.001* - - 
HOMA-IR 0.492/<0.001* 0.247 0.070 
Cholesterol (mmol/l) 0.018/0.877 - - 
HDL cholesterol (mmol/l; lg) -0.517/<0.001* - - 
LDL cholesterol (mmol/l; lg) -0.477/<0.001* - - 
TG (mmol/l; lg) 0.556/<0.001* 0.542 0.002† 
FFA (mmol/l) 0.054/0.695 - - 
Creatinine (µmol/l) -0.109/0.356 - - 
eGFR (ml/min/1.73 m
2
) -0.045/0.701 - - 
CRP (mg/l; lg) 0.315/0.007* 0.057 0.633 
Adiponectin (mg/l) -0.368/0.001* - - 
Leptin (µg/l) -0.302/0.183 - - 
Table 2 Univariate correlations with FGF21 in the entire study population (N = 74) and multivariate re-
gression analysis between FGF21 (lg; dependent variable) and age, group, gender,WHR, HOMA-IR (lg), 
TG (lg) as well as CRP (lg). Non-normally distributed variables were logarithmically transformed (lg) 
prior to multivariate testing. r- and p-values, as well as standardized β-coefficients and p-values, are giv-
en, respectively. Abbreviations are indicated in Table 1. * Indicates significant correlation as assessed by 
Spearman’s correlation method. † Indicates significant correlation in multivariate analysis. 
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FGF21 (ng/l) 938.8 (979.1) 930.0 (1086.4) 1.000 
BMI (kg/m
2
) 27.4 (4.6) 27.2 (5.1) 0.066 
WHR 0.95 (0.14) 0.96 (0.09) 0.820 
SBP (mmHg) 129 (22) 130 (10) 0.844 
DBP (mmHg) 85 (16) 81 (11) 1.000 
HbA1c (%) 7.8 (2.0) 7.1 (1.4) 0.123 
HbA1c (mmol/mol) 61.8 (21.6) 54.1 (15.0) 0.123 
FG (mmol/l) 8.5 (4.5) 7.7 (6.1) 0.898 
FI (pmol/l) 325.6 (413.3) 302.0 (384.3) 0.492 
HOMA-IR 16.0 (17.9) 12.6 (20.0) 0.770 
Cholesterol (mmol/l) 7.49 (5.74) 4.85 (7.53) 0.492 
HDL cholesterol (mmol/l) 0.57 (0.26) 0.61 (0.31) 0.865 
LDL cholesterol (mmol/l) 1.23 (1.80) 1.43 (1.62) 0.557 
TG (mmol/l) 12.39 (15.24) 5.27 (5.95) 0.014
*
 
FFA (mmol/l) 0.72 (0.27) 0.68 (0.39) 0.945 
Creatinine (µmol/l) 62.5 (33) 49 (27) 0.633 
eGFR (ml/min/1.73m²) 102.3 (35.1) 123.8 (31.9) 0.652 
CRP (mg/l) 2.8 (7.3) 6.3 (6.1) 0.049
*
 
Adiponectin (mg/l) 1.9 (2.0) 1.4 (1.9) 0.910 
Leptin (µg/l) 5.5 (7.4) 11.8 (20.9) 0.109 
Table 3 Baseline characteristics, as well as parameters before and 6 months after initiation of metreleptin 
treatment in LD patients (N = 10). Abbreviations are indicated in Table 1. Values for median (interquar-
tile range) or absolute numbers (N) are shown. * indicates p < 0.05 as assessed by Wilcoxon signed rank 
test. 
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Figure 1 (A) liver weight/body weight [%], (B) cholesterol (Chol) content in liver, (C) triglyceride (TG) 
content in liver representative hematoxylin and eosin-stained liver sections, (D) plasma FGF21 concentra-
tion, and (E-H) mRNA expression of FGF21 relative to 36B4 in (E) subcutaneous adipose tissue, 
(F) visceral adipose tissue, (G) brown adipose tissue, and (H) liver of 20-week-old wild-type (N ≥ 10) 
and LD (N ≥ 8) mice. Data are presented as means ± standard error. * Indicates p < 0.05, ** p < 0.01, and 
**** p < 0.0001 as assessed by unpaired Student’s t-test.  
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5.5 Discussion 
We show for the first time that circulating FGF21 concentrations are significantly 
higher in non-HIV LD patients as compared to controls matched for age, gender, and 
BMI. This finding is in line with reports in HIV-associated LD. Thus, significantly 
higher circulating FGF21 has been demonstrated in HIV1-infected patients with associ-
ated LD as compared to healthy controls [21,22], as well as compared to HIV1-infected 
patients without LD [21]. In line with published evidence [5,28] and contrary to FGF21, 
adiponectin and leptin serum levels are significantly lower in our LD group as com-
pared to controls which is most probably due to the reduction of adipose tissue in LD. 
In order to reveal the source of increased FGF21 serum concentration in LD, we have 
assessed FGF21 mRNA expression in insulin-sensitive tissues including liver, muscle, 
BAT, VAT and SAT of an LD mouse model. LD mice not only have 4.5-fold increased 
FGF21 plasma levels but also show significantly higher FGF21 mRNA expression in 
SAT, VAT, BAT, and liver as compared to wild-type animals. In agreement with our 
findings, Véniant and co-workers demonstrate increased FGF21 in BAT and white adi-
pose tissue of LD mice [29]. Furthermore, lipodystrophic A-ZIP F-1 mice show in-
creased circulating FGF21 and upregulated FGF21 in liver as compared to controls sim-
ilar to our findings [30]. However, FGF21 mRNA expression in BAT of A-ZIP F-1 
mice is decreased [30]. One plausible reason for this discrepancy is the difference in LD 
mouse models used. 
Future experiments are necessary to elucidate the pathophysiological significance of 
increased FGF21 in HIV-associated and non-HIV LD. FGF21 has recently been intro-
duced as an adipokine with positive effects on glucose homeostasis, lipid metabolism, 
and vascular health [11–13]. Thus, FGF21 strongly decreases TG serum concentration 
to near normal levels in ob/ob and db/db mice and mice with transgenic FGF21 overex-
pression are resistant to dietinduced obesity [11]. Furthermore, FGF21 treatment of dia-
betic rhesus monkeys over 6 weeks causes a dramatic decline in fasting TG, FG, and 
FI [12]. Moreover, FGF21 overexpression in 3T3-L1 adipocytes markedly decreases 
intracellular TG content and upregulates β-klotho, fibroblast growth factor receptor 1, 
adipose triglyceride lipase, as well as hormone-sensitive lipase [31]. In addition, intrac-
erebroventricular administration of FGF21 in obese rats improves hepatic insulin sensi-
tivity through suppression of gluconeogenic gene expression and hepatic glucose pro-
duction, as well as increases in energy expenditure [32]. Besides its beneficial metabolic 
effects, FGF21-deficient mice on an apolipoprotein E
-/-
 background show increased ath-
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erosclerotic plaque formation and premature death whereas replenishment of FGF21 
protects against atherosclerosis [13]. Considering these independent results and our cur-
rent findings, FGF21 upregulation might be a compensatory mechanism to improve 
metabolic and vascular health in LD. Alternatively, FGF21 resistance leading to com-
pensatory upregulation of FGF21 might occur in LD. Interestingly, FGF21 resistance 
has been convincingly demonstrated in obesity which shares important characteristics 
with LD including dyslipidemia, diabetes mellitus, and premature atherosclerotic dis-
ease [33]. 
We show that FGF21 concentrations are positively and independently associated 
with markers of lipid metabolism, i.e. TG, which is in line with previous reports from 
HIV-associated LD and from non-LD cohorts. Thus, FGF21 levels are significantly and 
positively associated with TG in HIV-positive patients with LD [21]. Furthermore, 
Li et al. show a positive and independent association between FGF21 and TG in sub-
jects with impaired glucose tolerance [34]. In addition, an independent and positive cor-
relation between serum FGF21 levels and TG is demonstrated in another Chinese co-
hort [35]. Consistent with these findings, we have shown a significant and positive cor-
relation between circulating FGF21 and markers of dyslipidemia in patients with gesta-
tional diabetes mellitus [36]. Besides TG, fibrate treatment independently correlates 
with FGF21 in our cohort. These data are in accordance with recent studies indicating 
that peroxisome proliferator–activated receptor α activation by both FFAs [37,38] and 
fibrates [39] increases circulating FGF21 levels. Since the difference in FGF21 concen-
trations between LD patients and controls does not remain significant after adjustment 
for fibrates (data not shown), our results suggest that both elevated TG and fibrate 
treatment are major determinants of increased serum FGF21 in non-HIV LD. Interest-
ingly, no data are available concerning fibrate treatment in patients and controls in the 
two studies on circulating FGF21 in HIV-associated LD [21,22]. 
Metreleptin treatment over 6 months does not significantly alter FGF21 serum levels 
in 10 patients suffering from non-HIV LD. Likewise, FGF21 concentrations are not 
significantly altered at 1 week, 1 month, 3 months, and 1 year of metreleptin treatment 
(data not shown). However, our study has several limitations: only a small number of 
patients has been included. Moreover, metreleptin effects on glucose homeostasis and 
lipid metabolism have been highly variable for the individual patient (data not shown). 
Furthermore, 8 out of 10 LD patients in our metreleptin treatment group suffer from 
partial LD which is a higher proportion as compared to other metreleptin stud-
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ies [7,40,41]. Moreover, it is well known that metabolic abnormalities, as well as 
metreleptin treatment effects, are more pronounced in generalized LD as compared to 
partial LD [40,42]. Thus, larger patient cohorts including more generalized LD patients 
might be required to reveal a significant effect of metreleptin treatment on FGF21 se-
rum levels. 
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5.6 Conclusions 
Serum concentrations of FGF21 are elevated in non-HIV LD patients with adipose 
tissue and liver being potential sources of increased production. TG and fibrate treat-
ment are independent positive predictors of circulating FGF21. Future studies are nec-
essary to determine the pathophysiological significance of elevated FGF21 levels in LD. 
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5.8 Supplementary Figure 
 
Supplementary Figure 1 (A) Body weight, (B) HbA1c, (C) fasting glucose, (D) fasting insulin, (E) total 
cholesterol, (F) triglycerides, (G) plasma adiponectin, and (H) plasma leptin in 20-week-old wild-type 
(N ⩾ 8) and LD (N ⩾ 7) mice. Data are presented as mean ± standard error. * Indicates p < 0.05, 
** p < 0.01, and **** p < 0.0001 as assessed by unpaired Student’s t-test.  






Progranulin is increased in human and murine 
lipodystrophy 
 
Konstanze Miehle*, Thomas Ebert*,†, Susan Kralisch*, Annett Hoffmann*, 
Jürgen Kratzsch‡, Haiko Schlögl*, Michael Stumvoll* and Mathias Fasshauer*,† 
 
 
*Department of Internal Medicine (Endocrinology and Nephrology), Univer-
sity of Leipzig, Leipzig, Germany, 
†Leipzig University Medical Center, IFB Adiposity Diseases, Leipzig, Ger-
many and  
‡Institute for Laboratory Medicine, Clinical Chemistry and Molecular Diag-




Diabetes Res Clin Pract. (2016) 120:1-7. 
  
CHAPTER 6 129 
 
6.1 Abstract 
Aims: Lipodystrophies (LD) are genetic or acquired disorders sharing the symptom 
of partial or complete adipose tissue deficiency and a dysregulation of adipokines in-
cluding leptin and adiponectin. Progranulin, an adipokine with proinflammatory and 
insulin resistance-inducing characteristics, has not been investigated in LD so far. 
Methods: Circulating progranulin was determined in LD patients (N = 37) and in 
age-, gender-, and body mass index-matched healthy control subjects (N = 37). Addi-
tionally, we investigated progranulin expression in an LD mouse model as compared to 
wild-type mice. Moreover, we elucidated circulating progranulin before and during 
metreleptin supplementation in 10 patients with LD. 
Results: Median [interquartile range] circulating progranulin was increased in pa-
tients with LD (82.9 [25.9] µg/l) as compared to controls (73.6 [22.8] µg/l) (p = 0.005). 
C-reactive protein (CRP) remained an independent and positive predictor of progranulin 
in multivariate analysis. Progranulin mRNA was significantly upregulated in all adipose 
tissue depots, i.e. visceral, subcutaneous, and brown adipose tissue, and in muscle of LD 
animals vs wild-type mice. Progranulin levels did not significantly change during 
metreleptin supplementation. 
Conclusions: Progranulin serum concentration is increased in patients with LD, and 
shows an independent and positive correlation with CRP. Different adipose tissue de-
pots and muscle might be potential origins of elevated progranulin. 
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6.2 Introduction 
The term lipodystrophy (LD) summarizes a group of genetic or acquired disorders 
sharing the symptom of partial or complete adipose tissue deficiency [1,2]. Patients with 
LD are predisposed to severe metabolic derangement including dyslipidemia, hepatic 
steatosis, insulin resistance/diabetes mellitus, and polycystic ovary syndrome 
(PCOS) [1]. As a consequence, these patients have an increased risk for severe compli-
cations, such as liver cirrhosis, pancreatitis, and coronary heart disease [1,3]. 
Since the late 90s, dysregulation of adipokines, i.e. adipocyte-secreted factors, has 
been suggested to influence LD [4]. The adipokines leptin and adiponectin are signifi-
cantly downregulated in LD in humans [5], as well as in murine LD models [6]. Most 
interestingly, administration of leptin, adiponectin, and a combination of both improved 
significantly lipid and glycemic control profiles in mice with congenital LD [4], as well 
as in lipoatrophic peroxisome proliferator-activated receptor (PPAR) γ
+/–
 mice treated 
with the PPARγ/retinoid X receptor inhibitor HX531 [7]. Furthermore and in accord-
ance with the rodent data, Oral and co-workers elegantly demonstrated that leptin thera-
py improved glycemic control and decreased triglyceride levels in patients with LD [8]. 
Progranulin (also referred to as proepithelin, pc-cell derived growth factor, 
acrogranin, and granulin-epithelin precursor) has been described by Matsubara and co-
workers as a novel adipokine inducing insulin resistance [9]. Progranulin is upregulated 
by tumor necrosis factor (TNF) α and dexamethasone in cellular models of insulin re-
sistance [9]. Furthermore, progranulin knockout mice are resistant to high fat diet-
induced insulin resistance, adipocyte hypertrophy, and obesity [9]. Moreover, the au-
thors demonstrated that progranulin levels in blood and adipose tissue were markedly 
increased in obese mice [9]. In agreement with these findings, Youn and co-workers 
revealed that serum progranulin concentrations are also elevated in patients with obesity 
and diabetes mellitus type 2 as compared to individuals with normal glucose toler-
ance [10]. Thus, progranulin appears to be a novel insulin resistance-inducing adipokine 
which is associated with adipose tissue mass. 
To date, regulation of the insulin resistance-inducing adipokine progranulin has not 
been studied in patients with LD. Thus, we determined progranulin in patients with LD 
and in age-, gender-, and body mass index (BMI)-matched healthy control subjects. To 
detect relevant changes in progranulin plasma levels and mRNA expression in insulin-
sensitive tissues, we have investigated progranulin in an LD mouse model as compared 
to control mice. Moreover, we investigated circulating progranulin before and during 
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metreleptin supplementation in 10 patients with LD to reveal a possible impact of 
metreleptin supplementation on progranulin. 
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6.3 Materials and methods 
LD patients and controls 
The study cohort and metreleptin treatment criteria have been described recent-
ly [11,12]. In brief, 37 patients with generalized (N = 4) and partial (N = 33) LD 
(32 female, 5 male) and 37 age-, gender-, and BMI-matched healthy controls were in-
cluded in the study (entire study population: age 16-75 years, BMI 17.4–46.1 kg/m
2
). 
All LD patients fulfilled the consensus statement criteria 2013 of the American Associa-
tion of Clinical Endocrinologists (AACE) for LD [2]. At the time of recruitment, none 
of the LD patients was pregnant or suffered from cancer or acute infection. None of the 
37 LD patients was on metreleptin treatment at the time of characterization. In 24 LD 
patients, a genetic diagnosis had been established. Of those, 18 showed lamin A, 
5 PPARγ, and one polymerase I and transcript release factor mutations. Of the remain-
ing 13 LD patients, 7 were suspected to have a genetic origin since a positive family 
history was present, 2 patients were suffering from autoimmune LD, and 4 patients had 
idiopathic LD. Thirty-two partial LD patients had femorogluteal LD and one patient 
was affected by a localized form of the disease. Of the 32 female LD patients, 17 were 
pre- and 15 were postmenopausal. Ten LD patients (8 female, 2 male) were treated with 
metreleptin for 1 year. Laboratory measurement has been carried out prior to and during 
metreleptin supplementation (at 1 week, and 1, 3, 6, and 12 months, respectively). The 
6 months data were used for calculation because glycemic and lipid profiles at this time 
were superior to other time points. The Ethics Committee of the Leipzig University ap-
proved this study. Moreover, all patients and controls gave written informed consent. 
Laboratory measurement 
In all subjects, venous blood withdrawal was performed after an overnight fast. Adi-
pokines were analyzed in serum by enzyme-linked immunosorbent assay (ELISA) tech-
nique using commercially available kits purchased from R&D Systems, Minneapolis, 
MN for progranulin, from Mediagnost, Reutlingen, Germany, for adiponectin and lep-
tin, and from R&D Systems, Minneapolis, MN for interleukin (IL)-6 and TNFα Stand-
ard laboratory methods were used for determination of routine blood biochemistry 
markers, i.e. fasting insulin (FI), fasting glucose (FG), glycosylated hemoglobin A1c 
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(HbA1c), creatinine, triglycerides (TG), total, high density lipoprotein (HDL), and low 
density lipoprotein (LDL) cholesterol, free fatty acids (FFA), as well as C-reactive pro-
tein (CRP). Homeostasis model assessment of insulin resistance (HOMA-IR) calcula-
tion has been performed referring to Matthew et al. [13]. Renal function was assessed 
by measuring creatinine and calculating eGFR by the CKD-EPI equation [14]. 
Mouse study 
Mouse experiments were performed as described recently [12]. In brief, 
Tg(aP2-SREBF1c)9884Reh/0 mice (Jackson Laboratory, Bar Harbor, ME) were used as 
an animal model of lipodystrophy and C57BL/6NTac mice (F15; Jackson Laboratory, 
Bar Harbor, ME) served as controls. Both mouse models were on a low-density lipopro-
tein receptor knockout background, maintained in pathogen-free facilities under con-
trolled temperature (21 ± 1 °C) and darkness occurring between 6 AM and 6 PM, and 
maintained on a cholesterolenriched semisynthetic Clinton/Cybulsky diet (V1534, Sniff, 
Soest, Germany). All animal experiments were conducted according to accepted stand-
ards of humane animal care, and were approved by the local ethics committee (approval 
No. TVV37/12). After 20 weeks, animals were killed. Immediately thereafter, samples 
of visceral (VAT), brown (BAT), as well as subcutaneous (SAT) adipose tissue, muscle, 
and liver were taken and deep-frozen in liquid nitrogen. 
We performed progranulin (PGRN) mRNA amplification relative to 36B4 by quanti-
tative real-time RT-PCR on a LightCycler 480 real-time PCR 96-well thermocycler 
using LightCycler 480 Probes Master Mix (Roche Diagnostics GmbH, Berlin, Germa-
ny) as mentioned previously [15]. 
Primers for PGRN were: 5’-GACCCCGACGCAGGCAGACC-3’ (forward), 5’-CAG 
CAGGCAACAGGGCAGAACT-3’ (reverse); Primers for 36B4 were: 5’-AAGCGCGT 
CCTGGCATTGTCT-3’ (forward), 5’-CCGCAGGGGCAGCAGTGGT-3’ (reverse). 
Progranulin plasma levels in mice were quantified with a commercially available ELI-
SA from Biovendor (Modrice, Czech Republic). 
Statistical analysis 
We used SPSS Statistics Version 20.0 (IBM, Armonk, NY) for statistical analysis. 
Power analysis was conducted with the software G*Power [16]. Reported data are pre-
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sented as median and interquartile range and as means ± standard error for human and 
mouse studies, respectively. The nonparametric Mann–Whitney U test was used to iden-
tify differences between LD and controls. Correlations were assessed by means of the 
non-parametric Spearman’s rank correlation. To reveal independent relationships, mul-
tivariate linear regression analyses were conducted. Prior to multivariate analyses, test-
ing for normal Gaussian distribution was done by Shapiro–Wilk W-test. Parameters 
without normal distribution were logarithmically transformed. In all multivariate linear 
analyses, parameters that correlated significantly with progranulin in univariate analysis 
were included in the same model except for covariates. Furthermore, age and gender 
were included in all multivariate models. For the assessment of differences in progranu-
lin serum concentration before and during metreleptin supplementation, the non-
parametric Wilcoxon signed rank test was applied. Differences between control and LD 
mice were assessed by unpaired Student’s t-test. In all analyses p < 0.05 was established 
as statistically significant. 
  




In the total cohort, median [interquartile range] progranulin was 78.5 [22.0] µg/l. 
Median [interquartile range] progranulin serum concentration was significantly higher 
in LD patients (82.9 [25.9] µg/l) as compared to controls (73.6 [22.8] µg/l; p = 0.005; 
Table 1). When partial and generalized LD patients were analyzed separately, there was 
a trend towards higher circulating progranulin levels in partial LD patients (81.9 µg/l; 
n = 33) as compared to age-, gender-, and BMI-matched controls (74.6 µg/l; N = 33) 
(p = 0.079), as well as in generalized LD patients (128.1 µg/l; N = 4) as compared to 
non-LD controls (67.6 µg/l; N = 4) (p = 0.057). Interestingly, circulating progranulin 
was significantly higher in generalized (128.1 µg/l; N = 4) as compared to partial 
(81.9 µg/l; N = 33) LD (p = 0.005). In contrast, serum progranulin was not significantly 
affected by gender, LD etiology (i.e. genetic vs autoimmune vs idiopathic), fat loss dis-
tribution in partial LD (i.e. femorogluteal vs localized), and menopausal status (data not 
shown). Parameters of glucose and lipid metabolism (i.e. elevation of HbA1c, FI, and 
HOMA-IR, as well as decline of HDL cholesterol and elevation of TG, respectively) 
were significantly dysregulated in patients with LD as compared to the control cohort 
(p ≤ 0.001) (Table 1). In addition, LD patients had significantly higher TNFα, as well as 
lower adiponectin and leptin levels (p < 0.001; Table 1). Variance of BMI values de-
creased from 16.9 kg/m
2
 in all LD patients (N = 37) to 13.9 kg/m
2
 in partial LD patients 
only (N = 33). 
Progranulin was significantly and positively correlated with WHR, HbA1c, TG, 
CRP, IL-6, and TNFα (p < 0.05) when evaluating the study group as a whole (Table 2). 
Moreover, progranulin was significantly and negatively associated with HDL cholester-
ol and LDL cholesterol in univariate analysis (p < 0.05) (Table 2). However, progranu-
lin levels did not significantly correlate with blood pressure, parameters of renal func-
tion, as well as the adipokines adiponectin and leptin (Table 2). Multiple linear regres-
sion analysis revealed an independent and positive association between circulating 
progranulin and CRP (Table 2). The significant associations between progranulin on 
one hand and IL-6 (β = 0.265, p = 0.062) and TNFα (β = 0.230, p = 0.120) on the other 
hand were lost in multivariate models when these parameters were included instead of 
CRP. In LD patients, progranulin was significantly and negatively associated with body 
CHAPTER 6 136 
 
cell mass and basal metabolic rate but not with fat mass as a fat index (Supplemental 
Table 1). 
Progranulin plasma levels and mRNA expression in LD mice 
Circulating progranulin was higher in LD mice (860 µg/l) as compared to control an-
imals (721 µg/l); however, this difference did not reach statistical significance 
(p = 0.11) (Figure 1A). Progranulin mRNA was 2.8-fold higher in VAT (Figure 1B), 
3.0-fold higher in SAT (Figure 1C), 2.7-fold higher in BAT (Figure 1D), and 1.8-fold 
higher in muscle (Figure 1E) of LD animals as compared to controls (all p < 0.05). No 
significant difference in progranulin mRNA expression between LD and wild-type ani-
mals was found in liver (Figure 1F). In contrast to progranulin, plasma levels, as well as 
mRNA expression in VAT, SAT, and BAT, of the adipokine leptin were significantly 
decreased in LD mice as compared to non-LD controls (data not shown). 
Progranulin in metreleptin-treated LD patients 
Anthropometric and laboratory characteristics of the 10 LD patients included in the 
metreleptin treatment study are given in Table 3 for baseline and 6 months of treatment, 
respectively. As compared to baseline, TG levels were significantly declined 
(5.27 [5.95] mmol/l vs 12.39 [15.24] mmol/l) (p = 0.014) and CRP levels were signifi-
cantly increased (6.3 [6.1] mg/l vs 2.8 [7.3] mg/l) (p = 0.049) after 6 months of 
metreleptin supplementation (Table 3). Contrary to expectations, there were no signifi-
cant differences in circulating progranulin between baseline (85.7 [26.5] µg/l) and 
6 months (86.9 [28.5] µg/l) (p = 0.922) (Table 3). 
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 Controls LD p 
N 37 37  
Progranulin (µg/l) 73.6 (22.8) 82.9 (25.9) 0.005
*
 
Age (years) 48 (22) 43 (23)  0.382 
Gender (male/female) 5/32 5/32 - 
BMI (kg/m
2
) 26.2 (3.3) 26.3 (4.8) 0.440 
WHR 0.86 (0.14) 0.98 (0.08) <0.001
*
 
SBP (mmHg) 124 (24) 131 (17) 0.093 
DBP (mmHg) 78 (13) 80 (16) 0.659 
HbA1c (%) 5.2 (0.5) 6.4 (2.4) <0.001
*
 
HbA1c (mmol/mol) 33.3 (4.9) 46.4 (26.2) <0.001
*
 
FG (mmol/l) 5.4 (1.5) 5.8 (5.0) 0.130 
FI (pmol/l) 61.2 (45.6) 131.7 (250.8) <0.001
*
 
HOMA-IR 2.2 (1.9) 5.2 (13.9) 0.001* 
Cholesterol (mmol/l) 5.46 (1.35) 5.88 (1.92) 0.220 
HDL cholesterol (mmol/l) 1.48 (0.44) 0.95 (0.68) <0.001
*
 
LDL cholesterol (mmol/l) 3.43 (0.95) 2.92 (2.02) 0.497 
TG (mmol/l) 1.15 (0.59) 2.95 (6.97) <0.001
*
 
FFA (mmol/l) 0.47 (0.30) 0.59 (0.26) 0.065 
Creatinine (µmol/l) 63 (25) 65 (18) 0.981 
eGFR (ml/min/1.73m²) 94.9 (13.9) 100.6 (27.5) 0.131 
CRP (mg/l) 1.1 (4.1) 2.7 (3.7) 0.308 
IL-6 (ng/l) 1.1 (0.9) 1.3 (1.2) 0.356 
TNFα (ng/l) 1.7 (1.0) 2.5 (2.3) <0.001* 
Adiponectin (mg/l) 7.7 (10.0) 2.3 (2.7) <0.001
*
 
Leptin (µg/l)  13.8 (11.7) 5.3 (3.9) <0.001
*
 
Table 1 Baseline characteristics of the entire study population (N = 74). BMI, Body mass-index; CRP, 
C-reactive protein; DBP, Diastolic blood pressure; eGFR, Estimated glomerular filtration rate; FFA, Free 
fatty acids; FG, Fasting glucose; FI, Fasting insulin; HbA1c, Glycosylated hemoglobin A1c; HDL, High-
density lipoprotein; HOMA-IR, Homeostasis model assessment of insulin resistance; IL, Interleukin; LD, 
Lipodystrophy; LDL, Low-density lipoprotein; SBP, Systolic blood pressure; TG, Triglycerides; TNF, 
Tumor necrosis factor; WHR, Waist to hip-ratio. Values for median (interquartile range) or absolute 
numbers (N) are shown. * indicates p < 0.05 as assessed by Mann-Whitney U-test. 
  













Age (years) 0.043/0.715* -0.004 0.976 
Group (LD vs Non-LD) - -0.236 0.266 
Gender - -0.061 0.628 
BMI (kg/m
2
) 0.020/0.869 - - 
WHR 0.259/0.028* -0.062 0.740 
SBP (mmHg; lg) 0.105/0.374 - - 
DBP (mmHg) 0.085/0.474 - - 
HbA1c (%;lg) 0.307/0.012* 0.124 0.434 
HbA1c (mmol/mol; lg) 0.307/0.012* - - 
FG (mmol/l) 0.146/0.215 - - 
FI (pmol/l) 0.174/0.150 - - 
HOMA-IR 0.206/0.087 - - 
Cholesterol (mmol/l) -0.105/0.373 - - 
HDL cholesterol (mmol/l; lg) -0.346/0.003* -0.268 0.171 
LDL cholesterol (mmol/l; lg) -0.233/0.046* 0.141 0.441 
TG (mmol/l; lg) 0.345/0.003* -0.081 0.752 
FFA (mmol/l) 0.064/0.639 - - 
Creatinine (µmol/l) -0.013/0.912 - - 
eGFR (ml/min/1.73 m
2
) -0.025/0.830 - - 
CRP (mg/l; lg) 0.347/0.003* 0.314 0.031† 
IL-6 (ng/l) 0.364/0.001* - - 
TNFα (ng/l) 0.359/0.002* - - 
Adiponectin (mg/l) -0.182/0.120 - - 
Leptin (µg/l) 0.324/0.152 - - 
Table 2 Univariate correlations with progranulin in the entire study population and multivariate regres-
sion analysis between progranulin (lg; dependent variable) and age, group, gender, WHR, HbA1c (lg), 
HDL cholesterol, LDL cholesterol (lg), TG (lg), as well as CRP (lg). Non-normally distributed variables 
were logarithmically transformed (lg) prior to multivariate testing. r- and p-values, as well as standardized 
β-coefficients and p-values, are given, respectively. Abbreviations are indicated in Table 1. * indicates 
significant correlation as assessed by Spearman’s correlation method. † indicates significant correlation in 
multivariate analysis.   
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Progranulin (µg/l) 85.7 (26.5) 86.9 (28.5) 0.922 
BMI (kg/m
2
) 27.4 (4.6) 27.2 (5.1) 0.066 
WHR 0.95 (0.14) 0.96 (0.09) 0.820 
SBP (mmHg) 129 (22) 130 (10) 0.844 
DBP (mmHg) 85 (16) 81 (11) 1.000 
HbA1c (%) 7.8 (2.0) 7.1 (1.4) 0.123 
HbA1c (mmol/mol) 61.8 (21.6) 54.1 (15.0) 0.123 
FG (mmol/l) 8.5 (4.5) 7.7 (6.1) 0.898 
FI (pmol/l) 325.6 (413.3) 302.0 (384.3) 0.492 
HOMA-IR 16.0 (17.9) 12.6 (20.0) 0.770 
Cholesterol (mmol/l) 7.49 (5.74) 4.85 (7.53) 0.492 
HDL cholesterol (mmol/l) 0.57 (0.26) 0.61 (0.31) 0.865 
LDL cholesterol (mmol/l) 1.23 (1.80) 1.43 (1.62) 0.557 
TG (mmol/l) 12.39 (15.24) 5.27 (5.95) 0.014
*
 
FFA (mmol/l) 0.72 (0.27) 0.68 (0.39) 0.945 
Creatinine (µmol/l) 63 (33) 49 (27) 0.633 
eGFR (ml/min/1.73m²) 102.3 (35.1) 123.8 (31.9) 0.652 
CRP (mg/l) 2.8 (7.3) 6.3 (6.1) 0.049
*
 
IL-6  (ng/l) 1.6 (1.2) 2.1 (2.7) 0.492 
TNFα (ng/l) 3.2 (4.6) 2.8 (2.3) 0.734 
Adiponectin (mg/l) 1.9 (2.0) 1.4 (1.9) 0.910 
Leptin (µg/l) 5.5 (7.4) 11.8 (20.9) 0.109 
Table 3 Clinical characteristics before and 6 months after initiation of metreleptin treatment in LD pa-
tients (N = 10). Abbreviations are indicated in Table 1. Values for median (interquartile range) or absolute 
numbers (N) are shown. * indicates p < 0.05 as assessed by Wilcoxon signed rank test. 
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Figure 1 (A) Plasma progranulin, and (B–F) mRNA expression of progranulin (PGRN) relative to 36B4 
in (B) visceral adipose tissue (VAT), (C) subcutaneous adipose tissue (SAT), (D) brown adipose tissue 
(BAT), (E) muscle, and (F) liver of 20-week-old wild-type (Con; N ≥ 10) and LD (N ≥ 10) mice. Data are 
presented as means ± SEM. * indicates p < 0.05; ** indicates p < 0.01 as assessed by unpaired Student’s 
t-test.  
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6.5 Discussion 
Here we demonstrate that patients with LD have significantly higher progranulin se-
rum levels than age-, gender- and BMI-matched control subjects. It is interesting to note 
in this context that circulating progranulin is also increased in patients with PCOS 
which is a common feature of LD and that progranulin may be a novel biomarker for 
cardiovascular risk in PCOS [17]. A mouse model of generalized LD has been used to 
identify the origin of increased progranulin levels in LD. Here, we show that progranu-
lin mRNA expression is significantly higher in VAT, SAT, BAT, and muscle of LD 
animals as compared to controls. These findings are of particular importance since pa-
tients with partial LD have significantly increased VAT mass [2] and progranulin is 
positively associated with computed tomography (CT) scan-derived VAT area [18]. 
Hence, increased progranulin serum concentrations in LD might originate from mRNA 
upregulation clinically most importantly in VAT and muscle since animals and humans 
with LD have only limited amounts of SAT. In this regard it is of interest that Youn and 
co-workers suggest that both adipocytes and cells of the stromal vascular fraction of 
adipose tissue contribute to progranulin expression in adipose tissue [10]. Thus, in-
creased progranulin in LD could represent a dysfunction of the adipocyte-macrophage 
interaction [10]. Unfortunately, fat indices derived by dual-energy X-ray absorptiome-
try, CT-scans, and magnetic resonance imaging were not available for the studied cohort 
because of time, resource, and radiation protection restrictions. Furthermore, a contribu-
tion of the liver to elevated circulating progranulin in LD cannot be excluded since there 
is a trend towards higher progranulin mRNA expression in liver of LD mice as com-
pared to control animals. Moreover, the highest increase in progranulin plasma levels is 
measured in patients with generalized LD who have almost no adipose tissues. In addi-
tion, there is no correlation between progranulin levels and body fat mass in humans. 
Obviously, the exact mechanisms of progranulin elevation in LD are still not clear and 
have to be investigated in future trials. 
We demonstrate an independent and positive association between progranulin and 
CRP as a marker of inflammation. In agreement with our findings, CRP is the strongest 
independent predictor of circulating progranulin in a study comprising 154 Caucasian 
subjects representing a wide range of obesity, insulin sensitivity, and glucose toler-
ance [10]. Moreover, Matsubara and co-workers convincingly demonstrate that 
progranulin induces the proinflammatory cytokine IL-6 in adipose tissue of mice in vivo 
and in 3T3-L1 adipocytes in vitro [9]. It is interesting to note in this context that IL-6 is 
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significantly and positively associated with circulating progranulin in our cohort in uni-
variate analysis and a positive trend (β = 0.265, p = 0.062) remains in multivariate anal-
ysis. Further experiments suggest that the resultant increase in IL-6 enhances suppressor 
of cytokine signaling-3 expression through activating janus kinase and signal transducer 
and activator of transcription signaling leading to insulin resistance in fat cells [9]. Con-
versely, insulin resistance induced by chronic administration of progranulin is sup-
pressed by application of neutralizing antibodies against IL-6 in vivo [9]. Considering 
this, elevated progranulin might contribute to impaired metabolic status in LD by its 
proinflammatory and insulin resistance-inducing capacities. However, further experi-
ments are needed to better clarify the impact of progranulin in LD pathophysiology. 
Progranulin is not affected by metreleptin supplementation over a 6 months period in 
10 patients with LD despite a significant increase in CRP levels at this time point. This 
increase in CRP appears paradoxical and to our knowledge a similar finding has not 
been shown in other leptin-deficient cohorts on metreleptin treatment. Clearly, a larger 
and independent study is necessary to confirm these findings. Furthermore, metreleptin 
treatment significantly lowers TG but no other markers of the adverse metabolic profile 
in LD. Certainly some limitations of this study need to be pointed out: Only 10 patients 
have been included in the study. Moreover, we see a marked heterogeneity in 
metreleptin treatment outcome (data not shown). Besides this, only 2 out of the 
10 patients in this pilot study are patients with generalized LD suggesting an un-
derrepresentation of generalized LD in our cohort. This is of particular interest since 
generalized LD is frequently accompanied with a more profound metabolic derange-
ment and a better outcome of metreleptin treatment in contrast to the partial form of the 
disease [19,20]. Obviously, a potential influence of metreleptin supplementation on 
progranulin levels in patients with different forms of LD has to be established in studies 
including more patients. 
In conclusion, we demonstrate that progranulin serum levels are increased in patients 
with LD. Moreover, progranulin correlates independently and positively with CRP. Ele-
vated progranulin might derive from VAT and muscle. However, the pathophysiologi-
cal impact of elevated progranulin in LD remains to be determined in future studies. 
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6.7 Supplementary Figures 






Fat mass (kg) -0.144/0.394 
FFM (kg) -0.285/0.088 
TBW -0.277/0.096 
Basal metabolic rate (kcal) -0.424/0.009
*
 
Supplemental Table 1 Univariate correlation in the LD group (N = 37) between circulating progranulin 
and body impedance analysis-derived parameters. BCM, Body cell mass; ECM, Extracellular mass; FFM, 
Fat free mass; TBW, Total body water. r- and p-values are given. *indicates significant correlation as 
assessed by Spearman’s correlation method. 
  




In this thesis, dose-dependent effects of leptin on atherosclerotic plaque formation 
and reproductive function were assessed in leptin-deficient mice. In addition, several 
novel adipokines, i.e. chemerin, FGF21, and progranulin, were characterized in leptin-
deficient LD.  
A leptin-deficient atherosclerosis-prone (LDLR
−/−
;ob/ob) mouse model was treated 
with saline or increasing doses of recombinant leptin (0.1, 0.5 or 3.0 mg/kg BW/d) over 
the course of 12 weeks. In the first publication (Chapter 2), atherosclerotic lesion area 
was found to be reduced dose-dependently by leptin within the studied subphysiological 
to physiological range. The beneficial effects of leptin on atherogenesis appeared to be 
mediated indirectly through improved liver metabolism, reduced blood lipids, and in-
creased levels of the insulin-sensitizing and antiatherogenic adipokine adiponectin. This 
study is the first to elucidate dose-dependent effects of leptin within the subphysiologi-
cal to physiological range on atherogenesis. In accordance with these findings, two re-
ports have previously shown a beneficial effect of leptin on atherogenesis [199,200]. 
Lloyd and colleagues developed two different mouse models to mimic the human meta-
bolic syndrome [199]. They crossed ApoB48
-/-





mice, thereby, creating triple knockout animals. To evaluate the potential for new thera-
peutic modalities, these mice were treated for 12 weeks with low doses of leptin ranging 
from 0.02 to 0.12 mg/kg BW/d. Both mouse models showed extensive atherosclerotic 




;ob/ob mice decreased by about 40% with leptin treatment [199]. In our 
hands, a similar leptin-mediated reduction in plasma Chol and atherosclerotic plaque 
area was seen in LDR
-/-
;ob/ob mice. Another study supporting our current findings in-
vestigated the effect of leptin on dyslipidaemia and atherosclerosis in a type 1 diabetic 





which develop spontaneous type 1 diabetes associated with leptin-deficiency and hyper-
cholesterolemia and treated them daily for 12 weeks with 0.4 mg/kg BW leptin. The 
animals showed a treatment-associated 40% reduction in plasma Chol levels, as well as 
a 60% reduction in plaque area [200]. 
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In contrast to these and our current findings, other studies suggested that leptin can 
also have proatherogenic properties. Bodary and colleagues challenged 16 weeks old 
ApoE
-/-
 male mice for 4 weeks daily with 125 µg leptin or vehicle [201]. With leptin 
treatment, atherosclerotic lesions were 1.5-fold larger in the carotid arteries and 2-fold 
larger in the brachiocephalic artery as compared to vehicle-treated animals [201]. In 
another study, Zeadin and co-workers also used high doses of leptin, i.e. 125 µg/d [202]. 
Female ApoE
-/-
 mice were treated daily with leptin or saline over the course of 8 weeks. 
Leptin-treated animals showed no changes in lesion size but an 8.3-fold higher lesion 
calcification as compared to controls [202]. The primary difference between the latter 
two studies and our current findings, as well as the studies by Llyod et al. [199] and Jun 
et al. [200] is the leptin dose used for treatment. Thus, leptin´s effects on atherogenesis 
might be dose-dependent with low doses being beneficial through improvements in 
metabolic health and high doses possibly having direct proatherogenic effects. Clearly, 
this hypothesis needs to be tested in future experiments. 
In the current study, leptin-mediated improvements in liver metabolism were accom-
panied by decreased hepatic TG and Chol content, as well as improved mRNA expres-
sion of lipid metabolism genes similar to published reports [203–205]. To investigate 
the pure leptin effect on fatty liver, i.e. independent of insulin, a recent study used a 
genetically modified mouse model that develops severe fatty liver but is insulin-
hypersensitive (AlbCrePtenff mice) [206]. These mice were treated with leptin and its 
effects on food intake were controlled for with a pair-fed group. Consistent with our 
results, leptin treatment decreased liver weight and hepatic TG content [206].  
Leptin-mediated increases in circulating adiponectin observed in the current study 
might have additional beneficial effects on atherogenesis and metabolic disease. Thus, 
Okamoto and colleagues showed an atheroprotective effect of adiponectin [207]. 
ApoE
-/-
 mice were injected with an adenovirus expressing adiponectin and showed a 
30% reduction in lesion size [207]. Further evidence for an additive effect of adiponec-
tin and leptin has been provided in two studies [208,209]. Qi and co-workers showed 
that exogenous adiponectin decreases BW in mice through an increase in thermogenesis 
with an even more pronounced effect seen in combination with exogenous leptin [208]. 
In line with these findings, adiponectin potentiates the effect of leptin on arcuate Pomc 
neuron electrical excitability [209]. These results and our current findings are in agree-
ment with the hypothesis that leptin and adiponectin may have additive beneficial ef-
fects on vascular and metabolic disease. 
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In Chapter 3, the influence of leptin on male reproductive function was assessed us-
ing the same leptin-deficient animal model. Direct dose-dependent beneficial effects of 
leptin on reproductive parameters in testis were observed. Thus, leptin increased testis 
weight, intratesticular testosterone, and FSH, as well as markers of Leydig cell function 
and spermatogenesis. A separate set of experiments with acute treatment of leptin-
deficient ob/ob mice over 72 h suggested that part of the beneficial changes are body 
weight-independent, thereby, strongly suggesting some direct effects of leptin on repro-
duction. Our study is the first to elucidate dose-dependent effects of leptin within the 
subphysiological to physiological range on male fertility. Similar to our present find-
ings, male ob/ob mice treated over 60 days with 20 µg/g initial BW/d leptin have previ-
ously been shown to have increased testis weight [210]. Treatment of ob/ob animals 
over a shorter time frame (14 d), but with higher leptin doses (100 µg/d), leads to a 
similar outcome, i.e. increased testis weight and upregulated FSH [211]. In agreement 
with our results on Leydig cell function and spermatogenesis, Mounzih and co-workers 
demonstrated that seminiferous tubules become more abundant and contain more ma-
ture germ cells following leptin treatment of ob/ob mice [210]. Furthermore, leptin sig-
nificantly increases progressive and total sperm motility, acrosome reaction, and nitric 
oxide production in sperm [212,213]. High-dose leptin treatment (200 µg/d) in another 
leptin-deficient mouse model (FVB.B6-Ins2Akita/MlnJ) over 14 days increased testis 
weight and partially restored fertility [214]. In contrast to our findings, there was no 
leptin-mediated increase in intratesticular testosterone or genes involved in testosterone 
steroidogenesis [214]. Taking these and our results into consideration, subphysiological 
to physiological leptin levels appear to improve both spermatogenesis and Leydig cell 
function. 
A limitation of our studies was that supraphysiological leptin levels were not charac-
terized. Current evidence suggests that under supraphysiological conditions, leptin 
might have proatherosclerotic effects [201,202]. It is of note that high levels of leptin 
stimulate inflammation [123] which might promote both atherogenesis and reproductive 
dysfunction. Clearly, future studies elucidating dose-dependent effects of supraphysio-
logical leptin levels need to be performed to adequately address these open questions. 
Leptin-deficiency observed in LD affects metabolic parameters in a similar manner 
to obesity with insulin resistance and hypertriglyceridemia being prominent features of 
both conditions. In human non-human immunodeficiency virus (HIV) LD patients, up-
regulation of circulating chemerin, FGF21, and progranulin levels as compared to 
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matched controls was shown for the first time (Chapters 4-6). In both human and mouse 
LD, leptin and adiponectin levels were significantly reduced. Furthermore, LD mice 
showed increased liver weight, as well as increased hepatic Chol and TG content.  
Chemerin is an adipokine known for its proinflammatory and insulin resistance-
inducing capacity [215,216]. Chemerin serum levels were positively associated with 
HbA1c and CRP in LD patients. In an LD mouse model, increased chemerin mRNA 
expression was observed in VAT and BAT as compared to wild type mice. These find-
ings are compatible with the hypothesis that chemerin might contribute to impaired glu-
cose metabolism and that VAT and BAT are sources of increased production of the adi-
pokine in LD. Clearly, more mechanistic studies are necessary to elucidate the impact of 
the adipokine on metabolic disease in LD. 
FGF21 is an insulin-mimetic, lipid-lowering, and antiatherogenic adipokine 
[19,217,218]. Circulating FGF21 is increased in human LD, as well as being associated 
positively and independently with serum TG. Similarly, FGF21 plasma levels were in-
creased in LD mice and FGF21 mRNA was upregulated in SAT, VAT, BAT, and liver 
as compared to wild type animals. Our study assessed FGF21 serum levels for the first 
time in non-HIV LD. In accordance with our findings, two other reports comparing 
HIV-infected patients with LD to healthy controls showed an increase in circulating 
FGF21 that correlated positively with plasma TG [219,220]. In agreement with our 
mouse data, FGF21 mRNA upregulation was seen in BAT and WAT of LD mice [221]. 
Another LD mouse model showed increases in circulating FGF21, TG, liver weight, and 
hepatic FGF21 mRNA expression similar to our report [222]. It appears counterintui-
tive that an adipokine with beneficial metabolic effects such as FGF21 is upregulated in 
LD. However, evidence has been presented that FGF21 resistance occurs in obesity 
similar to leptin and insulin resistance [223]. Based on these findings it can be hypothe-
sized that increased FGF21 in LD might also indicate resistance to the adipokine with 
concomitant upregulation. Another possible explanation is that adipose tissue is the 
main target of FGF21 where it causes an uptake of TG-rich lipoprotein from the blood 
[224]. Since LD patients lack adipose tissue, there is no appropriate recipient for TG-
rich lipoproteins and FGF21 might possibly be upregulated to counteract hypertriglycer-
idemia. Interestingly, adipose tissue transplantation but not FGF21 administration im-
proved glucose and lipid homeostasis in LD mice in a previous study [221]. In contrast, 
FGF21 treatment over 28 days increased adiponectin levels and insulin sensitivity in 
seipin-deficient LD animals [225]. Clearly, more work is needed to better elucidate the 
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role of FGF21 in LD. Taking these and our results into consideration, reversal of FGF21 
resistance in both obesity and LD might be a novel mechanism to improve metabolic 
health in both conditions. 
The adipokine progranulin is known to induce insulin resistance [226]. Circulating 
progranulin is increased in LD patients, independently and positively associating with 
CRP. At the gene expression level, there was an upregulation of progranulin in VAT, 
SAT, BAT, and muscle of LD mice. These findings are in accordance with the hypothe-
sis that progranulin might contribute to impaired glucose metabolism in LD and that 
adipose tissues and muscle are sites for increased production of the adipokine. The in-
fluence of progranulin on metabolic disease in LD needs to be more thoroughly eluci-
dated in future studies. 
In summary, leptin is a crucial adipokine that impacts on metabolic and vascular dis-
ease, as well as reproductive function. A fine-tuned level of circulating leptin is required 
for optimal health. LD is a devastating condition in which afflicted individuals are inca-
pable of forming sufficient SAT in different regions and, thus, lack circulating leptin 
with metabolic abnormalities including severe insulin resistance and hypertriglycer-
idemia. The adipokines chemerin, FGF21, and progranulin are upregulated in LD. 
Chemerin and progranulin in particular might contribute to a metabolically compro-
mised state in LD that ironically is indistinguishable from obesity. In contrast, increased 
FGF21 might reflect FGF21 resistance caused by receptor dysfunction and/or the lack 
of target adipose tissue. Reestablishment of the correct balance of these and other adi-
pokines might improve metabolic health in LD. 
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